Characterization of the CASZ1-dependent Mechanisms Underlying Vertebrate Blood Vessel Development by Charpentier, Marta Szmacinski
 
 
CHARACTERIZATION OF THE CASZ1-DEPENDENT MECHANISMS UNDERLYING 
VERTEBRATE BLOOD VESSEL DEVELOPMENT   
 
 
Marta S. Charpentier 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department 
of Genetics in the School of Medicine. 
 
 
 
Chapel Hill  
2014 
 
 
 
                                                                                                                              Approved by: 
                                                                                                                              Frank L. Conlon  
                Victoria L. Bautch 
                                                                                                                              Kathleen Caron 
                                                                                                                              Albert S. Baldwin                                                                                                                          
                           Gregory Matera 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2014 
Marta S. Charpentier 
ALL RIGHTS RESERVED 
iii 
 
ABSTRACT  
Marta S. Charpentier: Characterization of the CASZ1-dependent mechanisms underlying 
vertebrate blood vessel development  
(Under the direction of Frank L. Conlon) 
 
 The vascular system is the first organ system to form during embryonic development. Its 
proper establishment is required for embryonic growth and survival as well as tissue 
homeostasis. Blood vessels are comprised of endothelial cells which must coordinate multiple 
behaviors such as migration, adhesion, sprouting, and proliferation to properly assemble into 
cord-like structures and then undergo further remodeling and branching to form a patent vascular 
network. Disruptions in these processes result in a number of human disease states including 
tumorigenesis, stroke, and atherosclerosis necessitating a better understanding of the factors and 
pathways that regulate these key developmental steps. Despite the large number of identified 
growth factors and proteins that are critical for vascular development, the field still lacks a 
thorough understanding of how endothelial gene programs are regulated. CASTOR (CASZ1) is 
an evolutionarily conserved transcription factor expressed in the cardiovascular system. 
Mutations in the human Casz1 locus have been recently genetically associated with 
cardiovascular disease risk factors including hypertension and high blood pressure although the 
mechanisms by which CASZ1 functions in vascular biology are unknown. 
 
 Here we demonstrate that CASZ1 is critical for proper vascular assembly and 
morphogenesis during embryonic development. Mechanistically, we have determined that 
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CASZ1 directly binds to and regulates the expression of Epidermal growth factor-like domain 7 
(Egfl7), an extracellular matrix (ECM) protein previously implicated in vessel sprouting and 
vascular lumen formation. We further showed that the CASZ1/Egfl7 transcriptional pathway is 
required to promote the activation of the RhoA GTPase signaling pathway to directly modulate 
endothelial cell adhesion, proliferation, and cell shape in order to support proper cellular 
behavior for vessel development. Moreover, for the first time we have uncovered the molecular 
and cellular basis for vascular lumen formation in Xenopus and show that EGFL7 is required for 
the proper cell shape changes and resolution of cell-cell junctions necessary to facilitate the 
transition of cord-like structures into functional vascular tubes. Collectively, this work provides 
insight into how transcription factors, ECM proteins, and intracellular signaling pathways are 
coordinated to achieve timely and appropriate assembly of a hierarchically branched and 
perfusable vascular network. 
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CHAPTER 1: INTRODUCTION
1
 
        
 The cardiovascular system is one of the first organ systems to arise during 
embryogenesis. Its proper establishment during early development is critical for meeting the 
demands of a rapidly growing embryo in need of nutrients, oxygen, and waste removal. 
Vertebrate blood vessels develop via two distinct mechanisms known as vasculogenesis and 
angiogenesis. During vasculogenesis, the de novo assembly of new blood vessels, a subset of 
mesodermal cells differentiates into endothelial cell (EC) precursors called angioblasts. 
Angioblasts proliferate and migrate to specified positions in the embryo where they coalesce into 
cord-like structures to form the primary vascular plexus. These early EC behaviors are elicited 
through growth factor-mediated signaling including vascular endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), and bone morphogenetic protein (BMP) (Patel-Hett and 
D'Amore, 2011). Rapidly thereafter, endothelial cords transform into patent tubes and become 
further specified to contribute to either the venous, arterial, or lymphatic vasculature (Swift and 
Weinstein, 2009). The primitive plexus undergoes dramatic remodeling during angiogenesis 
when new vessels sprout, elongate, and expand to form a complex network of arteries and veins. 
Henceforth, the majority of vascular development proceeds via angiogenesis, which can also be 
sub-divided into two processes. In sprouting angiogenesis, new vessels branch from preexisting 
                                                          
1
This chapter previously appeared as a review article in the journal BioEssays. The original citation is as follows: 
Charpentier M.S. and Conlon F.L. Cellular and molecular mechanisms underlying blood vessel lumen formation. 
BioEssays 36, no.3 (March 2014): 251.   
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vessels whereas in intussusceptive angiogenesis, existing vessels internally split to form new 
vessels (Djonov et al., 2000; Eilken and Adams, 2010). In later stages of vascular remodeling, 
mural cells including smooth muscle cells and pericytes, are recruited to surround the EC-lined 
tubes and impart vessel stabilization and maturation (Potente et al., 2011).  
 
 In the adult, the vasculature is mostly quiescent, with little to no vessel growth or 
remodeling. However, in response to injury, reduced oxygen or hypoxic conditions, 
inflammation, tumor growth, or pregnancy, ECs are poised to react and form new blood vessels 
in a process known as neoangiogenesis. The ability of a cohort of ECs to dynamically assemble 
into a vascular network is remarkable, given the multitude of individual cellular behaviors that 
must first be coordinated, including migration, cell-cell and cell-extracellular matrix (ECM) 
adhesion, proliferation, ECM degradation, and sprouting. Therefore, it is not surprising that 
dysregulation of these behaviors can have detrimental effects on health and survival; for 
example, during the pathogenesis of numerous vascular diseases, including atherosclerosis and 
myocardial ischemia, as well as during tumor progression (Chappell and Bautch, 2010; Potente 
et al., 2011). Understanding the cellular and molecular mechanisms underlying EC behavior will 
provide a basis for the development of therapeutics for these diseases. 
 
 Over the years, substantial contributions have been made toward understanding the 
mechanisms underlying sprouting angiogenesis that have significantly impacted the development 
of therapeutics that promote or inhibit vessel growth in a wide range of diseases (Carmeliet and 
Jain, 2011a; Said et al., 2013). Considerably less is known about the lumen formation process, 
critical for establishing a patent and functional vascular system during development as well as 
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for efficient delivery of therapeutics to their targets during disease treatment. In this review, we 
will discuss the diverse mechanisms by which the lumens of various vascular beds arise. 
Although there is some debate as to which of these mechanisms predominate during 
development, the identification of several molecules and models of lumen formation has without 
a doubt shed light on this seemingly mysterious process, and has in recent years greatly 
expanded the number of groups now studying lumen morphogenesis.  
 
Vessel Lumens Arise by Distinct Mechanisms  
 The ability to culture primary mammalian ECs has significantly enabled the study of 
cellular behaviors associated with blood vessel assembly, such as proliferation, motility, and 
sprouting angiogenesis. The recent advent of three-dimensional models has further enhanced the 
ability to visualize EC morphogenesis into vascular tubes (Davis et al., 2000; Kleinman and 
Martin, 2005; Nakatsu et al., 2003; Nehls and Drenckhahn, 1995). Specifically, in response to 
suspension in three-dimensional collagen or fibrin matrices, human umbilical vein endothelial 
cells (HUVECs) were shown to individually generate luminal spaces via a vacuolation 
mechanism known as cell hollowing. Live imaging revealed that cells use pinocytosis to 
internalize the plasma membrane and generate multiple vesicles that coalesce to form an 
intracellular lumen, defined as an ECM-free space surrounded by a single EC (Davis and 
Bayless, 2003). Contacts made between adjacent cells facilitate the fusion of vacuoles, resulting 
in a network of capillary-like tubes (Figure 1.1A). This process depends on signaling between 
ECs and the ECM via integrins, particularly integrin α2β1 in collagen matrices, and integrins 
αvβ3 and α5β1 in fibrin matrices (Bayless et al., 2000; Davis and Camarillo, 1996). Although 
these observations were made in cultured cells in a manipulated environment, the generation of 
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an intracellular lumen via vacuolation was also observed in zebrafish intersegmental vessels 
(ISVs) (Kamei et al., 2006).  
 
 Recent studies, however, have indicated that the lumen is more often generated 
extracellularly where it lies between two adjacent ECs connected by junctions, raising questions 
regarding whether cell vacuolation is the primary mechanism of lumen formation (Figure 1.1B). 
Also known as cord hollowing, in the mouse dorsal aorta (DA) adjacent ECs are initially in 
contact with one another via adherens junctions (Strilic et al., 2009). The cells become polarized 
even before beginning to separate from each other with a number of molecules localizing 
specifically to the apical surface where the lumen will be generated. The establishment of 
apicobasal polarity is suggested to further promote cell separation by causing junctions to 
redistribute away from the cell-cell interface to the periphery. Furthermore, small GTPase 
signaling was also shown to enhance EC elongation in order to accommodate the luminal 
compartment in the center (Strilic et al., 2009). In addition to the mouse DA, extracellular 
lumens also arise in zebrafish ISVs. In contrast to the idea that intracellular vacuoles reside 
within the ISV ECs and fuse to form a seamless unicellular tube, labeling of multiple junction 
and polarity markers has in fact revealed that cells first establish apical polarity and form 
complex junctions that dynamically rearrange to generate a multicellular tube containing an 
extracellular lumen (Blum et al., 2008; Wang et al., 2010). However, ISV lumens are not 
generated strictly by cord hollowing as Wang et al. showed that the formation and fusion of 
vacuoles within ISVs also promote rapid expansion of the luminal compartment (Wang et al., 
2010). 
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  It is therefore increasingly clear that vessels arise in a heterogeneous manner and likely 
use a number of mechanisms to conveniently and efficiently generate lumens. Extracellular 
lumen formation may be the predominant mechanism by which major vessels such as the DA 
form, whereas small-calibre vessels like the ISVs and capillaries, which have also been 
demonstrated to resemble unicellular tubes in rats (Yoshida et al., 1989), may use a combination 
of both cord and cell hollowing. Nonetheless, analyses of the molecular determinants of 
extracellular and intracellular lumen formation have greatly contributed to our understanding of 
the cellular processes that must be coordinated in order to promote this complex step of blood 
vessel development (Table 1.1).  
 
Vessels Remodel Lumens During Branching and Fusion 
 The processes described above reveal how the lumen forms de novo and independently of 
blood flow. More frequently, new vessels are formed during anastomosis, or fusion between two 
distinct perfused vessels that must combine luminal compartments to give rise to a patent 
network. The formation of the zebrafish dorsal longitudinal anastomosing vessel (DLAV) occurs 
via anastomosis between adjacent segmental arteries (Herwig et al., 2011). The DLAV is 
comprised of both multicellular and, in the majority of cases, unicellular tubes. Using a 
transgenic line expressing the tight junction molecule zonula occludens-1 (ZO-1) tagged to GFP, 
Herwig et al. found that multicellular lumens are generated by the rearrangement of junctions 
between three adjacent cells, resulting in the establishment of new contacts between the outer 
cells and the merging of local lumens into one continuous luminal compartment. Conversely in 
most instances, junctions between two cells are not as dynamic. Instead, a lumen is generated 
within a single cell by invagination of the apical membrane throughout the length of the cell 
resulting in a unicellular tube with an intracellular lumen. The luminal membrane of this single 
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cell invaginates through the point of cell-cell contact to ultimately fuse with the neighboring 
lumen (Herwig et al., 2011). 
 
 The presence of unicellular tubes is not unique to the DLAV and is conserved in other 
zebrafish vessels, such as the palatocerebral artery (PLA) in the cranial vasculature (Lenard et 
al., 2013). Using a similar fusion process, two distinct lumenized sprouts come into contact with 
each other, marked by junction markers such as ZO-1, and combine their luminal compartments 
by apical membrane invagination, resulting in two adjoining unicellular tubes comprised of 
intracellular lumens. However, later remodeling events reveal that these unicellular vessels are 
transient, and multicellular tubes take precedence within the PLA. The two cells adjacent to the 
unicellular tube are initially not in contact with each other but move and redistribute their 
junctions to form a new contact, thereby forcing the cell comprising the unicellular tube to split 
to one side of the tube (Figure 1.2). Therefore, an extracellular lumen surrounded by multiple 
ECs is generated, analogous to the mouse DA lumen assembled via cord hollowing. In both the 
DLAV and PLA, apical membrane invagination and the subsequent generation of the lumen is 
dependent on blood flow, likely because of the force generated by increased blood pressure. 
However, polarity and junctional rearrangements still take place in the absence of flow (Herwig 
et al., 2011; Lenard et al., 2013).      
 
 The presence of vacuole-like structures was not addressed in the above zebrafish studies 
and hence it is debatable whether vacuole coalescence and apical membrane invagination truly 
represent distinct mechanisms of lumen formation. However, because in both cases the lumen is 
completely surrounded by a single cell and devoid of any junctions throughout the unicellular 
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region, vacuole coalescence and apical membrane invagination can likely be annotated as sub-
categories of intracellular lumen formation (Figure 1.1A). It is also unknown what molecular 
forces govern lumen formation during vessel fusion. Because several distinct cellular behaviors 
are necessary for successful anastomosis, including migration, sprouting, and adhesion, it may be 
difficult to tease apart the specific molecular mechanism underlying apical membrane 
invagination and subsequent cell splitting. It is likely that multiple mechanisms are involved, and 
that different combinations of interacting factors and intersecting signaling pathways at each step 
of vascular morphogenesis may elicit more precise cellular responses.  
 
The Establishment of Polarity Initiates Lumen Formation 
Distinct Surface Markers Define the Apical and Basal Membranes 
 Despite the distinction between intracellular, extracellular, and transcellular lumens, a 
common theme reconciling these differences is that in all cases, cells must first establish polarity 
to define the apical/luminal ("inside") and basal/abluminal ("outside") vessel surface (Lizama 
and Zovein, 2013). This specialized distinction between the inside and outside of the tube is not 
unique to ECs. Multiple other tubular organs such as the kidney and intestine also display 
apicobasal polarity, and many of the molecular players currently being investigated in vessel 
lumen formation unsurprisingly have reported roles in epithelial tubulogenesis as well 
(Rodriguez-Fraticelli et al., 2011). 
 
 A number of markers have been established that have preferential localization to either 
the apical or basal side of EC-lined tubes. Notably, cell-surface transmembrane proteins such as 
the CD34 sialomucins, consisting of CD34 and podocalyxin-like proteins 1 and 2 
(PODXL/PODXL2), and the Ezrin-Radixin-Moesin (ERM) protein moesin are enriched at the 
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apical membrane (Lampugnani et al., 2010; Nielsen and McNagny, 2008; Strilic et al., 2009; 
Wang et al., 2010). However, the function of these proteins extends beyond expression at the 
apical surface. The negatively charged sialic acids coating the extracellular domain of the CD34 
sialomucins are required for the electrostatic repulsion needed to separate the adjoining ECs 
from each other to accommodate the central luminal compartment (Strilic et al., 2010a). 
Furthermore, in PODXL-null mice, moesin no longer localizes to the apical membrane of the 
early DA, and only 40% of lumens fully develop (Strilic et al., 2009). ERM proteins modulate 
cytoskeletal dynamics and signal transduction by anchoring the actin cytoskeleton to various 
transmembrane proteins (Fehon et al., 2010; Speck et al., 2003). Accordingly, moesin depletion 
was associated with significantly diminished F-actin enrichment at the apical surface of the 
developing mouse DA and zebrafish ISVs, ultimately resulting in reduced or failed lumen 
formation (Strilic et al., 2009; Wang et al., 2010). In addition, the partition-defective (Par) 
polarity complex (Par3/Par6/atypical protein kinase C [aPKC]) has also been implicated in apical 
polarity in epithelial and ECs, and disruption of the Par complex is strongly associated with 
failed lumen formation (Joberty et al., 2000). Depletion of Par3 and Par6 in HUVECs embedded 
in collagen matrices results in failed intracellular lumen formation, whereas chemical inhibition 
of PKC in the mouse DA prevents moesin phosphorylation and subsequent lumen generation 
(Koh et al., 2008; Strilic et al., 2009). 
 
 On the basal surface of the vessel, ECs contact various constituents of the ECM that 
facilitate interactions with mural cells as well as influence whether vessels will become stable 
and quiescent or "activated" to sprout (Hynes, 2007). Basement membrane markers include 
fibronectin, laminin, collagen IV, and integrins. A recent study suggests that this specialized 
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separation of apical and basal membranes in vertebrate blood vessels is a consequence of EC 
evolution. Unlike vertebrate vessels, the lumen of the aorta in the invertebrate cephalochordate 
amphioxus, which lacks ECs, is directly lined with the laminin-containing basement membrane 
implying that ECs serve to separate basal surfaces from the luminal compartment (Kucera et al., 
2009; Strilic et al., 2010b). 
 
VE-Cadherin Promotes Proper Localization of Polarity Markers 
 What is the basis for initiating polarity in the first place? In the case of extracellular 
lumen formation, ECs first coalesce into cords where they adhere to each other via adherens 
junctions. Numerous markers, such as β-catenin and N-cadherin, constitute adherens junctions in 
multiple cell types. Vascular endothelial (VE)-cadherin (also known as Cdh5), however, 
specifically marks junctions in ECs (Lampugnani, 2012). Far from simply labeling cell-cell 
junctions, VE-cadherin plays a critical role in vascular morphogenesis. VE-cadherin deficiency 
in mice results in early embryonic lethality due to severe vascular defects, including failed 
establishment of yolk sac vasculature, disorganized and disconnected embryonic vessels, and 
notably, minimal or absent lumens (Carmeliet et al., 1999; Gory-Faure et al., 1999). A functional 
vascular network also fails to form in VE-cadherin-depleted zebrafish embryos in which vessel 
lumens are small (or absent) and fail to connect to form a complete circulatory loop (Montero-
Balaguer et al., 2009). In the adult, VE-cadherin is essential for maintaining vascular 
homeostasis and endothelial barrier integrity (Dejana et al., 2008; Dejana and Vestweber, 2013).  
 
 Subsequent studies in cultured ECs as well as in vivo have determined that the molecular 
basis for aberrant lumen morphogenesis in VE-cadherin-deficient animals is associated with 
impaired establishment of cell polarity. In VE-cadherin null mouse DAs, apical markers such as 
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CD34, PODXL, and moesin fail to localize to the cell-cell contact, and consequently lumens do 
not form (Strilic et al., 2009). These results were confirmed in detailed analyses of VE-cadherin-
depleted zebrafish where it was noted that moesin was no longer enriched at the luminal surface 
of the ISVs (Wang et al., 2010). In addition, the distribution of ZO-1-containing junctions was 
disorganized in VE-cadherin-depleted zebrafish, indicating a role for VE-cadherin in maintaining 
adherens junctions as well as tight junctions. Tubular HUVEC networks in collagen matrices 
also display specific localization of apical and basal markers (Lampugnani et al., 2010). 
However, in the absence of VE-cadherin, PODXL and collagen IV are aberrantly localized with 
little distinction between apical and basal membranes. Consequently, there are multiple small 
lumens instead of one central compartment. In addition, members of the Par complex are also 
absent from cell-cell contacts in VE-cadherin-depleted cells (Lampugnani et al., 2010). 
Moreover, VE-cadherin has been shown to directly associate with Par3 and Par6 in cultured ECs, 
strongly suggesting that the interplay between junctional and polarity molecules promotes lumen 
formation (Iden et al., 2006) (Figure 1.3). Interestingly, VE-cadherin is not required for polarity 
during PLA anastomosis. Instead, it is needed to stabilize the initial contact made between fusing 
sprouts, implying diverse roles for this junctional marker during various steps of vascular 
assembly (Lenard et al., 2013).   
 
Transcriptional Regulation of Lumen Formation  
CASTOR (CASZ1) 
 Transcriptional regulation of blood vessel development has been extensively studied, and 
numerous transcription factors have been identified that regulate endothelial gene expression (De 
Val, 2011; Park et al., 2013). However, because many of these factors fall in common families, 
such as the Ets and forkhead factors, deletion or mutation of individual genes results in little to 
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no vascular phenotypes, likely due to functional redundancy or cooperative regulation (Barton et 
al., 1998; De Val, 2011; De Val and Black, 2009; Lelievre et al., 2001). Recent work has 
provided evidence for a novel transcription factor, CASTOR (CASZ1), in vascular biology 
(Charpentier et al., 2013a). CASZ1 is an evolutionarily conserved para-zinc finger factor 
expressed in multiple tissues, including the cardiovascular system, across vertebrate species 
(Charpentier et al., 2013a; Christine and Conlon, 2008; Zaidel-Bar et al., 2007). Consistently, 
CASZ1 is required for cardiomyocyte differentiation and subsequent heart formation in Xenopus 
embryos (Christine and Conlon, 2008). Independent of its cardiac function, CASZ1 was recently 
shown to be required for blood vessel assembly and lumen formation (Charpentier et al., 2013a; 
Charpentier et al., 2013b). In CASZ1-depleted Xenopus embryos, ECs are properly specified but 
rather than assembling into a dense vascular network, vessels fail to branch and form an 
incomplete network of thickened cords that predominately run laterally to each other. 
Furthermore, vessels such as the posterior cardinal veins fail to form lumens. Recent genome-
wide association studies have uncovered a genetic link between the human Casz1 locus and 
hypertension, implying a role for CASZ1 in cardiovascular disease in addition to development 
(Takeuchi et al., 2010).  
 
CASZ1 Regulates Expression of ECM Factors During Vascular Development 
 The molecular mechanisms by which CASZ1 functions in the heart and vasculature 
remain to be elucidated. Thus far, efforts to identify direct transcriptional targets of CASZ1 have 
been restricted to the Xenopus cardiovascular system. Targets were isolated using a cloning 
chromatin immunoprecipitation method from dissected cardiovascular-enriched regions 
(Charpentier et al., 2013a; Charpentier et al., 2013b). One gene that was confirmed to be directly 
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bound and activated by CASZ1 was Epidermal Growth Factor-Like Domain 7 (Egfl7; also 
known as VE-statin). EGFL7 is a 30 kD protein secreted exclusively by ECs during embryonic 
development (Fitch et al., 2004; Parker et al., 2004). In the adult vasculature, Egfl7 levels are 
significantly reduced, but expression is upregulated in response to neoangiogenesis during injury 
repair, inflammation, and tumor growth (Fan et al., 2013; Nichol and Stuhlmann, 2012; Nikolic 
et al., 2010). Parker et al. were the first to demonstrate a role for EGFL7 in vessel lumen 
formation. In EGFL7-depleted zebrafish, ECs of several primary vessels fail to separate, 
resulting in disorganized or absent lumens (Parker et al., 2004). Using in vitro assays, these 
authors also showed that primary ECs retain stronger adhesion to substrates such as fibronectin 
and collagen I compared to EGFL7, thus implying that EGFL7 may provide a permissive 
environment for cell motility and vascular assembly. These results corroborate the Xenopus 
studies in which depletion of EGFL7 phenocopies depletion of CASZ1, resulting in reduced 
vessel branching and failed lumen formation (Charpentier et al., 2013a). Furthermore, analyses 
of transgenic mice expressing Egfl7 under the Tie2 promoter revealed abnormal EC aggregates, 
collapsed or uneven lumens, and knot-like structures within the veins, further implicating EGFL7 
in vascular patterning and morphogenesis (Nichol et al., 2010). However, the recent discovery of 
the microRNA miR-126 within the Egfl7 locus has caused some controversy over the specific 
function of EGFL7 because many of the earlier phenotypes attributed to deletion of EGFL7 were 
in fact due to the loss of miR-126 (Kuhnert et al., 2008; Schmidt et al., 2007). miR-126 is 
required for vascular integrity maintenance and VEGF-mediated angiogenesis, functions similar 
to, but not identical to, those described for EGFL7 (Fish et al., 2008; Wang et al., 2008). Hence, 
although EGFL7 acts initially to open vessel lumens early during vascular development, miR-
126 may serve to fine-tune later remodeling events and keep patent vascular networks stable.  
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  Interactions between ECs and their microenvironment are clearly significant for eliciting 
the proper behaviors associated with vascular assembly. However, the specific function of many 
ECM constituents, including EGFL7, remains unclear. Identification of interaction partners of 
EGFL7 and potential downstream signaling pathways are only beginning to be illuminated. 
Through interactions with the lysyl oxidase (LOX) enzymes, EGFL7 has been shown to 
negatively affect vascular elastogenesis, a process in which elastic fibers are deposited into the 
ECM and must be regulated to maintain proper blood vessel stretch and resiliency (Lelievre et 
al., 2008). EGFL7 has also been shown to antagonize Notch signaling in HUVECs, whole mouse 
embryos, and cultured neurospheres via its interaction with Notch receptors, particularly 
NOTCH4 (Nichol et al., 2010; Schmidt et al., 2009). Recently, EGFL7 was shown to interact 
with integrin αvβ3 to promote proper vessel structure and angiogenic sprouting (Nikolic et al., 
2013). However, it is still unclear how these interactions contribute to the role of EGFL7 during 
lumen formation.  
 
 The importance of EGFL7 in vascular assembly and morphogenesis is highlighted by 
current clinical trials in which antibodies against EGFL7 are being tested as tumor growth-
suppressing therapies in the treatment of colorectal cancer and non-small cell lung cancer 
(Parsatuzumab; http://www.gene.com/medical-professionals/pipeline). Understanding the mode 
of function and affected downstream pathways of such drug targets is beneficial for the potential 
discovery of new targets and may reveal a link to other pathways for which therapies have been 
developed, thereby providing potentially efficacious treatment options through combinatorial 
dosages of anti-EGFL7 and other known growth-suppressing agents.  
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Small GTPases Modulate the Cytoskeleton to Facilitate Lumen Formation   
 In addition to cell-cell contact and the establishment of polarity, lumen morphogenesis 
requires cells to make dynamic contacts with the underlying ECM as well as rearrange their 
internal actin cytoskeleton to adopt a suitable shape conducive to expansion of the luminal 
compartment. Directly involved in regulating cell motility and cytoskeletal organization, the Rho 
family of small GTPases has been at the forefront of cell biology for decades. The number of 
studies on their downstream effectors, roles in diverse biological processes such as gene 
expression, proliferation, and membrane trafficking, and implications for human health is 
continually growing (Burridge and Wennerberg, 2004; Karlsson et al., 2009; Parsons et al., 
2010). The most well-known GTPases, RhoA, Rac1, and Cdc42, have been extensively 
characterized in fibroblasts, where they have critical roles in organizing the actin cytoskeleton 
during cell migration and mitosis (Maddox and Burridge, 2003; Nobes and Hall, 1995a, b; Olson 
et al., 1995). It is therefore unsurprising that ECs also depend on GTPase activity for a multitude 
of cellular behaviors. However, the functions of the Rho GTPases in vascular development and 
disease are only just beginning to be uncovered, including their roles in lumen formation.  
 
Rac1 and Cdc42 Positively Regulate Lumen Formation 
 Rac1 and Cdc42 are classically known to promote lamellipodial and filopodial 
protrusions, respectively, at the leading edge of migrating cells including fibroblasts, ECs, and 
smooth muscle cells (Nobes and Hall, 1995b; Ridley, 2006; Ridley et al., 1992). Early cell 
culture studies first showed that Rac1 and Cdc42 have distinct functions in ECs, such as 
stabilizing cell-cell junctions to regulate vascular permeability and mediating downstream 
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signaling in response to shear stress (Beckers et al., 2010; Broman et al., 2006; Hoang et al., 
2011a, b; Spindler et al., 2010; Tzima et al., 2002; Wojciak-Stothard et al., 2001). Although 
global Rac1 inactivation in mice results in defects far preceding vascular development, 
endothelial-specific ablation of Rac1 results in embryonic lethality at slightly later stages with 
severe defects in angiogenic sprouting and remodeling of secondary vessels (Sugihara et al., 
1998; Tan et al., 2008). Genetic inactivation of Rac1 in cultured ECs reinforced the requirement 
for Rac1 in adhesion, migration, and tube assembly (Tan et al., 2008). Similarly, global ablation 
of Cdc42 also results in early developmental abnormalities prior to vessel development (Chen et 
al., 2000), however, mouse embryonic stem cells devoid of Cdc42 fail to assemble into vascular 
networks during embryoid body differentiation due to impaired directional migration (Qi et al., 
2011). Very recently, an endothelial-specific Cdc42-null mouse has been generated and displays 
severe defects in overall vasculogenesis likely due to increased EC apoptosis (Jin et al., 2013).  
 
 Rac1 and Cdc42 have been strongly implicated in promoting formation of epithelial tubes 
and therefore, have recently been the targets of study during vascular tubulogenesis (Jaffe et al., 
2008; Liu et al., 2007; Myllymaki et al., 2011). Indeed, inhibiting Rac1 or Cdc42 activity or 
expression in HUVECs suspended in collagen matrices prevents cell vacuolation and subsequent 
lumen formation (Bayless and Davis, 2002; Koh et al., 2008). Furthermore, signaling 
downstream of Rac1 and Cdc42 that is associated with polarity (Par complex) and cytoskeletal 
dynamics (Pak2/Pak4) is also required for intracellular lumen formation in collagen matrices 
(Koh et al., 2008; Koh et al., 2009; Sacharidou et al., 2010). In vivo, Cdc42 localizes to 
intracellular vacuolar structures in zebrafish ISVs; however, studies to examine whether 
depleting Cdc42 in these vessels hinders lumen formation have yet to be performed (Kamei et 
30 
 
al., 2006). In a mouse skin model of angiogenesis, retroviral delivery of VEGF and a dominant 
negative form of Cdc42 decreased the size and number of perfusable vessels whereas the 
constitutively active form promoted formation of lumens, thereby supporting a positive role for 
Cdc42 in lumen generation (Hoang et al., 2011b). Rac1 has also been linked to in vivo lumen 
formation through its interaction with cerebral cavernous malformation-1 (CCM1) protein. In 
CCM1-depleted zebrafish embryos, although lumens of major vessels form normally, the lumens 
of the smaller ISVs fail to form, most likely because intracellular vacuoles are not generated (Liu 
et al., 2011a). In addition, depleting CCM1 in HUVECs inhibits Rac1 activity, implying that 
GTPase signaling downstream of CCM1 is necessary for lumen morphogenesis in microvessels. 
Taken together, these studies support a function for Rac1 and Cdc42 in lumen generation, 
additionally potentiating the hypothesis that intracellular lumen formation may indeed be a 
mechanism by which small-calibre vessels open and expand.  
 
RhoA Activity Must Be Tightly Controlled During Lumen Formation  
 The major physiological outputs of RhoA-mediated signaling in various cell types 
include the formation of focal adhesions between cells and their underlying substrates as well as 
formation of stress fibers that promote actomyosin contraction (Chrzanowska-Wodnicka and 
Burridge, 1996; Ridley and Hall, 1992). The role for RhoA in lumen morphogenesis has been 
controversial. Early studies showed that disrupted RhoA function had no effect on intracellular 
vacuole formation in collagen matrices (Bayless and Davis, 2002; Koh et al., 2008). However, 
later studies demonstrated that disruption of microtubules using chemical agents, an event known 
to activate RhoA, results in the collapse of lumens in three-dimensional assays. This is prevented 
when RhoA activity is inhibited, implying that increased RhoA activity in fact antagonizes the 
stability of tubular networks (Bayless and Davis, 2004). Furthermore, Xu et al. recently showed 
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that negative regulation of RhoA signaling via interaction between Ras-interacting protein 1 
(RASIP1) and the GTPase activating protein (GAP) Arhgap29 is required for lumen formation 
(Xu et al., 2011). In the absence of either interacting protein, RhoA activity increases but Rac1 
and Cdc42 levels are decreased, in agreement with studies highlighting the requirement for the 
former two GTPases in lumen formation. Consequently, cultured and mouse embryo ECs are 
unable to maintain adhesion to the underlying ECM and display polarity defects with improper 
localization of apical and basal markers. These data strongly suggest that de-regulation of RhoA 
activity prevents proper cell behaviors associated with lumen formation. 
 
 However, results from a number of studies conflict with the hypothesis that RhoA 
suppresses lumen formation and instead, propose a positive role for RhoA during this process. 
Introduction of VEGF and a dominant negative form of RhoA in mouse skin resulted in fewer 
new blood vessels, and in the vessels that did form, most did not contain lumens (Hoang et al., 
2004). Further evidence highlighting a requirement for RhoA signaling was demonstrated in the 
mouse DA, where normal lumen formation proceeds when F-actin and non-muscle myosin II 
first localize to the apical surface between the two opposing ECs (Strilic et al., 2009). In the 
presence of a Rho kinase (ROCK) inhibitor, F-actin correctly positions at the cell-cell contact; 
however, myosin II fails to colocalize with F-actin, thus resulting in defective lumen formation. 
These results indicate that RhoA downstream signaling through ROCK is required for the proper 
EC shape changes that facilitate opening of the luminal compartment.  
 
 More recently, a study demonstrated that RhoA lies downstream of a transcriptional 
cascade responsible for promoting proper endothelial cell adhesion, shape, and proliferation to 
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facilitate vessel assembly (Charpentier et al., 2013a; Charpentier et al., 2013b). The transcription 
factor CASTOR (CASZ1), previously implicated in cardiac development (Christine and Conlon, 
2008) and genetically linked to hypertension and high blood pressure (Takeuchi et al., 2010), and 
its direct target Epidermal Growth Factor Like-Domain 7 (Egfl7) are required for vessel 
branching and lumen formation in Xenopus embryos (Charpentier et al., 2013a). EGFL7 is an 
ECM-associated protein exclusively secreted by ECs during embryonic development that has 
been demonstrated to play a role in vessel morphogenesis (Fitch et al., 2004; Parker et al., 2004). 
In CASZ1 and EGFL7-depleted HUVECs, RhoA expression levels, and consequently activity, 
are significantly diminished, resulting in reduced stress fiber and focal adhesion formation 
associated with contractility defects and loss of adhesion between cells and their underlying 
substrate. These defects can be rescued by reintroduction of EGFL7 strongly suggesting that the 
CASZ1/Egfl7 transcriptional hierarchy is required for proper expression of RhoA and the cellular 
outputs associated with its activation (Figure 1.4) (Charpentier et al., 2013a). Therefore, these 
results would favor a model by which RhoA is necessary for eliciting the proper EC behaviors 
(i.e. cell shape and adhesion) for vascular morphogenesis to proceed. Whether reduced RhoA 
levels explain the impaired lumen formation in CASZ1 and EGFL7-depleted Xenopus embryos 
remains to be established. However, because these small GTPases likely have roles in numerous 
processes during vascular development, this is a situation where small animal models can be 
particularly valuable. Pharmacological inhibition or the use of caged morpholinos to inhibit 
GTPase activity in specific tissues during a tightly controlled temporal window can be useful in 
teasing apart these diverse roles (Deiters et al., 2010; Langdon et al., 2012; Morckel et al., 2012). 
Nonetheless, it is evident that too much or too little GTPase signaling, particularly RhoA, can be 
detrimental to vascular morphogenesis.  
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Endothelial Cells Enclose Around a Central Lumen via a Novel Mechanism  
 The molecular players and pathways discussed above have been deciphered based on two 
primary mechanisms of lumen morphogenesis: intracellular lumen formation via vacuole 
coalescence or membrane invagination and the formation of extracellular lumens via cell-cell 
separation. Nonetheless, characterization of these mechanisms has been confined to limited, 
albeit informative, vascular contexts, such as cultured ECs suspended in ECM matrices, the 
mouse DA, and zebrafish ISVs. Recent evidence has elucidated a new mechanism by which 
lumens form. Helker et al. demonstrated that the zebrafish common cardinal veins (CCVs), 
which bifurcate from the major posterior cardinal vein, develop a central compartment via a 
novel lumen ensheathment mechanism (Helker et al., 2013). In this model, specified angioblasts 
destined to become ECs of the CCV are first positioned in a monolayer on top of the yolk 
syncytial layer (YSL). These cells then detach from the YSL and migrate to the epidermal side, 
joining together and shaping a new lumen-containing tube located between the YSL and the 
epidermis, prior to the commencement of circulation. The cells continue to migrate as a sheet to 
extend the tube and connect it to the heart inflow tract. Interestingly, although VE-cadherin was 
shown to be required for detachment and migration of ECs during this process, establishment of 
apicobasal polarity does not appear to be a prerequisite for lumen formation, based on the 
absence of the apical marker PODXL2. Because the ECs are not initially in contact with each 
other during the detachment and ensheathment steps, perhaps defining the apical surface between 
adjacent cells is superfluous. However, it would be interesting to determine whether CCVs form 
properly in moesin-depleted fish or other polarity mutants.  
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Conclusion and Implications 
 With the amount of heterogeneity that occurs in different vascular beds throughout 
embryonic and neonatal development, it would not be surprising to identify additional 
mechanisms of lumen formation. The assembly of the vasculature through distinct processes 
such as de novo EC coalescence into cords, angiogenesis, anastomosis, or in response to 
mechanical forces such as blood flow, may directly influence how the lumen is generated, 
expanded, and maintained. With advances in imaging technology and more detailed 
understanding of the spatial and temporal requirements of critical molecules during vascular 
morphogenesis, the discovery of novel lumen formation mechanisms is very likely (Table 1.1). 
The need for effective cancer therapies continues to sustain drug development industries, and 
trials testing the efficacy of anti-angiogenic therapies in controlling tumor vasculature growth are 
ongoing (Meadows and Hurwitz, 2012). Although the majority of current treatments are aimed at 
inhibiting vessel growth and expansion in order to starve tumors of oxygen and induce 
shrinkage, a seemingly contradictory idea know as "vascular normalization" has emerged 
(Carmeliet and Jain, 2011b). The tumor vasculature is highly abnormal; vessels are tortuous, 
leaky, uneven, and disorganized. Inducing tumor vessels and ECs to become more "normal" by 
stabilizing junctions and recruiting mural cells to provide cohesive coverage of EC-lined tubes 
may lead to improved perfusion of drugs and soluble factors directly to the tumor site as well as 
reduce the chance of metastasis. Obviously, these outcomes are concomitant with the presence of 
an impermeable, stable lumen. Thus, a greater understanding of lumen morphogenesis, 
particularly the molecular players involved, may contribute to new approaches for normalizing 
tumor vessels.  
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Figure 1.1. Mechanisms of blood vessel lumen formation. (A) Intracellular lumens refer to 
hollow spaces enclosed by a single endothelial cell and devoid of junctions. Intracellular lumen 
formation can be sub-divided into two mechanisms. (i) During vacuole coalescence (top panel), 
individual endothelial cells generate vacuole-like structures through membrane internalization. 
The vacuoles fuse to form a hollow compartment devoid of ECM. Therefore, when vacuolated 
cells assemble to form a network, contacts between adjacent cells are made (purple rectangles) 
however no junctions are found interrupting the cell-lumen boundary resulting in a unicellular 
tube. (ii) In apical membrane invagination (middle panel), once two distinct vessels (blue vs. 
pink) have established contact (purple oval), the luminal compartment is expanded by 
invagination of the membrane (light blue/pink). The membrane continues to extend through the 
point of contact resulting in one continuous lumen. Each cell now makes up a unicellular tube 
containing an intracellular lumen within the patent vessel. (B) During extracellular lumen 
generation (bottom panel), endothelial cells first form adherens junctions between their contact 
surfaces to generate cord-like structures. These junctions become redistributed from the center of 
the contact region to the periphery in order to allow a luminal compartment to take shape 
between the cells. Thus, multicellular tubes are generated in which the lumen is surrounded by 
two or more endothelial cells that remain in contact with each other as well as with adjacent 
cells.   
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Figure 1.2. Lumen formation during vessel fusion.  Unicellular tubes remodel into 
multicellular tubes by cell splitting. (A) Two unicellular tubes (blue and pink) are flanked by 
multicellular tubes (green/yellow and red/brown) with junctions represented by purple ovals. (B) 
Two cells flanking the blue unicellular tube (yellow and pink) rearrange their junctions and 
approach each other (black arrows) while the blue cell is forced to split to one side of the vessel 
(white arrow). (C) The yellow and pink cells establish a new contact (gray oval) and the blue cell 
has narrowed to one side of the vessel incorporating into a multicellular tube. (D) The second 
unicellular tube (pink) is now flanked by the blue and red cells which rearrange their junctions 
and approach each other (black arrows) forcing the pink cell to the opposite side (white arrow). 
(E) The blue and red cells establish a new contact (gray oval) and the whole vessel is now 
comprised of multicellular tubes.  
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Figure 1.3. Role of VE-Cadherin in establishment of polarity. In the presence of VE-
Cadherin (left panel), endothelial cells establish proper polarity with a specified apical surface, 
as marked by proteins such as the CD34 sialomucins, the ERM protein moesin, and members of 
the Par polarity complex, and a basal surface marked by ECM constituents and integrins. 
However, when VE-Cadherin is absent (right panel), apical and basal markers are disorganized 
and fail to localize to the appropriate surface resulting in smaller or absent vessel lumens. 
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Figure 1.4. RhoA lies downstream of the CASZ1/Egfl7 transcriptional network. (A) The 
zinc-finger transcription factor CASZ1 binds to and activates expression of Egfl7 in endothelial 
cells (top panel). EGFL7 is then secreted to the ECM and by a yet unknown mechanism, 
promotes RhoA expression and subsequent GTPase activity (star) leading to proper EC shape 
and adhesion to the substrate (as indicated by blue lines). (B) In the absence of CASZ1 (bottom 
panel), transcriptional regulation of Egfl7 is dysregulated and RhoA expression is diminished 
resulting in thin, elongated cells that no longer maintain adhesion to the substrate and eventually 
round up and detach.  
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Table 1.1. Molecular determinants that play diverse roles during lumen morphogenesis.   
Molecule Function/Localization during Lumen 
Formation 
Model System Reference 
VE-Cadherin Localizes to adherens junctions in ECs; 
Establishes apicobasal polarity 
Mouse, 
zebrafish, 
cultured ECs 
(Carmeliet et al., 1999; Gory-Faure et al., 1999; 
Lampugnani et al., 2010; Montero-Balaguer et 
al., 2009; Strilic et al., 2009; Wang et al., 2010) 
Par complex 
(Par3-Par6-
aPKC) 
Promotes endothelial polarization; Associates 
with tight and adherens junctions 
Mouse, cultured 
ECs 
(Iden et al., 2006; Koh et al., 2008; Strilic et al., 
2009; Zovein et al., 2010) 
Moesin Localizes to apical membrane; Recruits F-
actin to apical surface 
Mouse, 
zebrafish 
(Strilic et al., 2009; Wang et al., 2010) 
CD34/PODXL Localize to apical membrane; sialic acids 
promote cell-cell separation 
Mouse, cultured 
ECs 
(Lampugnani et al., 2010; Strilic et al., 2010a; 
Strilic et al., 2009) 
Rac1/Cdc42 Localize to vacuolar structures; Mediate 
downstream signaling during intracellular 
lumen formation 
Mouse, 
zebrafish, 
cultured ECs 
(Bayless and Davis, 2002; Hoang et al., 2011a, b; 
Kamei et al., 2006; Koh et al., 2008; Koh et al., 
2009; Liu et al., 2011a) 
RhoA Positive and negative roles; Modules proper 
adhesion to ECM and ROCK-mediated shape 
changes 
Mouse, cultured 
ECs 
(Bayless and Davis, 2004; Charpentier et al., 
2013a; Hoang et al., 2004; Strilic et al., 2009; Xu 
et al., 2011)  
Rasip1 Regulates RhoA activity with Arhgap29 to 
promote lumen formation 
Mouse, cultured 
ECs 
(Xu et al., 2011) 
Casz1 Binds and maintains Egfl7 expresion in ECs Xenopus, 
cultured ECs 
(Charpentier et al., 2013a) 
Egfl7 Secreted into ECM and required for initial 
establishment of lumens but specific function 
still unknown 
Xenopus, 
zebrafish, 
cultured ECs 
(Charpentier et al., 2013a; Parker et al., 2004) 
41 
 
REFERENCES 
Bayless, K.J., and Davis, G.E. (2002). The Cdc42 and Rac1 GTPases are required for capillary 
lumen formation in three-dimensional extracellular matrices. J Cell Sci 115, 1123-1136. 
 
Bayless, K.J., and Davis, G.E. (2004). Microtubule depolymerization rapidly collapses capillary 
tube networks in vitro and angiogenic vessels in vivo through the small GTPase Rho. J Biol 
Chem 279, 11686-11695. 
 
Bayless, K.J., Salazar, R., and Davis, G.E. (2000). RGD-dependent vacuolation and lumen 
formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices 
involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol 156, 1673-1683. 
 
Beckers, C.M., van Hinsbergh, V.W., and van Nieuw Amerongen, G.P. (2010). Driving Rho 
GTPase activity in endothelial cells regulates barrier integrity. Thromb Haemost 103, 40-55. 
 
Blum, Y., Belting, H.G., Ellertsdottir, E., Herwig, L., Luders, F., and Affolter, M. (2008). 
Complex cell rearrangements during intersegmental vessel sprouting and vessel fusion in the 
zebrafish embryo. Dev Biol 316, 312-322. 
 
Broman, M.T., Kouklis, P., Gao, X., Ramchandran, R., Neamu, R.F., Minshall, R.D., and Malik, 
A.B. (2006). Cdc42 regulates adherens junction stability and endothelial permeability by 
inducing alpha-catenin interaction with the vascular endothelial cadherin complex. Circ Res 98, 
73-80. 
 
Burridge, K., and Wennerberg, K. (2004). Rho and Rac take center stage. Cell 116, 167-179. 
 
Carmeliet, P., and Jain, R.K. (2011a). Molecular mechanisms and clinical applications of 
angiogenesis. Nature 473, 298-307. 
 
Carmeliet, P., and Jain, R.K. (2011b). Principles and mechanisms of vessel normalization for 
cancer and other angiogenic diseases. Nat Rev Drug Discov 10, 417-427. 
 
Carmeliet, P., Lampugnani, M.G., Moons, L., Breviario, F., Compernolle, V., Bono, F., Balconi, 
G., Spagnuolo, R., Oosthuyse, B., Dewerchin, M., et al. (1999). Targeted deficiency or cytosolic 
truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and 
angiogenesis. Cell 98, 147-157. 
 
Chappell, J.C., and Bautch, V.L. (2010). Vascular development: genetic mechanisms and links to 
vascular disease. Curr Top Dev Biol 90, 43-72. 
 
Charpentier, M.S., Christine, K.S., Amin, N.M., Dorr, K.M., Kushner, E.J., Bautch, V.L., Taylor, 
J.M., and Conlon, F.L. (2013a). CASZ1 Promotes Vascular Assembly and Morphogenesis 
through the Direct Regulation of an EGFL7/RhoA-Mediated Pathway. Dev Cell 25, 132-143. 
42 
 
 
Charpentier, M.S., Dorr, K.M., and Conlon, F.L. (2013b). Transcriptional regulation of blood 
vessel formation: The role of the CASZ1/Egfl7/RhoA pathway. Cell Cycle 12. 
 
Chen, F., Ma, L., Parrini, M.C., Mao, X., Lopez, M., Wu, C., Marks, P.W., Davidson, L., 
Kwiatkowski, D.J., Kirchhausen, T., et al. (2000). Cdc42 is required for PIP(2)-induced actin 
polymerization and early development but not for cell viability. Curr Biol 10, 758-765. 
 
Christine, K.S., and Conlon, F.L. (2008). Vertebrate CASTOR is required for differentiation of 
cardiac precursor cells at the ventral midline. Dev Cell 14, 616-623. 
 
Chrzanowska-Wodnicka, M., and Burridge, K. (1996). Rho-stimulated contractility drives the 
formation of stress fibers and focal adhesions. J Cell Biol 133, 1403-1415. 
 
Davis, G.E., and Bayless, K.J. (2003). An integrin and Rho GTPase-dependent pinocytic vacuole 
mechanism controls capillary lumen formation in collagen and fibrin matrices. Microcirculation 
10, 27-44. 
 
Davis, G.E., Black, S.M., and Bayless, K.J. (2000). Capillary morphogenesis during human 
endothelial cell invasion of three-dimensional collagen matrices. In Vitro Cell Dev Biol Anim 
36, 513-519. 
 
Davis, G.E., and Camarillo, C.W. (1996). An alpha 2 beta 1 integrin-dependent pinocytic 
mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen 
and tube formation in three-dimensional collagen matrix. Exp Cell Res 224, 39-51. 
 
Deiters, A., Garner, R.A., Lusic, H., Govan, J.M., Dush, M., Nascone-Yoder, N.M., and Yoder, 
J.A. (2010). Photocaged morpholino oligomers for the light-regulation of gene function in 
zebrafish and Xenopus embryos. J Am Chem Soc 132, 15644-15650. 
 
Dejana, E., Orsenigo, F., and Lampugnani, M.G. (2008). The role of adherens junctions and VE-
cadherin in the control of vascular permeability. J Cell Sci 121, 2115-2122. 
 
Dejana, E., and Vestweber, D. (2013). The role of VE-cadherin in vascular morphogenesis and 
permeability control. Prog Mol Biol Transl Sci 116, 119-144. 
 
Djonov, V., Schmid, M., Tschanz, S.A., and Burri, P.H. (2000). Intussusceptive angiogenesis: its 
role in embryonic vascular network formation. Circ Res 86, 286-292. 
 
Eilken, H.M., and Adams, R.H. (2010). Dynamics of endothelial cell behavior in sprouting 
angiogenesis. Curr Opin Cell Biol 22, 617-625. 
 
Fehon, R.G., McClatchey, A.I., and Bretscher, A. (2010). Organizing the cell cortex: the role of 
ERM proteins. Nat Rev Mol Cell Biol 11, 276-287. 
 
43 
 
Fitch, M.J., Campagnolo, L., Kuhnert, F., and Stuhlmann, H. (2004). Egfl7, a novel epidermal 
growth factor-domain gene expressed in endothelial cells. Dev Dyn 230, 316-324. 
 
Gory-Faure, S., Prandini, M.H., Pointu, H., Roullot, V., Pignot-Paintrand, I., Vernet, M., and 
Huber, P. (1999). Role of vascular endothelial-cadherin in vascular morphogenesis. 
Development 126, 2093-2102. 
 
Helker, C.S., Schuermann, A., Karpanen, T., Zeuschner, D., Belting, H.G., Affolter, M., Schulte-
Merker, S., and Herzog, W. (2013). The zebrafish common cardinal veins develop by a novel 
mechanism: lumen ensheathment. Development. 
 
Herwig, L., Blum, Y., Krudewig, A., Ellertsdottir, E., Lenard, A., Belting, H.G., and Affolter, M. 
(2011). Distinct cellular mechanisms of blood vessel fusion in the zebrafish embryo. Curr Biol 
21, 1942-1948. 
 
Hoang, M.V., Nagy, J.A., and Senger, D.R. (2011a). Active Rac1 improves pathologic VEGF 
neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. 
Blood 117, 1751-1760. 
 
Hoang, M.V., Nagy, J.A., and Senger, D.R. (2011b). Cdc42-mediated inhibition of GSK-3 beta 
improves angio-architecture and lumen formation during VEGF-driven pathological 
angiogenesis. Microvascular Research 81, 34-43. 
 
Hoang, M.V., Whelan, M.C., and Senger, D.R. (2004). Rho activity critically and selectively 
regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci U S A 101, 
1874-1879. 
 
Hynes, R.O. (2007). Cell-matrix adhesion in vascular development. J Thromb Haemost 5 Suppl 
1, 32-40. 
 
Iden, S., Rehder, D., August, B., Suzuki, A., Wolburg-Buchholz, K., Wolburg, H., Ohno, S., 
Behrens, J., Vestweber, D., and Ebnet, K. (2006). A distinct PAR complex associates physically 
with VE-cadherin in vertebrate endothelial cells. EMBO Rep 7, 1239-1246. 
 
Jaffe, A.B., Kaji, N., Durgan, J., and Hall, A. (2008). Cdc42 controls spindle orientation to 
position the apical surface during epithelial morphogenesis. J Cell Biol 183, 625-633. 
 
Jin, Y., Liu, Y., Lin, Q., Li, J., Druso, J.E., Antonyak, M.A., Meininger, C.J., Zhang, S.L., 
Dostal, D.E., Guan, J.L., et al. (2013). Deletion of Cdc42 Enhances ADAM17-Mediated 
Vascular Endothelial Growth Factor Receptor 2 Shedding and Impairs Vascular Endothelial Cell 
Survival and Vasculogenesis. Mol Cell Biol 33, 4181-4197. 
 
Joberty, G., Petersen, C., Gao, L., and Macara, I.G. (2000). The cell-polarity protein Par6 links 
Par3 and atypical protein kinase C to Cdc42. Nat Cell Biol 2, 531-539. 
 
44 
 
Kamei, M., Saunders, W.B., Bayless, K.J., Dye, L., Davis, G.E., and Weinstein, B.M. (2006). 
Endothelial tubes assemble from intracellular vacuoles in vivo. Nature 442, 453-456. 
 
Karlsson, R., Pedersen, E.D., Wang, Z., and Brakebusch, C. (2009). Rho GTPase function in 
tumorigenesis. Biochim Biophys Acta 1796, 91-98. 
 
Kleinman, H.K., and Martin, G.R. (2005). Matrigel: basement membrane matrix with biological 
activity. Semin Cancer Biol 15, 378-386. 
 
Koh, W., Mahan, R.D., and Davis, G.E. (2008). Cdc42- and Rac1-mediated endothelial lumen 
formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling. J Cell Sci 121, 989-
1001. 
 
Koh, W., Sachidanandam, K., Stratman, A.N., Sacharidou, A., Mayo, A.M., Murphy, E.A., 
Cheresh, D.A., and Davis, G.E. (2009). Formation of endothelial lumens requires a coordinated 
PKCepsilon-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 
activation. J Cell Sci 122, 1812-1822. 
 
Kucera, T., Strilic, B., Regener, K., Schubert, M., Laudet, V., and Lammert, E. (2009). Ancestral 
vascular lumen formation via basal cell surfaces. PLoS One 4, e4132. 
 
Lampugnani, M.G. (2012). Endothelial cell-to-cell junctions: adhesion and signaling in 
physiology and pathology. Cold Spring Harb Perspect Med 2. 
 
Lampugnani, M.G., Orsenigo, F., Rudini, N., Maddaluno, L., Boulday, G., Chapon, F., and 
Dejana, E. (2010). CCM1 regulates vascular-lumen organization by inducing endothelial 
polarity. J Cell Sci 123, 1073-1080. 
 
Langdon, Y., Tandon, P., Paden, E., Duddy, J., Taylor, J.M., and Conlon, F.L. (2012). SHP-2 
acts via ROCK to regulate the cardiac actin cytoskeleton. Development 139, 948-957. 
 
Lenard, A., Ellertsdottir, E., Herwig, L., Krudewig, A., Sauteur, L., Belting, H.G., and Affolter, 
M. (2013). In Vivo analysis reveals a highly stereotypic morphogenetic pathway of vascular 
anastomosis. Dev Cell 25, 492-506. 
 
Liu, H., Rigamonti, D., Badr, A., and Zhang, J. (2011). Ccm1 regulates microvascular 
morphogenesis during angiogenesis. J Vasc Res 48, 130-140. 
 
Liu, K.D., Datta, A., Yu, W., Brakeman, P.R., Jou, T.S., Matthay, M.A., and Mostov, K.E. 
(2007). Rac1 is required for reorientation of polarity and lumen formation through a PI 3-kinase-
dependent pathway. Am J Physiol Renal Physiol 293, F1633-1640. 
 
Lizama, C.O., and Zovein, A.C. (2013). Polarizing pathways: balancing endothelial polarity, 
permeability, and lumen formation. Exp Cell Res 319, 1247-1254. 
 
45 
 
Maddox, A.S., and Burridge, K. (2003). RhoA is required for cortical retraction and rigidity 
during mitotic cell rounding. J Cell Biol 160, 255-265. 
 
Meadows, K.L., and Hurwitz, H.I. (2012). Anti-VEGF therapies in the clinic. Cold Spring Harb 
Perspect Med 2. 
 
Montero-Balaguer, M., Swirsding, K., Orsenigo, F., Cotelli, F., Mione, M., and Dejana, E. 
(2009). Stable vascular connections and remodeling require full expression of VE-cadherin in 
zebrafish embryos. PLoS One 4, e5772. 
 
Morckel, A.R., Lusic, H., Farzana, L., Yoder, J.A., Deiters, A., and Nascone-Yoder, N.M. 
(2012). A photoactivatable small-molecule inhibitor for light-controlled spatiotemporal 
regulation of Rho kinase in live embryos. Development 139, 437-442. 
 
Myllymaki, S.M., Teravainen, T.P., and Manninen, A. (2011). Two distinct integrin-mediated 
mechanisms contribute to apical lumen formation in epithelial cells. PLoS One 6, e19453. 
 
Nakatsu, M.N., Sainson, R.C., Aoto, J.N., Taylor, K.L., Aitkenhead, M., Perez-del-Pulgar, S., 
Carpenter, P.M., and Hughes, C.C. (2003). Angiogenic sprouting and capillary lumen formation 
modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of 
fibroblasts and Angiopoietin-1. Microvasc Res 66, 102-112. 
 
Nehls, V., and Drenckhahn, D. (1995). A novel, microcarrier-based in vitro assay for rapid and 
reliable quantification of three-dimensional cell migration and angiogenesis. Microvasc Res 50, 
311-322. 
 
Nielsen, J.S., and McNagny, K.M. (2008). Novel functions of the CD34 family. J Cell Sci 121, 
3683-3692. 
 
Nobes, C.D., and Hall, A. (1995a). Rho, rac and cdc42 GTPases: regulators of actin structures, 
cell adhesion and motility. Biochem Soc Trans 23, 456-459. 
 
Nobes, C.D., and Hall, A. (1995b). Rho, rac, and cdc42 GTPases regulate the assembly of 
multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. 
Cell 81, 53-62. 
 
Olson, M.F., Ashworth, A., and Hall, A. (1995). An essential role for Rho, Rac, and Cdc42 
GTPases in cell cycle progression through G1. Science 269, 1270-1272. 
 
Parker, L.H., Schmidt, M., Jin, S.W., Gray, A.M., Beis, D., Pham, T., Frantz, G., Palmieri, S., 
Hillan, K., Stainier, D.Y., et al. (2004). The endothelial-cell-derived secreted factor Egfl7 
regulates vascular tube formation. Nature 428, 754-758. 
 
Parsons, J.T., Horwitz, A.R., and Schwartz, M.A. (2010). Cell adhesion: integrating cytoskeletal 
dynamics and cellular tension. Nat Rev Mol Cell Biol 11, 633-643. 
 
46 
 
Patel-Hett, S., and D'Amore, P.A. (2011). Signal transduction in vasculogenesis and 
developmental angiogenesis. Int J Dev Biol 55, 353-363. 
Potente, M., Gerhardt, H., and Carmeliet, P. (2011). Basic and therapeutic aspects of 
angiogenesis. Cell 146, 873-887. 
 
Qi, Y., Liu, J., Wu, X., Brakebusch, C., Leitges, M., Han, Y., Corbett, S.A., Lowry, S.F., 
Graham, A.M., and Li, S. (2011). Cdc42 controls vascular network assembly through protein 
kinase Ciota during embryonic vasculogenesis. Arterioscler Thromb Vasc Biol 31, 1861-1870. 
 
Ridley, A.J. (2006). Rho GTPases and actin dynamics in membrane protrusions and vesicle 
trafficking. Trends Cell Biol 16, 522-529. 
 
Ridley, A.J., and Hall, A. (1992). The small GTP-binding protein rho regulates the assembly of 
focal adhesions and actin stress fibers in response to growth factors. Cell 70, 389-399. 
 
Ridley, A.J., Paterson, H.F., Johnston, C.L., Diekmann, D., and Hall, A. (1992). The small GTP-
binding protein rac regulates growth factor-induced membrane ruffling. Cell 70, 401-410. 
 
Rodriguez-Fraticelli, A.E., Galvez-Santisteban, M., and Martin-Belmonte, F. (2011). Divide and 
polarize: recent advances in the molecular mechanism regulating epithelial tubulogenesis. Curr 
Opin Cell Biol 23, 638-646. 
 
Sacharidou, A., Koh, W., Stratman, A.N., Mayo, A.M., Fisher, K.E., and Davis, G.E. (2010). 
Endothelial lumen signaling complexes control 3D matrix-specific tubulogenesis through 
interdependent Cdc42- and MT1-MMP-mediated events. Blood 115, 5259-5269. 
 
Said, S.S., Pickering, J.G., and Mequanint, K. (2013). Advances in growth factor delivery for 
therapeutic angiogenesis. J Vasc Res 50, 35-51. 
 
Speck, O., Hughes, S.C., Noren, N.K., Kulikauskas, R.M., and Fehon, R.G. (2003). Moesin 
functions antagonistically to the Rho pathway to maintain epithelial integrity. Nature 421, 83-87. 
Spindler, V., Schlegel, N., and Waschke, J. (2010). Role of GTPases in control of microvascular 
permeability. Cardiovasc Res 87, 243-253. 
 
Strilic, B., Eglinger, J., Krieg, M., Zeeb, M., Axnick, J., Babal, P., Muller, D.J., and Lammert, E. 
(2010a). Electrostatic cell-surface repulsion initiates lumen formation in developing blood 
vessels. Curr Biol 20, 2003-2009. 
 
Strilic, B., Kucera, T., Eglinger, J., Hughes, M.R., McNagny, K.M., Tsukita, S., Dejana, E., 
Ferrara, N., and Lammert, E. (2009). The molecular basis of vascular lumen formation in the 
developing mouse aorta. Dev Cell 17, 505-515. 
 
Strilic, B., Kucera, T., and Lammert, E. (2010b). Formation of cardiovascular tubes in 
invertebrates and vertebrates. Cell Mol Life Sci 67, 3209-3218. 
 
47 
 
Sugihara, K., Nakatsuji, N., Nakamura, K., Nakao, K., Hashimoto, R., Otani, H., Sakagami, H., 
Kondo, H., Nozawa, S., Aiba, A., et al. (1998). Rac1 is required for the formation of three germ 
layers during gastrulation. Oncogene 17, 3427-3433. 
 
Swift, M.R., and Weinstein, B.M. (2009). Arterial-venous specification during development. 
Circ Res 104, 576-588. 
 
Takeuchi, F., Isono, M., Katsuya, T., Yamamoto, K., Yokota, M., Sugiyama, T., Nabika, T., 
Fujioka, A., Ohnaka, K., Asano, H., et al. (2010). Blood pressure and hypertension are 
associated with 7 loci in the Japanese population. Circulation 121, 2302-2309. 
 
Tan, W., Palmby, T.R., Gavard, J., Amornphimoltham, P., Zheng, Y., and Gutkind, J.S. (2008). 
An essential role for Rac1 in endothelial cell function and vascular development. FASEB J 22, 
1829-1838. 
 
Tzima, E., Del Pozo, M.A., Kiosses, W.B., Mohamed, S.A., Li, S., Chien, S., and Schwartz, 
M.A. (2002). Activation of Rac1 by shear stress in endothelial cells mediates both cytoskeletal 
reorganization and effects on gene expression. EMBO J 21, 6791-6800. 
 
Wang, Y., Kaiser, M.S., Larson, J.D., Nasevicius, A., Clark, K.J., Wadman, S.A., Roberg-Perez, 
S.E., Ekker, S.C., Hackett, P.B., McGrail, M., et al. (2010). Moesin1 and Ve-cadherin are 
required in endothelial cells during in vivo tubulogenesis. Development 137, 3119-3128. 
 
Wojciak-Stothard, B., Potempa, S., Eichholtz, T., and Ridley, A.J. (2001). Rho and Rac but not 
Cdc42 regulate endothelial cell permeability. J Cell Sci 114, 1343-1355. 
 
Xu, K., Sacharidou, A., Fu, S., Chong, D.C., Skaug, B., Chen, Z.J., Davis, G.E., and Cleaver, O. 
(2011). Blood Vessel Tubulogenesis Requires Rasip1 Regulation of GTPase Signaling. Dev Cell 
20, 526-539. 
 
Yoshida, Y., Yamada, M., Wakabayashi, K., Ikuta, F., and Kumanishi, T. (1989). Endothelial 
basement membrane and seamless-type endothelium in the repair process of cerebral infarction 
in rats. Virchows Arch A Pathol Anat Histopathol 414, 385-392.
48 
 
CHAPTER 2: CASZ1 PROMOTES VASCULAR ASSEMBLY AND MORPHOGENESIS 
THROUGH THE DIRECT REGULATION OF AN EGFL7/RHOA-MEDIATED 
PATHWAY
2
 
 
Introduction 
 Endothelial cells (ECs) are building blocks for the formation of a functional vascular 
system during embryonic development. Early stages of blood vessel development occur via 
vasculogenesis whereby mesodermal cells differentiate into EC progenitors that subsequently 
proliferate, migrate, and assemble into vascular cords. Cords then undergo tubulogenesis, or 
lumen formation, continuing to mature by angiogenesis where vessels sprout, branch, and 
remodel. Vessels then become surrounded and stabilized by pericytes and smooth muscle cells 
that provide structural support (De Val, 2011; Patan, 2000). The critical nature of these events is 
emphasized by observations that disruption of these processes is associated with human disease 
states including cancer, stroke, and atherosclerosis, therefore necessitating a better understanding 
of transcriptional networks that regulate these key developmental steps (Carmeliet, 2003; 
Carmeliet and Jain, 2011a; Potente et al., 2011). 
 
 While numerous transcription factors have been discovered to regulate endothelial gene 
expression, relatively few factors are necessary for development. Deletions or mutations of a 
number of single genes, especially members of Ets and forkhead families, result in moderate to
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 no vascular phenotypes likely due to functional redundancy (Barton et al., 1998; De Val, 2011; 
De Val and Black, 2009; Lelievre et al., 2001). Previous studies have implicated the zinc finger 
transcription factor CASZ1 in cardiovascular development with depletion of CASZ1 in Xenopus 
embryos resulting in failure of a subset of progenitor cells to differentiate into cardiomyocytes 
(Christine and Conlon, 2008). Recent genome-wide association studies have shown a genetic link 
between human Casz1 and high blood pressure and hypertension, suggesting a possible role for 
CASZ1 in EC biology (Levy et al., 2009; Takeuchi et al., 2010). However, no studies have 
addressed expression, function, or transcriptional targets of CASZ1 in vascular tissue. 
 
Despite an essential role for the vasculature in development and disease, our knowledge 
of molecular mechanisms controlling these events remains incomplete (De Val and Black, 2009). 
One protein recently shown to play a role in EC morphogenesis is Epidermal Growth Factor-
Like Domain 7 (Egfl7), an extracellular matrix (ECM) protein expressed exclusively in EC 
progenitors and vessels during embryonic and neonatal development. EGFL7 is also expressed in 
highly vascularized adult organs and is upregulated upon injury (Campagnolo et al., 2005; Fitch 
et al., 2004; Parker et al., 2004). Depletion studies in zebrafish have defined a role for EGFL7 in 
tubulogenesis likely through modulation of cell-matrix interactions (Nikolic et al., 2010; Parker 
et al., 2004). In addition, overexpression of Egfl7 in mouse results in abnormal patterning of 
embryonic and postnatal vasculature (Nichol et al., 2010). However, the specific function of 
EGFL7 has been complicated by recent discovery of microRNA miR-126, the only EC-specific 
microRNA, within intron 7 of the Egfl7 locus. While Egfl7 and miR-126 are co-expressed, the 
function of miR-126 has indicated a distinct role from its host gene in maintaining vessel 
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integrity and modulating angiogenesis through repression of targets Spred1 and PIK3R2 (Fish et 
al., 2008; Kuhnert et al., 2008; Wang et al., 2008).  
 
 In this study, we demonstrate CASZ1 is required for angiogenic sprouting and lumen 
morphogenesis. CASZ1 regulates EC contractility, adhesion, and sprouting promoting assembly 
and tubulogenesis of blood vessels. Furthermore, we demonstrate CASZ1 activates Egfl7/miR-
126 in mammals and Xenopus by directly binding to an intronic element but does not regulate 
miR-126 in Xenopus. Moreover, defects associated with CASZ1-depletion can be phenocopied 
by EGFL7-depletion, and importantly, rescued by restoration of Egfl7 levels. We further show 
CASZ1 transcriptional control of EGFL7 modulates EC behavior through RhoA. Collectively, 
our studies point to a network whereby CASZ1 regulates an EGFL7/RhoA-mediated pathway to 
promote vessel assembly and morphogenesis.  
 
Materials and Methods 
Xenopus Embryo Collection and Morpholino Design  
Preparation and collection of Xenopus embryos was performed as described (Showell et al., 
2006). Briefly, X. laevis eggs were collected after priming females with 10 U of human chorionic 
gonadotropin (hCG; Sigma) the night before. Eggs were fertilized with the testis of a male and 
treated with 2% cysteine hydrochloride to remove their jelly coat. Embryos were then injected at 
the one-cell stage with morpholino, cultured between 16-23° in Modified Barth's Solution 
(MBS), and staged according to criteria set out in the Normal Table of Xenopus laevis 
(Nieuwkoop and Faber, 1967). Morpholino sequences are as follows: 
Casz1 MO (80ng)-[5'TTTATACAATTCAGTCCTACCTGGC] Targets splice donor on Exon 8.  
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      [5' ATCTGCAAGGGAGAATCATTTGCTG] Targets splice acceptor on Exon 9. 
Egfl7 MO (40ng)-[5’ACAGCACTAAAGAGAGAGACACAAG] Targets splice acceptor on 
Exon 6.  
miR-126 MO (80ng)-[5’TGACACAGCGCGTACCAAAAGTAAT] Targets primary miR-126 
sequence preventing proper processing.  
Control MO-[5'CCTCTTACCTCAGTTACAATTTATA] Targets human beta-globin gene.  
 
In Situ Hybridization 
 Whole mount in situ analysis was carried out as described (Harland, 1991) using probes of 
Casz1 (Christine and Conlon, 2008), Msr (Devic, 1996), Ami (Inui and Asashima, 2006), Erg 
(cloned from st. 39 X. laevis cDNA), Egfl7 (cloned from st. 33-38 X. tropicalis cDNA), and 
EphrinB2 (cloned from st. 39 X. laevis cDNA). miR-126 locked nucleic acid probe from Exiqon 
(38523-05) and hybridization was performed according to manufacturer’s instructions at 51°C.  
 
Mouse Immunohistochemistry  
After sacrificing time-pregnant dams (E14.5), embryos were isolated in phosphate-buffered 
saline (PBS), fixed overnight in freshly dissolved paraformaldehyde (4% w/v in PBS), processed 
through a graded series of sucrose, embedded in OCT, and serial sectioned on a cryostat at 10 
µM.  Immunohistochemistry was carried out with rabbit anti-Casz1 (Santa Cruz Biotechnology 
#SC-135453) and rat anti-CD31 (BD Pharmingen #553370) as described (Goetz et al., 2006).  
Prior to incubation with primary antibodies, slides were pretreated with Sodium Citrate Buffer 
(pH6.0) for twenty minutes in a steamer (Sunbeam)  followed by preincubation with 1% fetal 
bovine serum (FBS) in PBS.  Secondary antibodies (Molecular Probes) used included donkey 
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anti-rabbit Alexa 488 and donkey anti-rat Alexa 546.  Nuclei were visualized using DAPI.  
Fluorescence was visualized using a Zeiss 700 confocal laser scanning microscope. 
 
Chromatin Immunoprecipitation (ChIP)  
Four hundred cardiovascular-enriched regions were dissected from st. 29 X. tropicalis embryos 
and processed for ChIP as reported (Weinmann and Farnham, 2002) (Taranova et al., 2006) with 
following exceptions: (1)Sonication was carried out with Branson Digital Sonifier at 20% 
amplitude (2.5 cycles, 30s [1s on/0.5s off]) to yield 4kb DNA fragments. (2)Affinity-purified 
rabbit anti-CASZ1 polyclonal antibody was added and incubated overnight at 4°C. (3)DNA was 
digested with NlaIII (NEB) and ligated into SphI-digested (NEB) pUC19 using DNA ligation kit 
(Stratagene). Ligated DNA was transformed into NEB10β electrocompetent cells. Transformants 
were selected by blue/white screening, cultured, and isolated plasmids were sequenced. CASZ1 
target DNA sequences were assessed by BLAT analysis using UCSC X. tropicalis Genome 
Browser (http://genome.ucsc.edu, August 2005 assembly). DNA scaffold location coordinates 
were imported into the annotated Joint Genome Institute. v4.1 database (http://genome.jgi-
psf.org/Xentr4/Xentr4.home.html). Validation of targets by ChIP PCR was performed as above 
with following exceptions: (1)Thirty st. 32 X. tropicalis embryos were collected and processed as 
described. (2)Nuclear samples were sonicated at 20% amplitude (5 cycles, 30s [1s on/0.5s off]) 
to generate ~300bp DNA fragments. 
 
Cloning and Sequencing of Egfl7 Intronic Regions  
The ISB-1 X. tropicalis BAC library obtained from Children’s Hospital Oakland Research 
Institute (CHORI) was screened for the Egfl7 locus using a probe corresponding to Egfl7 intron 5 
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that was amplified from X. tropicalis genomic DNA by polymerase chain reaction (PCR). Three 
BAC clones (A20, C10, F23) were identified and Egfl7 introns 2-4 were amplified from BAC 
clone A20 by PCR. The introns were subcloned and sequenced to confirm that they truly were X. 
tropicalis Egfl7 intronic regions.  
 
In vivo Transcriptional Assays  
Egfl7 intronic regions (introns 2,3,4,5) were subcloned into pGL3-Promoter firefly luciferase 
vector (Promega). X. laevis embryos were injected at 1-cell stage with 300 pg reporter plasmid 
and 10 pg Renilla reporter plasmid in presence or absence of CASZ1 mRNA. Injected embryos 
were cultured until st. 11.5. Ten injected embryos were lysed in 50 µl Passive Lysis Buffer 
(Promega) in triplicate. 20 µl of cleared lysates were assayed using Dual-Luciferase Reporter 
Assay System (Promega).  
 
Cell Culture 
Pooled population of HUVEC (Lonza) were maintained in Complete EBM-2 (Lonza) containing 
10% fetal bovine serum, 100 U/mL penicillin and streptomycin and used between passages 1-6. 
hCASZ1 was immunoprecipitated from HUVECs using polyclonal rabbit anti-human CASZ1 
(LifeSpan Biosciences) and probed by western blot with same antibody.  
 
Short Hairpin RNA (shRNA)  
shRNA viral constructs specific to human Casz1 and Egfl7 were obtained from Open Biosystems 
TRC1 shRNA library. Casz1, Egfl7, and control scrambled sequence (Addgene) shRNA 
lentiviral particles were prepared by UNC Lentiviral Core Facility. 40-50% confluent HUVECs 
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were infected with 1x10
6
 IU lentivirus combined with 10 µg/mL polybrene (Sigma) for 7.5 hr. 
Infected cells were placed under 1.5 µg/mL puromycin selection for 3 days and processed for 
further analysis. 
 
SYBR Green Quantitative RT-PCR 
 For assessing miR-126 knockdown by morpholino, RNA was isolated from stage 29 embryos 
using TRIzol (Invitrogen) and purified by phenol:chloroform extraction and ethanol 
precipitation. miR-126-specific cDNA was synthesized using 100 ng of RNA as described 
previously (Shi and Chiang, 2005). RNA was isolated from HUVECs using RNeasy mini kit 
(Qiagen) and cDNA synthesis with 100 ng of RNA was performed as described previously 
(Christine and Conlon, 2008). Expression levels were assessed using SYBR Green Master Mix 
(Sigma) on ABI 7900 Fast HT. RPS29 and miR-16 were used as the housekeeping references (de 
Jonge et al., 2007). Primer sequences can be found in Table 2.1. Following amplification, 
melting curves were generated to verify presence of a single amplification product. Each sample 
was analyzed in triplicate with a corresponding minus-RT control. Analysis generated Ct values 
based on thresholds determined by ABI 7900 software. Efficiency (E) of each primer set was 
determined based on a serial dilution DNA standard curve where E = 1/-slope.  Data was 
analyzed by the Pfaffl method(Pfaffl et al., 2002) and is represented as relative fold change 
±S.E.M. 
 
Live Time-Lapse Imaging 
Cells seeded on uncoated or Fibronectin-coated (10 µg/mL) 12-well dishes, or embedded in 
fibrin gel were imaged over 24 hr using Olympus IX70 inverted microscope encased in Plexiglas 
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housing to control internal environment (37°C, 5% CO2 and relative humidity of 60%). Images 
were collected by Volocity 5.4.1 software.  
 
Immunofluorescence  
Cells seeded in chamber slides (BD Falcon) were fixed with cold methanol/acetone, blocked, and 
incubated with phospho-histone H3 (Millipore) or cleaved caspase-3 (Cell Signaling) overnight. 
Cells were incubated with rabbit anti-Cy3 (Sigma), stained with DAPI, and mounted 
(DakoCytomation). For cytoskeletal staining, cells were serum-starved (EBM-2+0.75% FBS) 
overnight, half of the cells were treated with 10µM Y-27632 (Sigma). Cells were fixed in 4% 
PFA, permeabilized with 0.1% Triton X-100, and incubated overnight with anti-vinculin 
(Sigma), and anti-phospho-paxillin (pY118, Invitrogen). Cells were incubated with fluorescent 
secondary antibodies, stained with FITC-conjugated phalloidin (Invitrogen) and DAPI, mounted 
and imaged (Zeiss 710 or 700 microscope). 
 
Cell Morphology Quantification 
Phase contrast images of live cells were taken at 4x magnification using the Olympus IX81. 
Cells were measured using ImageJ whereby two measurements of the length of each cell were 
taken to account for cell curvature followed by one measurement of the width of the cell (n=450 
cells per condition). The sum of the two length measurements was then divided by the width to 
calculate the length-to-width (L:W) ratio.  
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FACS Analysis 
HUVECs were grown in 10 cm tissue culture dishes (Greiner CELLSTAR) to subconfluence. 
Cells were dissociated with trypsin-EDTA (Gibco) and fixation was carried out at -20°C in 70% 
ethanol for 2 hr. Cells were stained in PBS containing 0.1% Triton X-100, 0.2 mg/mL RNase A 
(Sigma), and 20 µg/mL propidium iodide for 30 min at room temperature. 7,500-10,000 cells 
were analyzed on the Dako CyAn using Summit 4.3 software with the aid of the UNC Flow 
Cytometry Core Facility. Data analysis was performed using ModFit. 
 
Sprouting Angiogenesis Assay 
Sprouting assays were performed as described (Nakatsu et al., 2003; Sweet et al., 2012). Cells 
were stained with phalloidin (FITC) to visualize actin and with DRAQ5 to mark EC nuclei, and 
imaged (Olympus FLV500 inverted confocal microscope, 20x objective). Assay quantified 
measuring total length of protruding sprouts and number of branch points. 
 
GST-RBD Pulldowns 
Active RhoA-pulldown experiments were carried out as described (Guilluy et al., 2011). Briefly, 
shRNA-infected cells were serum starved for 16 hr then stimulated for 5 min with 1 U/mL 
thrombin (Calbiochem) and lysed in 50 mM Tris (pH 7.6), 500 mM NaCl, 1% Triton X-100, 
0.1% SDS, 0.5% DOC, 10 mM MgCl2, and protease inhibitors (Roche). Lysates were clarified 
by centrifugation, rotated for 30 min with 30 µg purified GST-RBD (Rho binding domain) 
bound to glutathione-Sepharose beads (provided by Dr. K. Burridge, UNC-Chapel Hill), then 
washed twice and subsequently processed for SDS-PAGE. Blots were probed with anti-RhoA 
antibody (Santa Cruz. 1:250).     
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Generation of Egfl7 and miR-126 Adenoviruses 
For construction of Ad-Egfl7, human Egfl7 cDNA (Open Biosystems) was removed from 
pCMV-SPORT6 by digestion with Acc65I and NotI and inserted into the pAdTrack-CMV 
adenovirus vector (provided by UNC Gene Therapy Center) which drives expression of the 
inserted gene and GFP by two independent CMV promoters. For construction of Ad-miR-126, a 
477 bp portion of intron 7 of human Egfl7 containing the unprocessed stem loop of miR-126 was 
amplified from HUVEC genomic DNA and inserted into pAdTrack-CMV adenovirus vector. 
Adenoviral particles were packaged and generated by the UNC Gene Therapy Center. HUVECs, 
infected with lentivirus encoding shRNA, were co-infected with 25 MOI Ad-Egfl7 or Ad-miR-
126 for 24 hr before being used in downstream assays (e.g. time-lapse imaging). To assess 
efficacy of Ad-Egfl7, a Western blot was conducted using anti-EGFL7 (Santa Cruz, N-14; 
1:250). To assess efficacy of Ad-miR-126, qPCR using miR-126 specific primers was performed 
as described above.   
 
Western Blotting 
Western blots were performed with 50 µg protein using RhoA (Santa Cruz), phospho-myosin 
light chain 2 (Cell Signaling [Ser 19]), RhoC (Santa Cruz [K-12]). 
 
Statistical Analysis  
Data are expressed as means ± SEM as indicated. Statistical analysis was done by Student’s t-test 
and p<0.05 was considered significant.
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Table 2.1. Oligonucleotides used for quantitative real-time PCR.  
 
Gene  Species Forward Reverse 
Egfl7 Human 5' GGGATGACTGATTCTCCTCC 5' CACCAGAAGCCACATCAGCAG 
Casz1 Human 5' CCTTCTCCAAAACAGACTCC 5' GTTTACATCTTCAGTGACGGC 
miR-126 Human/Xenopus 5' TCGTACCGTGAGTAATAATGCG 5' GCGAGCACAGAATTAATACGAC 
Flk1 Human 5' GAAACTGACTTGGCCTCGG 5' GACCCGAGACATGGAATCAC 
RhoA Human 5' CAGTTCCCAGAGGTGTATGTG 5' GCGATCATAATCTTCCTGCC 
RhoB Human 5' GACACCGACGTCATTCTCATG 5' GATGATGGGCACATTGGGAC 
RhoC Human 5' CTACGTCCCTACTGTCTTTG 5' GCAGTCGATCATAGTCTTCC 
RPS29 Human 5' CGGTCTGATCCGGAAATATG 5' CCCGGATAATCCTCTGAAGG 
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Results 
 Analysis of Casz1 expression in Xenopus embryos showed transcripts in the vitelline vein 
network (vvn) at a stage when the network is primarily made up of vascular ECs and devoid of 
smooth muscle cells (Figure 2.1A)(Christine and Conlon, 2008; Cox et al., 2006; Warkman et 
al., 2005) suggesting Casz1 is expressed in vascular ECs. Furthermore, RT-PCR on vascular 
explants from late tailbud stage embryos (stage 32) demonstrated that Casz1 is co-expressed in 
the vitelline vein region with vascular markers, Msr and Erg (Figure S2.1A). Consistently, we 
found CASZ1 co-localizes with the EC-specific marker PECAM in blood vessels of mouse 
embryos (Figure 2.1B). We have also cloned human Casz1 and showed, as in Xenopus and 
mouse, Casz1 is expressed in primary human umbilical vein ECs (HUVEC)(Figure 2.1C-D). 
These results taken together with sequence homology and synteny of CASZ1 across vertebrates 
(Christine and Conlon, 2008)  demonstrate CASZ1 is an evolutionarily conserved transcription 
factor expressed in ECs. 
 
 To ascertain the function of CASZ1 in vascular development, we depleted CASZ1 in 
Xenopus embryos using a morpholino-based approach (Christine and Conlon, 2008). Whole-
mount in situ hybridization using a panel of EC markers such as Msr and Erg (Baltzinger et al., 
1999; Devic, 1996) demonstrated that at stages when ECs begin to migrate dorsally from ventral 
blood islands within the trunk region, there were no noticeable differences between control and 
CASZ1-depleted embryos (stage 29, Figures S2.1B, C, J, K). However, when ECs begin to 
assemble into cords (stage 32), defects became apparent whereby CASZ1-depleted embryos 
displayed a dramatically reduced vascular plexus (Figures 2.2A-D, S2.1D-E). Extension of 
intersomitic vessels from posterior cardinal veins, which is known to occur in Xenopus via 
sprouting angiogenesis in an anterior-to-posterior direction (Cleaver et al., 1997; Levine et al., 
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2003), was also absent or significantly delayed in CASZ1-depleted embryos (Figure 2.2A, C, E, 
G). By mid- to late tadpole stages (stages 36 and 39), vascular networks of CASZ1-depleted 
embryos were comprised of cords which ran predominately in a dorsal-to-ventral pattern and 
underwent little to no branching or remodeling (Figures 2.2E-H, S2.1F-I, S2.1L-M). Overall, at 
stage 36, total length of the vitelline vein vasculature and number of branch points and 
intersomitic vessels were all significantly decreased in CASZ1-depleted embryos implying a role 
for CASZ1 in sprouting and remodeling of the vasculature (Figure 2.2I). While our studies 
focused on vein-derived sprouts, CASZ1-depletion unlikely disrupts arterial/venous 
differentiation due to proper specification and localization of the aortic arches (arterial) and 
posterior cardinal veins as well as due to the lack of arterial marker expression in veins (data not 
shown).  
 
 Noting the posterior cardinal veins of CASZ1-depleted embryos appeared thickened 
(stage 36), we sought to determine the time course of lumen formation in Xenopus. At stage 29, 
control and CASZ1-depleted ECs, as marked by Msr, were localized to positions of the future 
veins but had not yet undergone lumen formation (Figure 2.2J, N). By stage 32, ECs separated in 
control embryos but remained as aggregates in CASZ1-depleted embryos (Figure 2.2K, O). By 
stages 36 and 39, the veins of control embryos exhibited well-formed lumens surrounded by 
Msr-positive ECs while CASZ1-depleted veins remained closed and failed to open even at late 
stages (Figure 2.2L, M, P, Q). Collectively, these studies demonstrate CASZ1 is required for 
angiogenic remodeling and lumen morphogenesis during vertebrate vascular development. 
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 Since we have previously established CASZ1 is required for heart development 
(Christine and Conlon, 2008), we determined if the vascular requirements for CASZ1 were 
secondary to its role in cardiac tissue. Taking advantage of the amenability of Xenopus embryos 
to organotypic culture (Mandel et al., 2010), we removed anterior regions of embryos, including 
all cardiac tissue at a stage prior to heart formation. Culture of explants showed in the absence of 
cardiac tissue, control explants formed vascular networks, as marked by the EC-specific gene 
Ami (Inui and Asashima, 2006), that were indistinguishable from un-manipulated embryos, 
demonstrating blood flow is not essential for correct patterning of the early vasculature (Figure 
S2.1N, P). Critically, we observed severe defects in vascular networks of CASZ1-depleted 
explants, strongly suggesting the role of CASZ1 in vascular development is independent of its 
role in cardiogenesis (Figure S2.1O, Q). 
 
 To examine vascular development in more detail and determine if the function of CASZ1 
is evolutionarily conserved, we depleted CASZ1 in HUVECs by lentiviral-mediated short hairpin 
RNA (shRNA, 16-fold decrease in Casz1 mRNA; Figure 2.3A). CASZ1-depleted cells displayed 
a thin and elongated morphology in stark contrast to characteristic cobblestone appearance of 
uninfected HUVECs or HUVECs infected with control shRNA (Figure 2.3B). To determine the 
precise requirement for CASZ1 and to characterize the dynamics of CASZ1-depleted HUVECs 
in real time, we coupled time-lapse imaging with quantitative analysis. Time-lapse movies 
showed that CASZ1-depleted cells initially adhered to plastic or fibronectin-coated substrates but 
a proportion of cells rounded up and detached (33%, Figure 2.3C, Movie S1, data not shown). Of 
CASZ1-depleted HUVECs that adhered, live imaging demonstrated the elongated morphology 
resulted from defects in contractility whereby the leading edge of CASZ1-depleted cells moved 
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forward without retraction of the trailing edge (Figure 2.3C, Movie S1). CASZ1-depleted cells 
also stopped dividing (0% shCasz1 vs. 20% control) and consistently, we failed to detect any 
phospho-histone H3 (pH3)-positive CASZ1-depleted cells (vs. 3% control cells; Figure S2.2A). 
Using fluorescence-activated cell sorting (FACS), we determined CASZ1-depleted ECs were 
blocked at the G1/S transition as seen by the significantly reduced number of cells in S-phase 
(Figure S2.2B). Blockage in G1/S progression was not associated with programmed cell death as 
determined by cleaved caspase-3 staining (Figure S2.2C). Furthermore, inability of CASZ1-
depleted cells to maintain adhesion to the substrate was not a secondary consequence of cell 
cycle arrest as wildtype HUVECs chemically treated with mitomycin C did not divide yet 
remained attached (data not shown). Taken together, these results indicate CASZ1 has a 
conserved role in vascular development and is required for EC adhesion, contractility, and G1/S 
cell cycle progression. 
 
To assess how adhesive and morphological defects of CASZ1-depleted cells manifested 
themselves in vessel assembly, we assessed sprouting using a sprouting angiogenesis assay in 
which HUVEC-coated beads were placed in fibrin. While control cells displayed elongated 
sprouts with multiple branch points, similar to our findings in Xenopus, CASZ1-depleted 
HUVECs had strikingly few sprouts and branches (Figure 2.3D). Live time-lapse imaging further 
showed that CASZ1-depleted cells extended out from beads to initiate sprout formation but then 
abruptly detached, indicating that CASZ1 is required for proper EC adhesion to promote 
angiogenic sprouting (Movie S4).   
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 To identify direct cardiac and endothelial transcriptional targets of CASZ1, we generated 
a CASZ1-specific antibody and performed cloning chromatin immunoprecipitation (ChIP) from 
dissected cardiovascular Xenopus tissue (stages 27-29, i.e. same time and tissue requiring 
CASZ1)(Figure 2.4A). We identified 110 putative transcriptional targets including Egfl7, an 
ECM protein specifically secreted by ECs shown to be associated with similar cellular processes 
as we observe for CASZ1; EC adhesion and vessel tubulogenesis (Figure 2.4B, Table 
S2.2)(Nichol et al., 2010; Nikolic et al., 2010; Parker et al., 2004). 
 
 Recently, studies in mouse and zebrafish identified the evolutionarily conserved miR-126 
contained within intron 7 of Egfl7 (Fish et al., 2008; Kuhnert et al., 2008; Wang et al., 2008). We 
cloned Egfl7 and miR-126 from Xenopus and showed EGFL7 is 47% identical to human and 
45% identical to mouse EGFL7, while Xenopus miR-126 is completely (100%) conserved 
between mouse and human (Fitch et al., 2004)(Figure S2.3A). Genome analysis and 
characterization of Xenopus BACs corresponding to the Egfl7/miR-126 locus confirmed that like 
other model systems, miR-126 is located within intron 7 of the Xenopus Egfl7 locus (Figure 
2.4B).  Expression analysis revealed Egfl7 is expressed in all major vessels at all stages of 
vasculogenesis in Xenopus, as reported for zebrafish, mouse, and human (Figure 2.4C, E, G, I) 
(Fitch et al., 2004; Parker et al., 2004). Though Egfl7 and miR-126 have been reported to be co-
transcribed and co-expressed in the vasculature, we found Xenopus miR-126 has an expression 
pattern distinct from Egfl7 as well as that reported in other species (Fish et al., 2008; Wang et al., 
2008). Most notably, miR-126 expression is initiated in ECs at stage 32, slightly later than Egfl7 
(stage 29), and we observed strong expression of miR-126, but not Egfl7, in the developing 
somites (Figure S2.3B-I). Taken together these data show that the sequence, genomic 
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arrangement, and vascular expression of Egfl7 and miR-126 are evolutionarily conserved, 
however in Xenopus, miR-126 has developed additional levels of regulation distinct from Egfl7.   
 
 Consistent with Egfl7 being a direct target of CASZ1, analysis in CASZ1-depleted 
embryos showed Egfl7 was initiated but not maintained in vascular tissues at all stages analyzed 
(Figure 2.4D, F, H, J). Consistently, Egfl7 levels were significantly reduced in CASZ1-depleted 
HUVEC (3-fold; Figure 2.4K). We further observed a dramatic reduction in miR-126 (9-fold) in 
CASZ1-depleted HUVECs (Figure 2.4K). These effects were specific as the EC marker Flk1 
was unaltered (Figure 2.4K). However, we did not observe reduction in miR-126 in CASZ1-
depleted Xenopus embryos at mid- and late-tadpole stages (stages 32-39, Figure S2.3E, G, I). 
Collectively, these studies demonstrate regulation of Egfl7 and miR-126 expression in human 
ECs is dependent on CASZ1 while Xenopus miR-126 appears to have evolved a CASZ1-
independent mechanism of regulation. 
 
 To determine whether CASZ1 directly regulates Egfl7, we performed in vivo 
transcriptional assays where single copies of intronic regions of Egfl7 corresponding to the 
putative CASZ1-bound region (introns 2-5) were placed upstream of a basal promoter driving 
luciferase activity. Of these intronic regions, only the 5’ half of intron 3 (E1) resulted in a dose-
dependent, reproducible increase in transcriptional activity in response to CASZ1 (Figure 2.4L-
M). To determine if CASZ1 endogenously binds to this element in vivo and to further refine the 
region within E1, we performed ChIP of endogenous CASZ1 from early embryos (stage 32), a 
time point when CASZ1 is required for Egfl7 expression. Results showed CASZ1 binds to 
nucleotides 59-173 of intron 3 (E1.2) but not the most 5’ end of E1 (E1.1)(Figure 2.4N, data not 
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shown). Thus, CASZ1 directly binds to the Egfl7 locus in vivo and can activate Egfl7 
transcription through a regulatory element within intron 3 of the Egfl7 locus. 
 
 To determine if CASZ1 acts through EGFL7 to regulate EC development, we depleted 
Egfl7 in embryos using a morpholino that left miR-126 expression intact (Figure S2.4A-E). 
Strikingly, EGFL7-depletion resulted in vascular phenotypes that phenocopied CASZ1-depletion 
(Figures 2.5A-H, S2.4F-S). As with CASZ1-depleted embryos, we found a reduction in density 
of ECs within the vitelline vein network (stage 32)(Figures 2.5A-D, S2.4F-G, S2.4J-M). 
Furthermore, while blood vessels did form in EGFL7-depleted embryos, there was significantly 
reduced branching and intersomitic vessel sprouting at later stages (Figures 2.5E-H, S2.4H-1, 
S2.4N-Q). Quantification of vitelline vein networks at stage 36 revealed results similar to 
CASZ1-depletion whereby the total length of the vasculature and number of branch points and 
intersomitic vessels of EGFL7-depleted embryos was significantly decreased compared to 
controls (Figure 2.5I). Furthermore, like CASZ1-depleted embryos, and in accordance with 
reports of EGFL7-depletion in zebrafish (Parker et al., 2004), lumens of posterior cardinal veins 
of EGFL7-depleted embryos failed to form (Figures 2.5J-M). Morpholinos targeting the Dicer 
cleavage site of Xenopus pri-miR-126 had no effect on Egfl7 expression (Figures S2.5A-E) and 
did not result in gross defects in vessel morphology or patterning, in accordance with reports in 
zebrafish (Figures S2.5F-U)(Fish et al., 2008). Consistently, lumens of posterior cardinal veins 
of miR-126-depleted embryos were indistinguishable from controls (Figures S2.5V-Y). Taken 
together these results imply EGFL7 functions downstream of CASZ1 to regulate angiogenesis 
and vascular remodeling 
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Similar to our studies in Xenopus, time-lapse imaging of HUVECs revealed depletion of 
EGFL7 by shRNA (shEgfl7, 11-fold decrease in mRNA; Figure 2.5N) phenocopied CASZ1-
depletion. Most notably, EGFL7-depleted cells demonstrated similar adhesion and proliferation 
defects as those of CASZ1-depleted cells (Figure 2.5O, Movie S2) and also displayed an 
elongated morphology similar to but not as extensive as observed in CASZ1-depleted cells. The 
sprouting angiogenesis assay further demonstrated similar defects to CASZ1-depleted cells 
whereby the total length of sprouts and number of branch points were significantly decreased in 
EGFL7-depleted cells compared to controls (Figure 2.5P). Live imaging showed failure to sprout 
was due to the inability of EGFL7-depleted cells to maintain adhesion (Movie S5). Results were 
specific since we observed minimal effect on expression of Casz1 or Flk1 (Figure 2.5N). 
Collectively, these studies show Egfl7 functions downstream of CASZ1 to control vascular 
morphogenesis in Xenopus and humans. In addition, miR-126 does not function downstream of 
CASZ1 in Xenopus vascular development. 
 
 To test if CASZ1 functions through Egfl7 or miR-126 to regulate vascular development 
and morphogenesis in human ECs, we assessed if restoration of Egfl7 or miR-126 levels rescues 
defects associated with CASZ1-depletion. While 29% of cells infected with shCasz1 rounded up 
and detached compared to 3% of control cells, infection of CASZ1-depleted cells with 
adenoviral constructs expressing either human Egfl7 (Ad-Egfl7) or miR-126 (Ad-miR-126) 
recovered proper adhesion as only 7.6% and 1% of cells detached, respectively (Figures 2.6A, 
S2.6A-B, Movie S3). However, restoration of Egfl7, but not miR-126, partially rescued EC 
morphology associated with CASZ1-depletion as measured by length-to-width ratio 
(L:W)(Figures 2.6B, S2.6C). Restoration of either Egfl7 or miR-126 failed to rescue proliferation 
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defects (data not shown). Taken together, these studies demonstrate that CASZ1 acts to control 
EC adhesion through direct transcriptional regulation of Egfl7 and miR-126. These data further 
indicate EGFL7 and miR-126 have distinct functions in regards to cell morphology since EGFL7 
but not miR-126 can rescue cell shape changes, and further imply CASZ1 control of G1/S 
progression occurs by Egfl7- and miR-126-independent pathways. 
 
 Past studies have provided evidence that two of the physiological outputs of the 
CASZ1/EGFL7 pathway, cell adhesion and morphology, are directly controlled by activation of 
Rho GTPases. Specifically, RhoA is required for actomyosin-dependent cell contractility and 
formation of focal adhesions (FA) (Burridge and Wennerberg, 2004; Katoh et al., 2011; Parsons 
et al., 2010). To identify mechanisms that mediate the physiological function of the 
CASZ1/EGFL7 pathway, we aimed to determine the relationship between CASZ1/EGFL7 and 
RhoA. We found RhoA activity and levels were dramatically diminished in CASZ1 and EGFL7-
depleted cells, however, levels of other Rho proteins such as RhoC were unaltered (Figure 2.6C, 
S2.6D-E). The decrease in RhoA protein occurred at the transcriptional level as RhoA but not 
RhoC mRNA levels were markedly diminished in both CASZ1 and EGFL7-depleted ECs 
(Figure 2.6D). However, RhoB levels were slightly increased possibly indicating a compensatory 
mechanism for loss of RhoA (Figure 2.6D). 
 
 We reasoned reduction of RhoA expression in CASZ1- and EGFL7-depleted cells would 
result in concomitant impaired downstream activity. Consistently, phosphorylation of regulatory 
subunit of myosin light chain (p-MLC) was decreased in CASZ1-depleted cells (Figure S2.6F). 
To further assess whether decreased RhoA activity directly plays a role in the adhesion and cell 
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shape defects we observe in CASZ1-depleted cells, we analyzed a panel of cytoskeletal and FA 
markers. Control cells displayed discrete bundles of F-actin stress fibers, as assayed by 
phalloidin staining, that contained short or punctate bands of FA markers vinculin and 
phosphorylated paxillin (Figure 2.6E, left panels). However, CASZ1-depletion mimicked 
treatment with the Rho kinase (ROCK) inhibitor Y-27632 resulting in diffuse actin networks 
devoid of stress fibers and failure of vinculin and phosphorylated paxillin to properly localize to 
adhesion sites on the periphery of the cell (Figure 2.6E, middle panels)(Narumiya et al., 2000). 
This phenotype was partially rescued by restoration of Egfl7 levels in CASZ1-depleted cells 
(Figure 2.6E, right panels). Taken together these studies show CASZ1 acts through the direct 
transcriptional regulation of EGFL7 to control EC adhesion and shape via the RhoA pathway.  
  
Discussion 
 In this work we demonstrate an essential and conserved role for the 
CASZ1/EGFL7/RhoA pathway in vascular patterning. Collectively, these data support a 
mechanism whereby CASZ1 directly binds to and maintains expression of Egfl7 in ECs. EGFL7 
is then localized extracellularly where it modulates signals between ECs and the underlying 
ECM. This in turn is responsible for transcriptional upregulation and activity of the RhoA 
GTPase which ultimately mediates EC contractility and adhesive properties to promote 
assembly, lumen formation, and functionality of the vasculature (Figure 2.7).    
 
 During embryogenesis, ECs assemble into cord-like structures that undergo further 
remodeling to form the primary vascular plexus. We have shown CASZ1 acts through the direct 
transcriptional regulation of EGFL7 to promote two critical processes during this period of 
embryogenesis: sprouting angiogenesis and lumen morphogenesis. The presence of thickened 
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cords lacking lumens in CASZ1-depleted embryos, together with the observation that CASZ1-
depleted ECs fail to sprout properly or adhere to extracellular substrates, strongly implies that 
CASZ1 functions through the EGFL7/RhoA pathway to maintain proper EC adhesion during 
vessel assembly.  
 
 RhoA has been shown to be a central component of pathways which facilitate vascular 
remodeling. In this regard, RhoA has been demonstrated to be required for stress fiber formation, 
acting through the actomyosin contractile machinery, and for FA formation (Burridge and 
Wennerberg, 2004; Chrzanowska-Wodnicka and Burridge, 1996; Katoh et al., 2011; Nobes and 
Hall, 1995b). In accordance with CASZ1 acting through RhoA to promote proper EC adhesion, 
we find that depleting CASZ1 phenocopies inhibition of RhoA and leads to a lack of discrete 
stress fibers, decreased myosin II activity, and strikingly, the absence of FA markers at sites of 
substrate contact. Moreover, these alterations in EC adherence can all be rescued in a CASZ1-
depleted background by restoration of Egfl7. 
 
 The role of RhoA in tubulogenesis has been controversial. While reports have 
demonstrated RhoA activity is central for lumen formation, for example in the formation of the 
mouse dorsal aorta (Strilic et al., 2009), other reports have shown that in culture RhoA is not 
required for lumen formation but rather, for maintenance of patent vessels (Bayless and Davis, 
2002). However, the in vivo relevance of the latter observation is yet to be determined since the 
mechanism by which lumens arise in 3D collagen culture differs significantly from that of cord 
hollowing in vivo (Davis et al., 2007; Strilic et al., 2009). Paradoxically, it has been recently 
demonstrated RhoA and myosin II activity must be suppressed to promote lumen formation of 
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mouse vessels via negative regulation by Ras interacting protein 1 (RASIP1) (Xu et al., 2011). 
Collectively these studies along with our present findings imply that a precise level of RhoA 
activity is required for lumen formation with either too low or too high activity leading to failure 
of vascular cords to hollow and form lumens. 
 
 The finding that RhoA protein and mRNA expression are significantly diminished in 
CASZ1 and EGFL7-depleted HUVECs indicates transcriptional control of RhoA is impaired. 
Very few studies to date have focused on how RhoA transcription is controlled. While EGFL7 
has been shown to interact with lysyl oxidases responsible for vascular elastogenesis as well as 
some Notch receptors on both ECs and neural stem cells, it is still unclear how these interactions 
may be influencing RhoA transcription or activity (Lelievre et al., 2008; Nichol et al., 2010; 
Schmidt et al., 2009). However, our results would support a mechanism by which CASZ1 
modulates RhoA signaling through EGFL7 as restoration of Egfl7 levels in CASZ1-depleted 
cells rescues adhesion, proper FA marker localization, and stress fiber formation. It was recently 
shown that RhoA is directly activated by the Myc-Skp2-Miz1-p300 transcriptional complex 
(Chan et al., 2010). Given a role for c-Myc in embryonic vascular development and later 
angiogenic remodeling (Baudino et al., 2002; Kokai et al., 2009; Rodrigues et al., 2008), it will 
be interesting to investigate whether CASZ1 transcriptional regulation of Egfl7 directly plays 
into Myc-mediated transcriptional control of RhoA.   
 
 Studies on Egfl7 and miR-126 have identified a 5.4Kb upstream sequence that is 
sufficient to drive EC-specific expression of a reporter gene in mouse, and mutation of two 
evolutionarily conserved Ets binding sites within this element eliminated expression in culture 
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(Wang et al., 2008). We have demonstrated CASZ1 is required for expression of Egfl7 where 
CASZ1 is endogenously bound to intron 3 of the Egfl7 locus in developing embryos and 
depletion of EGFL7 phenocopies CASZ1-depletion in embryos and HUVEC. Consistently, we 
note CASZ1 is not required for onset of Egfl7 expression in embryos but rather its maintenance. 
Based on our studies, we favor a model by which Ets factors activate Egfl7 via an upstream 
element and CASZ1 binds to intron 3 and functions to maintain Egfl7 levels. This model is 
complementary to findings for the role of Ets factors in regulating the spatial pattern of Egfl7 in 
mouse (Wang et al., 2008).  
 
 Our finding that EGFL7 and miR-126 are both regulated in a CASZ1-dependent manner 
in humans is congruent with reports in mouse. However, despite complete conservation of miR-
126 across species, we also demonstrate miR-126 has undergone an evolutionarily divergent and 
unique means of regulation exemplified by our findings that Xenopus miR-126 is expressed in 
domains mutually exclusive to Egfl7 (i.e. somites) and expression of Xenopus miR-126 in the 
vasculature is CASZ1-independent. These observations are broadly consistent with recent reports 
that miR-126 transcription can occur independently of host gene transcription through 
differential intronic promoters (Monteys et al., 2010).  
 
 The vascular system arises via concerted efforts of individual ECs to harness their unique 
behaviors to assemble into tubular structures. The molecular and cellular mechanisms by which 
the vasculature arises are still unclear but we have identified previously unknown roles for 
CASZ1 in regulating sprouting and morphogenesis. While endothelium becomes stabilized and 
quiescent after embryonic development, vessels retain sensitivity to changes in environment due 
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to injury, inflammation, or improper cardiac output thus making them susceptible to vascular 
dysfunction. In this regard, it is interesting that human CASZ1 has been linked to adult vascular 
diseases such as hypertension (Takeuchi et al., 2010). Events resulting in vascular dysfunction 
during this disease are associated with aberrant ECM remodeling, proliferation, and adhesion, all 
of which we have demonstrated to also be dysregulated upon depletion of CASZ1 (Lemarie et 
al., 2010). Therefore it will be intriguing to examine mechanisms by which CASZ1 itself is 
regulated and identify additional transcriptional targets that could trigger development of 
innovative therapeutic strategies in cardiovascular disease. 
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Figure 2.1. CASZ1 expression in vascular ECs is evolutionarily conserved. (A) In situ 
analysis of Casz1 Xenopus embryos (stage 41). Lateral view with anterior to left. Casz1 is 
expressed in vascular structures including vitelline vein network (vvn, enlarged panel on right). 
(B) CASZ1 (green) co-localizes with PECAM (red) in neural blood vessels of E14.5 mouse 
embryos. (C) RT-PCR analysis of human Casz1 in HUVEC cDNA. Gapdh was used as loading 
control. (D) Immunoprecipitation (IP) of CASZ1 from HUVECs. Control lane (left) represents 
IP with no antibody (Ab). Arrowhead represents 125kD human CASZ1. 
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Figure 2.2. CASZ1 is required for vascular development and lumen formation. (A-H) In 
situ analysis with EC marker Msr control and CASZ1-depleted embryos (stages 32-36;  lateral 
view with anterior to left). Vessel patterning and branching within vitelline vein network (vvn) 
are severely compromised at stage 32 in CASZ1-depleted embryos (A,C high magnification of 
vvn in B,D) and stage 36 (E,G high magnification of vvn in F,H). Note poor sprouting of 
intersomitic vessels (isv) in CASZ1-depleted embryos at both stages (enlarged box in A,C,E,G). 
(n=10 embryos/condition/stage, 3 independent experiments). (I) Quantification of vascular 
defects in control and CASZ1-depleted embryos (stage 36) representing combined total length of 
vessels, number of branch points within vvn, and number of isvs/embryo, respectively. Data 
represent mean ± SEM. (n=7 control and 10 Casz1 MO embryos). *: p<0.05; **:p<0.01; 
***:p<0.001. (J-Q) Histological analysis illustrates time course of lumen formation in Xenopus 
from stages 29-39 (J-M). Note posterior cardinal vein (pcv) lumens begin to open between stages 
32 and 36 in control embryos (K,L) but fail to form in CASZ1-depleted embryos (N-Q). Dorsal 
is top, ventral is bottom. Arrowheads correspond to positions of pcv which are enlarged in lower 
panels (n=2-5 embryos/ condition/stage).  
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Figure 2.3. CASZ1 regulates EC behavior. (A) mRNA levels of Casz1 after infection of 
HUVECs with shCasz1. Casz1 is decreased by 16-fold. mRNA levels relative to Rps29 ± SEM. 
***: p<0.001. (B) Phase contrast images of control and shCasz1 HUVECs. Controls display 
cobblestone-like morphology while CASZ1-depleted cells are thin and elongated (red 
arrowheads for examples of each). (C) Time-lapse images of control and shCasz1 cells. Red 
arrowheads represent dividing control cell and rounded up CASZ1-depleted cell. Minutes 
elapsed presented at bottom right, taken every 5 min for 24 hr. Red arrow refers to elongated 
shCasz1 cell with trailing edge defects. Graph represents quantification of cells that round up and 
detach during imaging. Data represent mean ± SEM of 3 experiments conducted on independent 
batches of shRNA-infected cells (n=200 cells). **:p<0.01. (D) Sprouting angiogenesis assay was 
performed with control and CASZ1-depleted HUVEC. On day 6, cultures were fixed and stained 
for phalloidin (green) and DRAQ5 (blue). Graphs represent mean ± SEM of total sprout length 
and number of branch points/bead (n=11 beads/condition). Experiments were repeated twice on 
independent batches of shRNA-infected cells. **:p<0.01; ***p<0.001.  
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Figure 2.4. CASZ1 directly activates Egfl7 transcription. (A) Illustration of cardiovascular-
enriched region dissected from X. tropicalis for chromatin immunoprecipitation (ChIP). (B) 
Genomic structure of Xenopus Egfl7 locus denoting CASZ1 ChIP fragment. White boxes: exons; 
shaded boxes, miR-126 in intron 7 and intronic region potentially containing CASZ1 element 
(+/- 4kb). (C-J) In situ analysis of Egfl7 of stages 29-39 control and CASZ1-depleted embryos 
(lateral view with anterior to left). Note downregulation of Egfl7 in vitelline vein network (vvn) 
and intersomitic vessels (isv) in CASZ1-depleted embryos. Pcv-posterior cardinal vein. (K) 
Relative mRNA expression of Egfl7, miR-126, and Flk1 after infection of HUVECs with 
shCasz1. mRNA levels relative to Rps29 ± SEM. ***:p<0.001; NS: not significant. (L) 
Schematic demarcating Egfl7 genomic DNA regions (in bp) tested for transcriptional activation. 
E1 (-55–1614) within intron 3 but not E2 (1773–3840) resulted in increased luciferase (luc) 
activity. (M) Egfl7 genomic region E1 in presence or absence of Casz1. Bars represent fold 
increase in activity relative to control ± SEM. Experiments were repeated twice on independent 
batches of embryos, **:p<0.01. (N) Identification of 90bp region endogenously bound by 
CASZ1located within non-overlapping region of E1.2 (113-227) PCR amplicon.  
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Figure 2.5. EGFL7-depletion in embryos and HUVECs phenocopies CASZ1-depletion. 
(A-H) In situ analysis with EC marker Msr control and EGFL7-depleted embryos (stages 32-36, 
lateral view with anterior to left). Note lack of branching in vitelline vein network (vvn) at stage 
32 (A,C high magnification of vvn in B,D) and stage 36 (E,G high magnification of vvn in F,H). 
Intersomitic vessel (isv) sprouting is also impaired (A,C,E,G). (n=10 embryos/condition/stage, 3 
independent experiments). (I) Quantification of vascular defects control and EGFL7-depleted 
embryos (stage 36) representing total vessel length, number of branch points within vvn, and 
number of isvs/embryo. Data represent mean ± SEM. (n=7 control and 10 Egfl7 MO embryos). 
*: p<0.05; **:p<0.01; ****:p<0.0005. (J-M) Histological analysis reveals lumenless posterior 
cardinal veins (pcv) in stage 36 (K) and stage 39 (M) Control and EGFL7-depleted embryos 
(J,L), dorsal top, ventral bottom, arrowheads correspond to pcv positions enlarged in lower 
panels (n=3 embryos/condition/stage). (N) mRNA expression of Egfl7, miR-126, Casz1, and 
Flk1 after infection of HUVECs with shEgfl7. Egfl7 is decreased 11-fold. mRNA levels relative 
to Rps29 ± SEM. ***:p<0.001; NS: not significant. (O) Quantification of cells that round up and 
detach during imaging. Data represent mean ± SEM of 2 experiments conducted on independent 
batches of shRNA-infected cells. (n=100 cells). **:p<0.01. (P) Sprouting angiogenesis assay was 
performed with control and EGFL7-depleted HUVEC. On day 6, cultures were fixed and stained 
for phalloidin (green) and DRAQ5 (blue). Graphs represent mean ± SEM of total sprout length 
and number of branch points/bead (n=11 beads/condition). Experiments were repeated twice on 
independent batches of shRNA-infected cells. **:p<0.01; ***p<0.001. 
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Figure 2.6. EGFL7 and miR-126 play distinct roles downstream of CASZ1. (A) 
Quantification of cells co-infected with shCasz1 and Ad-Egfl7 or Ad-miR-126 that round up and 
detach versus shCasz1 or control shRNA alone. Data represent mean  ± SEM of 2 average 
experiments conducted on independent batches of shRNA-infected cells. (n=100 cells). 
**:p<0.01; ****:p<0.0005. (B) Quantification of cell morphology determined by measuring 
length-to-width (L:W) ratio. Morphology was improved in cells co-infected with shCasz1 and 
Ad-Egfl7 but not in cells co-infected with Ad-miR-126. Data represent mean ± SEM of 3 
experiments conducted on independent batches of shRNA-infected cells. (n=300-600 cells). 
**:p<0.01; ****:p<0.0005. (C) RhoA protein expression in shRNA-infected HUVECs. RhoA 
levels were markedly decreased by depletion of CASZ1 and EGFL7. Graph of densitometry of 
RhoA levels relative to GAPDH. (D) Relative RhoA, RhoB, and RhoC mRNA expression after 
shRNA infection. mRNA levels relative to Rps29 ± SEM. *:p<0.05; ***:p<0.001; NS: not 
significant. (E) Stress fibers and FAs disrupted in CASZ1-depleted HUVECs resemble cells 
treated with ROCK inhibitor Y-27632 (10µM). Restoration of Egfl7 in CASZ1-depleted cells 
rescues proper FA localization. Phalloidin marks F-actin filaments (green), vinculin (red) and 
phosphorylated paxillin (yellow) mark FAs. 
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Figure 2.7. A model describing CASZ1 function in endothelial cells. CASZ1 functions by 
binding to an intronic element within the Egfl7 locus to activate proper levels of Egfl7 in 
endothelial cells. EGFL7 is then secreted to the extracellular matrix (ECM) where it likely binds 
cell-surface receptors which signal downstream to activate RhoA expression. Consequently, 
RhoA signaling modulates endothelial cell behaviors such as adhesion and contractility to 
promote  vessel assembly and morphogenesis. 
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Figure S2.1. CASZ1 is required for vascular development. (A) Vascular explants excluding 
the head, heart, and somitic region were dissected from stage 32 embryos for RNA isolation and 
cDNA synthesis. RT-PCR showed that Casz1 is co-expressed in this region with other vascular 
markers, Msr and Erg. Eomesodermin (Eomes), a marker of the forebrain and primitive 
mesendoderm, was a negative control while Ef1α was a loading control. (B-I) Whole-mount in 
situ analysis with EC marker Erg of stages 29-39 control and CASZ1-depleted embryos (lateral 
view with anterior to left). Erg was a secondary marker used to confirm vascular defects were 
not specific to Msr. Vessel branching and patterning were severely compromised in CASZ1-
depleted embryos. Note lack of branching within vitelline vein network (vvn) as well as reduced 
sprouting of intersomitic vessels (isv). Posterior cardinal vein (pcv). (n=10 
embryos/condition/stage, 3 independent experiments). (J-M) Whole-mount in situ analysis with 
EC marker Msr of stage 29 and 39 control and CASZ1-depleted embryos. (n=10 
embryos/condition/stage, 3 independent experiments). (N-Q) The anterior-most region including 
the cardiac portion was dissected from early tailbud stage 29 control and CASZ1-depleted 
embryos prior to heart tube formation and therefore circulation. Explants were cultured until 
early tadpole stage 36 when the embryo has an established circulation and assayed by in situ 
hybridization with the endothelial marker Ami. (N,P) In the absence of functional circulation, 
control explants form a dense grossly normal vascular network similar to un-manipulated 
embryos (lateral view with anterior to the left). (O,Q) In the absence of CASZ1-depleted cardiac 
tissue and circulation, we observe an identical vascular phenotype in the trunk explants as we do 
in the un-manipulated embryo indicating the vascular defects in the CASZ1-depleted embryos 
are independent of the cardiac defects.  
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Figure S2.2. CASZ1 is required for EC proliferation. (A) Control and shCasz1 cells were 
stained with anti-phospho-histone H3 (pH3-red) and DAPI (blue) to identify mitotic cells. 
Images were taken at 25x magnification while far right panels were taken at 63x. White 
arrowheads indicate pH3-positive cells. Graph represents quantification of pH3-positive cells. 
Data represent mean ± SEM of 3 independent experiments. (n=1000-2500 cells). (B) FACS 
analysis showing CASZ1-depleted cells arrest at G1/S with reduced proportion of cells in S 
phase compared to controls. (C) Control and CASZ1-depleted HUVECs were stained with anti-
cleaved caspase-3 (red) and DAPI (blue) to identify apoptotic cells (top two panels). As a 
positive control, wildtype HUVECs were serum starved for 24 hr to induce apoptosis (lower 
panels). Images were taken at 25x magnification while far left panels were taken at 63x 
magnification. White arrowheads indicate cleaved caspase-3-positive cells. Graph represents 
quantification of cleaved caspase-3-positive cells. Data represent mean ± SEM of 2 independent 
experiments. (n=200-1000 cells). 
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Figure S2.3. Sequence alignment of miR-126 and expression of miR-126 in CASZ1-depleted 
embryos. (A) Xenopus miR-126 was cloned from genomic DNA and confirmed to be located in 
Egfl7 intron 7. Evolutionary conservation of mature miR-126 is shown. (B-I) Whole mount in 
situ analysis of miR-126 of stage 29-39 control and CASZ1-depleted embryos (lateral view with 
anterior to the left). miR-126 expression commences in the  vasculature including the vitelline 
vein network (vvn) at stage 32 (D,E) and remains intact at all stages thereafter even in the 
absence of CASZ1 suggesting that it may be differentially regulated than its host gene. Note the 
robust expression of miR-126 in somites (s). (n=10 embryos/condition/stage, 3 independent 
experiments).      
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Figure S2.4. EGFL7-depletion phenocopies CASZ1-depletion during vascular 
development. (A) RT-PCR analysis of early tailbud stage 29 embryos injected at the one-cell 
stage with 40 ng Egfl7 MO demonstrating inhibition of proper splicing of Egfl7 pre-mRNA. 
Control MO-injected embryos are negative controls and genomic DNA is a positive control for 
PCR amplification. (B-C) Whole mount in situ analysis of miR-126 expression in control and 
EGFL7-depleted early tadpole stage 36 embryos. There are no detectable alterations in miR-126 
expression in EGFL7-depleted embryos. (D-E) Whole mount in situ analysis of Casz1 
expression in control and miR-126-depleted early tadpole stage 36 embryos. There are no 
detectable changes in Casz1 expression in miR-126-depleted embryos. (F-I) Whole-mount in 
situ analysis with EC marker Msr of stage 29 and 39 control and EGFL7-depleted embryos. 
(n=10 embryos/condition/stage, 3 independent experiments). (J-Q) Whole-mount in situ analysis 
with EC marker Erg of stages 29-39 control and EGFL7-depleted embryos (lateral view with 
anterior to left). Vascular branching and patterning were severely disrupted in EGFL7-depleted 
embryos. Vitelline vein network-vvn, posterior cardinal vein- pcv, intersomitic vessels- isv. 
(n=10 embryos/condition/stage, 3 independent experiments). 
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Figure S2.5. miR-126 depletion does not phenocopy CASZ1-depletion during vascular 
development. (A) Relative expression of miR-126 in embryos injected with miR-126 MO 
compared to control. Bars represent expression relative to miR-16 ± SEM. *:p<0.05. (B-C) 
Whole mount in situ analysis of Egfl7 expression in control and miR-126-depleted early tadpole 
stage 36 embryos. There are no detectable alterations in Egfl7 expression in miR-126-depleted 
embryos. (D-E) Whole mount in situ analysis of Casz1 expression in control and miR-126-
depleted early tadpole stage 36 embryos. There are no detectable changes in Casz1 expression in 
miR-126-depleted embryos. (F-U) Whole mount in situ analysis of Msr (F,G,J,K,N,O,R,S) and 
Erg (H,I,L,M,P,Q,T,U) of stages 29-39 control and miR-126-depleted embryos (lateral view with 
anterior to the left). The vasculature forms normally in miR-126-depleted embryos with no 
apparent disruptions in vascular patterning or assembly. Vitelline vein network- vvn, posterior 
cardinal vein- pcv, intersomitic vessels- isv. (n=10 embryos/condition/stage, 3 independent 
experiments). (V-Y) Histological analysis shows normal lumens of pcv in stage 36 (W) and stage 
39 (Y) miR-126-depleted embryos compared to controls (V,X). Dorsal is top, ventral is bottom. 
Arrowheads correspond to positions of pcv which are enlarged in lower panels. (n=2 
embryos/condition/stage). 
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Figure S2.6. Efficacy of Ad-Egfl7 and Ad-miR-126. (A) Western blot of EGFL7 protein in 
HUVECs infected with control shRNA alone or co-infected with 25 MOI (multiplicity of 
infection) Ad-Egfl7. (B) Relative expression of miR-126 in HUVECs co-infected with shCasz1 
and 25 MOI Ad-miR-126 compared to shCasz1 alone. mRNA levels are relative to miR-16 ± 
SEM. *:p<0.05. (C) Phase contrast images demonstrate elongated shCasz1-infected cells become 
more uniform in length and width after co-infection with Ad-Egfl7 but remain thin and elongated 
after co-infection with Ad-miR-126. (D) RhoA activity in un-stimulated (-) and Thrombin-
stimulated (Thr) shRNA-infected HUVECs. RhoA activity was markedly decreased by depletion 
of CASZ1 and EGFL7. (E) Western blot representing unaltered RhoC protein levels in HUVECs 
infected with shCasz1, shEgfl7, or control shRNA. (F) Western blot showing decreased 
phosphorylation of myosin light chain (p-MLC) in CASZ1-depleted HUVECs versus control. 
Graph represents densitometry of p-MLC relative to GAPDH.   
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Table 2.2. Putative direct targets of CASZ1. 
Putative CASZ1 Targets Target DNA Location General Function 
N-myc Downregulated Gene 1 (Ndrg1) 3743 bp 3' Cell Growth Pathway 
Jumonji Domain Containing 1A Internal Cell Growth Pathway 
Cyld 8075 bp 5' Cell Growth Pathway 
MDM2 4868 bp 3' Cell Growth Pathway 
MDM4 Internal Cell Growth Pathway 
Cyclin L2 16 bp 3' Cell Growth Pathway 
Inhibitor of Growth 1 (Ing1) 309 bp 5' Cell Growth Pathway 
Gli2 3680 bp 3' Cell Growth Pathway 
Plexin A2 Internal Migration/Adhesion 
Neurexin 3 Internal Migration/Adhesion 
FAT-J Internal Migration/Adhesion 
Wnt1 Induced Secreted Pathway 1 (Wisp1) Internal and 2867 bp 3' Wnt Signaling Pathway 
Novel Band 4.1-like Protein 4 (NBL4) 6788 bp 5' Wnt Signaling Pathway 
Shisa2 Internal Wnt Signaling Pathway 
Prickle1 Internal Wnt Signaling Pathway 
Msx1 8775 bp 5'  Patterning 
Alk2/ACVR1 9351 bp 5'  Patterning 
Troponin T Type 3 (Tnnt3) 4654 bp 5' Structural 
Myosin 5C internal Structural 
Cytochrome b5 internal Metabolism 
Cytochrome b5 reductase isoform 2 10,000 bp 3' Metabolism 
Cytochrome C Oxidase Subunit VIII-Heart specific isoform 3859 bp 3' Metabolism 
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CHAPTER 3: VASCULAR LUMEN FORMATION IN XENOPUS 
 
Introduction 
 The formation of a functional vascular system during embryogenesis is critical for growth 
and survival. The development of a majority of organs and tissues first requires the proper 
establishment of a closed circulatory loop capable of transporting blood and nutrients, removing 
waste, and facilitating gas exchange. Blood vessels initially arise via vasculogenesis, which is 
characterized by the de novo assembly of endothelial precursors called angioblasts into primitive 
capillary-like networks (Flamme et al., 1997). Further expansion and remodeling of this primary 
plexus occurs by angiogenesis, or the sprouting of new vessels from preexisting vessels. 
Sprouting angiogenesis is the primary means by which a hierarchically branched and perfusable 
vascular system comprised of veins, arteries, and capillaries is ultimately formed (Risau, 1997).  
 
 Vascular development appears to be well-conserved from fish to mammals. An inherent 
feature that makes Xenopus an ideal model in which to study the early events associated with 
endothelial cell assembly is their external development thus enabling one to easily visualize 
embryonic blood vessel formation with minimal physical manipulation. Some of the earliest 
vessels that arise via vasculogenesis in Xenopus include the paired posterior cardinal veins, the 
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dorsal aorta, the vitelline vein network, the aortic arches, and the endocardium, all of which are 
specified from the mesoderm (Cleaver et al., 1997). However, the cellular origins of these 
vessels differ as has been demonstrated by fate-mapping experiments. Ciau-Uitz and colleagues 
demonstrated that by the 32-cell stage, the endothelial lineage becomes restricted to four 
blastomeres each of which give rise to different endothelial cell populations (Ciau-Uitz et al., 
2000; Walmsley et al., 2002). For example, the vitelline vein network originates from 
progenitors distinct from those of the posterior cardinal veins. Angioblasts of the vitelline vein 
network form in close association with hematopoietic precursors in clusters called the ventral 
blood islands. The blood islands are considered to be the initial source of embryonic blood but a 
second wave of hematopoiesis from a distinct mesodermal source has also been shown to occur 
during the development of adult blood (Dzierzak and Speck, 2008; Flajnik et al., 1984; Kau and 
Turpen, 1983; Maeno et al., 1985; Turpen and Knudson, 1982). The dorsal lateral plate 
mesoderm (DLPM) contributes to the posterior cardinal veins, which run bilaterally along the 
length of the embryo, and the dorsal aorta, which runs along the midline ventral to the notochord. 
Adult hematopoietic cells form from the floor of the dorsal aorta, hence the distinction between 
the sources of embryonic and adult blood (Dzierzak and Speck, 2008; Leung et al., 2013). 
 
  The posterior cardinal veins and the dorsal aorta constitute the major embryonic vessels 
and begin forming shortly after neurulation. DLPM angioblasts first align into two bilateral strips 
in an anterior-to-posterior direction beginning at stage 20 (Walmsley et al., 2002). Between 
stages 27 and 33, a subset of these cells migrates over the underlying endoderm to the midline 
where they settle just beneath the hypochord to ultimately form the dorsal aorta (Cleaver and 
Krieg, 1998). It has been shown that this wave of angioblast migration occurs in response to 
105 
 
vascular endothelial growth factor (VEGF) expressed by the hypochord (Cleaver and Krieg, 
1998). It is still unclear whether DLPM cells are the sole contributors to the dorsal aorta as 
studies in chick have also demonstrated a contribution from somitic mesoderm (Pardanaud et al., 
1996; Sato et al., 2008). Migration is completed by stage 33/34 thereby specifying the positions 
where the posterior cardinal veins and dorsal aorta will later differentiate. Tubular vessels 
become apparent beginning at stage 36 concomitant with the commencement of circulation. 
 
 Very few studies to date have examined how vessels generate lumens in Xenopus, 
although Vokes and colleagues demonstrated that the endoderm is required specifically for tube 
formation but not angioblast specification (Vokes and Krieg, 2002). Indeed, vascular lumen 
formation is still an incompletely understood process in other species as well. Studies using 
cultured human endothelial cells, zebrafish, and mouse have elucidated some important 
molecular determinants of vascular lumen formation (Bayless and Davis, 2002; Blum et al., 
2008; Davis and Camarillo, 1996; Helker et al., 2013; Herwig et al., 2011; Strilic et al., 2009; 
Wang et al., 2010). The predominant mechanism by which lumens are generated has been 
termed cord hollowing or extracellular lumen generation indicating a cell-cell separation event 
with the luminal compartment lying between multiple cells. Previous studies in the mouse 
elegantly demonstrated that angioblasts of the dorsal aorta are initially in close contact with each 
other displaying multiple junctions along the contact region (Strilic et al., 2009). Prior to cell-cell 
separation, these vascular cords establish apicobasal polarity with specific proteins including 
moesin, CD34 sialomucins, and non-muscle myosin II localizing to the apical/ luminal surface. It 
is believed that this polarization event drives the redistribution of junctions away from the cord 
center (Strilic et al., 2010a; Strilic et al., 2009). Furthermore, Rho kinase (ROCK)-dependent 
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signaling facilitates the appropriate cell shape changes needed to accommodate the developing 
lumen. Similar cord hollowing mechanisms have been observed in zebrafish vessels however 
additional mechanisms including intracellular lumen formation via coalescence of pinocytic 
vacuoles or apical membrane invagination and lumen ensheathment have also been demonstrated 
thus signifying that different species and/or different vascular beds may use a number of diverse 
ways to generate as well as maintain vascular lumens (Blum et al., 2008; Helker et al., 2013; 
Herwig et al., 2011; Kamei et al., 2006; Wang et al., 2010)[Reviewed in Chapter 1].  
 
 Epidermal Growth Factor-Like domain 7 (EGFL7) is a small protein of 20-30 kD that is 
highly expressed in endothelial cells actively engaging in vessel assembly during embryonic 
development, injury, pregnancy, and tumor growth (Campagnolo et al., 2005; Fan et al., 2013; 
Fitch et al., 2004; Parker et al., 2004). Structural analysis of EGFL7 has revealed it to contain an 
Emilin-like domain characteristic of secreted proteins and indeed, EGFL7 is secreted by 
endothelial cells and deposited into the extracellular matrix (ECM) (Fitch et al., 2004; Lelievre et 
al., 2008). Numerous studies have implicated EGFL7 in vascular lumen morphogenesis as well 
as sprouting angiogenesis. In zebrafish, EGFL7 was shown to be required for the establishment 
of vascular lumens likely by providing a permissive environment for endothelial cell adhesion 
and migration (Parker et al., 2004). In accordance with these studies, we have shown that EGFL7 
is also required for vascular lumen formation in Xenopus and modulates endothelial cell 
behaviors such as cell shape and adiesoin to promote vessel sprouting (Charpentier et al., 2013a). 
Overexpression studies in mouse have further indicated that EGFL7 plays a role in vessel 
patterning and remodeling potentially through its interaction with Notch receptors (Nichol et al., 
2010). Finally, EGFL7 is a currently being investigated in phase II clinical trials by Genentech 
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for its role in promoting tumor angiogenesis. Generation of anti-EGFL7 antibodies has been 
shown to augment the efficacy of anti-VEGF therapies in pruning and damaging tumor vessels in 
non-small cell lung cancer (Johnson et al., 2013). Thus, understanding the function and 
regulation of this protein is of therapeutic value.  
 
 For the first time, we demonstrate the cellular and molecular mechanisms underlying 
vascular lumen formation in Xenopus using the posterior cardinal veins and the dorsal aorta as 
models. While lumens do appear to be generated via cord hollowing, we note some distinct 
features in Xenopus such as the absence of apicobasal polarity. Furthermore, we investigated the 
underlying defects associated with impaired lumen formation in EGFL7-depleted embryos and 
determined that cells fail to undergo proper cell shape changes and resolve cell-cell junctions in 
order to accommodate the luminal compartment.  
  
Materials and Methods 
Xenopus Embryo Manipulation and Collection 
Xenopus embryos were prepared and collected as previously described (Showell et al., 2006). 
Embryos were staged according to Nieuwkoop and Faber (1967). Egfl7 and control morpholinos 
were used as previously described (Charpentier et al., 2013a). Five hundred pg of mRNA 
encoding membrane-GFP/pCS2 (Provided by John Wallingford lab, UT Austin) was co-injected 
with 35 ng of Egfl7 or control morpholino in 1-cell stage embryos. For explant assays, the 
anterior region of stage 28 embryos consisting of the head and heart was removed using 
sterilized forceps. Explants were cultured for 24 hours in 0.1X Modified Barth's Solution (MBS) 
containing 10 ug/mL gentamycin before fixation. 
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Whole Mount in situ Hybridization 
In situ hybridization was carried out as previously described using an anti-sense probe against 
Erg (Charpentier et al., 2013a; Harland, 1991). For experiments in which in situ hybridization 
was coupled with immunohistochemistry, changes to the published in situ protocol were made as 
follows: 1.) Embryos were fixed in 4% paraformaldehyde for 2 hours at room temperature or 4° 
overnight then stored in 1X phosphate buffered solution (PBS); 2.) Fixed embryos were rinsed 
three instead of five times in PBS-T (0.1% Tween-20) prior to Proteinase K treatment; 3.) 
Embryos were incubated in10 ug/mL Proteinase K (Roche) for 10 minutes; 4.) Embryos were 
rinsed once in PBS-T following Proteinase K treatment and were then immediately fixed in 4% 
PFA for 20 minutes; 5.) Following color reaction in BM Purple (Roche), embryos were washed 
several times in 1X PBS and then immediately processed for histology and immunostaining.  
    
Histology 
For time course analysis of lumen formation, in situ hybridization was performed as above using 
the Erg probe. After completion of BM purple color reaction, embryos were dehydrated 
gradually into methanol for at least 24 hours. Embryos were subsequently rehydrated in PBS and 
taken through a gradient of PBS/glycerol before being embedded in a gelatin solution (0.4% 
Gelatin Type A, 27% BSA, 18% sucrose, PBS) mixed with glutaraldehyde. A Leica VT1200S 
vibratome was used to cut 20 um transverse sections. Sections were directly mounted onto slides 
and imaged on an Olympus IX81 inverted fluorescent microscope. For immunohistochemistry, 
following the modified in situ protocol above, embryos were embedded in 4% low melting point 
agarose (Promega) made in 1X PBS. A Leica VT1200S vibratome was used to cut 70 um 
transverse sections which were collected in 0.5X PBS.  
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Immunohistochemistry 
Immunohistochemistry was carried out on sections in a 48-well plate beginning with three 30-
minute PBS-T (1% Triton X-100) washes then incubation for one hour in PBS-T containing 10% 
fetal bovine serum (FBS). Primary antibodies as listed in Table 1 were applied overnight at 4°. 
The following day, sections were washes five times for one hour each in PBS-T before 
incubation with secondary antibodies as listed in Table 1 overnight at 4°. The following day 
sections were again rinsed five times in PBS-T, incubated with 200 ng/mL DAPI/PBS solution 
(Sigma) for 30 minutes, and mounted. Images and Z-stacks were taken with a Zeiss 700 confocal 
microscope.  
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Antibody Catalog Number Dilution Used 
GFP Molecular Probes, A6455 1:1000 
GFP (JL8) Clontech, 632381 1:1000 
ZO-1 Invitrogen, 33-9100 1:100 
Claudin-5 Santa Cruz Biotechnologies, sc-28670 1:500 
Laminin Sigma, L9393 1:250 
Fibronectin Sigma, F3648 1:250 
Atypical PKC zeta Santa Cruz Biotechnologies, sc-216 1:500 
Occludin Invitrogen, 42-2400 1:250 
Alexa Fluor 488 Goat anti-Mouse Molecular Probes, A-11001 1:1000 
Alexa Fluor 488 Donkey anti-Rabbit Molecular Probes, A-21206 1:1000 
Alexa Fluor 546 Goat anti-Mouse Molecular Probes, A21123 1:1000 
Alexa Fluor 546 Goat anti-Rabbit Molecular Probes, A-11010 1:1000 
Table 3.1. List of antibodies used in immunohistochemistry.  
 
Results 
 The mechanisms underlying vascular lumen formation in Xenopus are unknown. To 
begin to investigate this event, we first performed a time course analysis using in situ 
hybridization with an endothelial probe to identify the developmental window when lumens 
arise. We focused our studies on three major vessels, the paired posterior cardinal veins and the 
dorsal aorta, which can all be visualized simultaneously in transverse sections. Initially, 
angioblasts of the DLPM coalesce in two bilateral strips corresponding to the positions of the 
paired posterior cardinal veins (Ciau-Uitz et al., 2000; Walmsley et al., 2002). Beginning around 
stage 32, a subset of these angioblasts migrates over the underlying endoderm towards the 
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midline in response to VEGF signals emanating from the hypochord, a transient structure that 
lies directly ventral to the notochord (Cleaver, 1998; Cleaver et al., 2000). These angioblasts will 
ultimately contribute to the dorsal aorta which will form just beneath the hypochord. This wave 
of migration is completed by stage 33/34 when all three populations of angioblasts can be 
detected by in situ hybridization with the endothelial marker Erg (Figure 3.1A). At this stage, the 
angioblasts have not yet formed functional vessels and cells are coalesced into distinct clusters. 
However by stage 35/36, vascular lumens of both posterior cardinal veins and the dorsal aorta 
become evident indicating that they likely arise simultaneously (Figure 3.1B). As embryogenesis 
progresses, the lumens expand in size and are functional in their ability to circulate blood (Figure 
3.1C). Therefore, we focused our studies on the stage prior to lumen formation (stage 33) and 
immediately following the emergence of lumens (stage 36) to examine the cellular and molecular 
events underlying the formation of functional vascular tubes.  
 
 Previous reports have indicated that circulation is required for vessel remodeling and 
integrity (Lucitti et al., 2007; Udan et al., 2013b; Zhong et al., 2011). To determine whether 
lumens can form in the absence of circulation, we took advantage of the ability to culture 
Xenopus embryo explants. We removed the anterior region of the embryo, including the head 
and the heart, at a stage prior to cardiac development (i.e. stage 28). Within six hours, this wound 
completely heals and the explants can be cultured to the desired developmental time point. We 
assessed the presence of vascular lumens at stage 36 using in situ hybridization with Erg 
followed by histology. The lumens of the posterior cardinal veins and dorsal aorta were 
indistinguishable between un-manipulated and explant embryos (Figure 3.1D-E). These results 
therefore strongly indicate that cardiac development and establishment of circulation are not 
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prerequisites for at least the initial establishment of vascular lumens. However, it remains 
plausible that in the continued absence of circulation, lumens may become unstable and collapse 
as has been demonstrated previously (Chen et al., 2012; Kochhan et al., 2013). 
 
 To investigate lumen morphogenesis at the cellular level, we next coupled whole mount 
in situ hybridization and immunohistochemistry to investigate the cellular morphology prior to 
and following lumen formation. In one-cell stage embryos, we first injected mRNA encoding 
GFP tagged to the small peptide CAAX which results in the ubiquitous sequestration of GFP to 
the cell membrane (MEM-GFP) and therefore enabled us to visualize cell-cell boundaries. We 
performed in situ hybridization with Erg to label our endothelial cell populations and at stage 33, 
we can identify angioblasts of the posterior cardinal veins based on expression of Erg (Figure 
3.2A). Additionally, the posterior cardinal veins develop between the somites and kidneys, 
anatomical landmarks that have a characteristic appearance and therefore can also be used to 
identify the appropriate cells. Angioblasts of the dorsal aorta are more easily identified as they 
are arranged ventral to the hypochord and right on top of the endoderm (Figure 3.2B). At this 
stage, angioblasts can be seen in close contact to one another as a cord-like structure. In 
accordance with this observation, angioblasts of the mouse dorsal aorta are also initially arranged 
as a cord prior to lumen formation (Strilic et al., 2009). The angioblasts of the posterior cardinal 
veins appear to have a polygonal cobblestone-like morphology while dorsal aorta angioblasts 
appear slightly narrower and more elongated (Figure 3.2A-B). In agreement with the overall 
vessel morphology shown previously, at stage 36 vascular lumens of all vessels become 
discernible and are accompanied by alterations to endothelial cell morphology (Figure 3.2C-D). 
Similar to the mouse dorsal aorta, in Xenopus, the posterior cardinal vein and dorsal aorta cells 
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become narrower and more elongated likely in order to accommodate the developing luminal 
compartment. Taken together, thus far it appears that Xenopus lumen formation is facilitated by 
endothelial cell shape changes indicating this is a conserved event between amphibians and 
mammals.  
 
 In addition to cell morphology alterations, studies in human tissue culture models, 
zebrafish, and mouse have elucidated additional molecular determinants such as the role of cell-
cell junctions and establishment of apicobasal polarity to play an important role during vascular 
lumen formation. To that end, we next examined the expression and distribution of cell junction 
molecules as a function of time. Tight junctions between endothelial cells during early stages of 
vessel assembly have been reported in zebrafish (Jin et al., 2005). We first looked at the 
expression of zonula occludens-1 (ZO-1), a well-established marker of tight junctions ((Dejana 
et al., 2009)+more). In addition to expression in endothelial cells, ZO-1 labels tight junctions in 
other cell types such as the kidney and epithelium. At stage 33, ZO-1 is expressed in a discrete 
dot-like pattern between Erg-expressing angioblasts of the posterior cardinal veins (Figure 
3.3A). Multiple ZO-1-containing puncta are observed at the cell-cell interface indicating contacts 
between the cells. The junctions are redistributed but are maintained at points of cell-cell contact 
at stage 36 when lumens have formed (Figure 3.3B). In the dorsal aorta at stage 33, ZO-1 is also 
expressed in discrete points between angioblasts and sometimes also appears in a linear pattern 
potentially reflecting the more elongated morphology of the dorsal aorta angioblasts compared to 
those of the posterior cardinal veins (Figure 3.3C). At stage 36, the dorsal aorta luminal 
compartment is surrounded by endothelial cells maintaining ZO-1-containing tight junctions, 
similar to the veins (Figure 3.3D). 
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 Claudin-5 is another marker of tight junctions that has been shown to be restricted to cell 
types of the cardiovascular lineage (Morita et al., 1999). Examination of Claudin-5 expression in 
the posterior cardinal veins and dorsal aorta reveals that in contrast to ZO-1, Claudin-5 is absent 
from tight junctions between angioblasts at stage 33 (Figure 3.4A, C). However, once lumens 
have formed, Claudin-5 is distinctly detected at points of cell-cell contact in both the veins and 
the aorta (Figure 3.4B, D). Taken together, these results indicate that tight junctions are 
hierarchically assembled, with expression of ZO-1 marking tight junctions prior to as well as 
following lumen formation and Claudin-5 marking tight junctions only once lumens are evident 
potentially denoting mature and differentiated vessels as opposed to immature angioblasts. A 
similar spatial and temporal expression pattern has also been noted in zebrafish vessels (Jin et al., 
2005).   
 
 In mouse and zebrafish, it has been shown that the driving force between cell-cell 
separation during lumen formation is the establishment of apicobasal polarity. Specifically, the 
apical or luminal surface is defined by the localization of certain markers, including moesin and 
CD34 sialomucin podocalyxn-like protein (PODXL), to this surface even prior to cell-cell 
separation (Strilic et al., 2009; Wang et al., 2010). To address whether a similar mechanism takes 
place during Xenopus lumen formation, we examined the distribution of the apical marker, 
atypical protein kinase C-zeta (aPKC), which is known to be expressed in endothelial cells as 
well as epithelial tissues such as the kidney (Chen and Zhang, 2013; Joberty et al., 2000; Koh et 
al., 2008). At stage 33, aPKC can be detected on the apical surface of the kidney but is absent 
from the basal surface (Figure 3.5A). However, aPKC expression is absent from either surface 
in Erg-expressing endothelial cells of the posterior cardinal veins implying that apical polarity is 
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not established prior to the emergence of lumens (Figure 3.5A). In mouse and zebrafish, 
localization of markers to the apical surface persists after the cells separate and a lumen is 
formed. In contrast, in stage 36 Xenopus posterior cardinal veins, aPKC continues to be absent 
from the luminal surface however is maintained in the kidney (Figure 3.5B). aPKC expression 
is also absent at both stages of dorsal aorta lumen development (Figure 3.5C-D). These results 
show that apical polarity does not appear to be a determinant of vascular lumen formation in 
Xenopus.  
     
 In addition to apical polarity, a hallmark of mature vessels is the deposition of distinct 
proteins into the basement membrane surrounding the basal surface of endothelial cells. These 
proteins include laminin, collagen, and fibronectin which play a role in recruiting mural cells 
such as smooth muscle cells to endothelial cell-lined tubes as well as provide cues instructing 
vessels to stay quiescent or initiate sprouting (Davis and Senger, 2005; Hynes, 2007; Stratman et 
al., 2009). Laminin is expressed in epithelial tissues in addition to endothelial cells and can be 
detected on the basal surface of the kidney in Xenopus but not on the apical surface (Figure 
3.6A). Intriguingly, in stage 36 posterior cardinal veins and aortas, laminin is not only expressed 
on the basal surface of the vessels but is also enriched on the apical surface (Figure 3.6A-B). 
Furthermore, staining of the veins and aorta with fibronectin also reveals both basal and apical 
expression (Figure 3.6C-D). Taken together with the aPKC staining, these results indicate that 
unlike other species, Xenopus vessels are not in fact polarized and lumens likely form via a 
mechanism independent of initial establishment of apicobasal polarity. 
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 We and others have previously reported that the small ECM protein Epidermal Growth 
Factor-Like domain 7 (EGFL7) is required for vascular lumen formation (Charpentier et al., 
2013a; Parker et al., 2004). However, the underlying basis for impaired lumen formation in the 
absence of EGFL7 remains unclear. Time course analysis by in situ hybridization with Erg 
indicates that angioblasts have properly migrated and are correctly positioned at the locations of 
the paired posterior cardinal veins and the dorsal aorta in stage 33 EGFL7-depleted Xenopus 
embryos indicating that initial specification and migration of angioblasts is not defective (Figure 
3.7A). However, at stage 36, EGFL7-depleted angioblasts fail to separate and neither the 
posterior cardinal vein or dorsal aorta lumens form (Figure 3.7B). At the cellular level, EGFL7-
depleted angioblasts of the posterior cardinal veins have a comparable polygonal cell 
morphology to control embryos prior to lumen formation at stage 33 (Figure 3.7C). In addition, 
depletion of EGFL7 did not affect the cellular morphology of dorsal aorta angioblasts at stage 33 
and they remain in a slightly narrower, elongated shape similar to control cells (Figure 3.7E). 
However at stage 36, EGFL7-depleted posterior cardinal vein angioblasts fail to change their cell 
shape and remain cobblestone-like (Figure 3.7D). Accordingly, EGFL7-depleted dorsal aorta 
angioblasts also fail to undergo further elongation that typically accompanies lumen formation 
(Figure 3.7F). Taken together, these results indicate that EGFL7 is required for the proper cell 
shape changes underlying formation of vascular lumens.  
 
   To investigate the underlying basis for failed lumen formation in the absence of EGFL7, 
we first examined the distribution of cell junctions in EGFL7-depleted angioblasts. Staining of 
the posterior cardinal vein angioblasts with ZO-1 at stage 33 did not reveal any noticeable 
differences in tight junction localization compared to control embryos (Figure 3.8A). ZO-1-
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containing junctions appeared as distinct puncta between adherent angioblasts. Similarly, ZO-1 
localization appeared normal in stage 33 EGFL7-depleted dorsal aorta angioblasts (Figure 3.8C). 
However, at stage 36, EGFL7-depleted angioblasts continued to remain attached to each other as 
evidenced by the retention of tight junctions between cells (Figure 3.8B, D). Therefore, it 
appears that junctions do not properly redistribute away from the cord center in the absence of 
EGFL7. Further analysis of tight junctions by Claudin-5 expression indicated that prior to lumen 
formation, Claudin-5 is absent from tight junctions between angioblasts of the posterior cardinal 
vein and dorsal aorta, similar to control embryos (Figure 3.9A, C). Interestingly, despite the 
impaired formation of lumens in stage 36 posterior cardinal veins or dorsal aortas, Claudin-5-
containing tight junctions become apparent between EGFL7-depleted angioblasts (Figure 3.9B, 
D). While the onset of Claudin-5 does not appear to be altered in the absence of EGFL7, these 
results raise the possibility that EGFL7-depleted angioblasts may be delayed in either undergoing 
appropriate cell shape changes or resolving ZO-1-containing tight junctions. Therefore, by the 
time lumens should be generated (stage 36), additional Claudin-5-containing tight junctions are 
formed potentially prohibiting any further attempts for the cells to separate and leaving them 
"stuck" together.  
 
Discussion 
 The transition from cords of angioblasts into functional vascular tubes is a dynamic 
morphogenetic process requiring cells to alter their behaviors to promote the expansion of a 
luminal compartment. Here we have demonstrated some of the cellular and molecular 
determinants underlying lumen formation of major vessels in Xenopus. Following specification 
of the endothelial lineage from the dorsal lateral plate mesoderm and subsequent migration of 
angioblasts to the position of the dorsal aorta, angioblasts of the posterior cardinal veins and 
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aorta are initially found adhered to one another through the formation of ZO-1-containing tight 
junctions. In addition, the cells exhibit a cobblestone-like appearance at this stage further 
indicative of immature angioblasts. These initial events appear to be highly conserved as similar 
cord-like structures have been observed in zebrafish and mouse major vessels (Jin et al., 2005; 
Strilic et al., 2009). In all three species, the presence of lumens is accompanied by elongation of 
cell shape and redistribution of junctions away from the cord center. Furthermore in Xenopus, we 
have shown that lumen-containing vessels are also characterized by the formation of additional 
tight junctions expressing Claudin-5. In zebrafish, ZO-1 expression also precedes Claudin-5 
expression potentially indicating that Claudin-5 marks more mature vessels (Jin et al., 2005). 
However, while Claudin-5 expression was restricted to the arterial lineage in zebrafish, we did 
not observe a difference in expression between arteries and veins in Xenopus. 
 
 The most surprising finding during Xenopus lumen formation is that apicobasal polarity 
does not seem to established. While enrichment of makers such as moesin, CD34 sialomucin 
podocalyxn-like protein (PODXL), and non-muscle myosin II to the apical surface is evident 
even as early as the vascular cord stage in mouse and zebrafish, we fail to ever detect apical 
expression of aPKC in vessels prior to or following lumen formation (Nielsen and McNagny, 
2008; Strilic et al., 2009; Wang et al., 2010). This finding is fascinating for a number of reasons. 
First, depletion of proteins that localize to the apical membrane such as moesin and PODXL in 
mouse or zebrafish results in significantly impaired lumen formation indicating that their 
presence at the apical surface is required for cell-cell separation events (Strilic et al., 2009; Wang 
et al., 2010). Second, the adherens junction molecule VE-Cadherin has also been shown to play a 
role in establishing vessel apicobasal polarity and in the absence of VE-Cadherin, vessels display 
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non-specific and abnormal localization of apical and basal markers and lumens fail to form 
properly (Lampugnani et al., 2010; Strilic et al., 2009; Wang et al., 2010). Third, it was shown 
that the negative charge of the sialic acids on PODXL is the primary force responsible for cell-
cell repulsion. Collectively, these previous studies implicate a strong role for polarity in dictating 
cell behavior and establishing proper vessel structure so our finding that lumens in Xenopus form 
despite enrichment of markers to the apical surface indicates that lumens must arise in a polarity-
independent manner. A recent study that uncovered a novel mechanism of lumen formation in 
zebrafish in which endothelial cells collectively migrate to wrap around a luminal compartment 
also noted the absence of polarity markers thus supporting a polarity-independent mechanism 
(Helker et al., 2013). However, what then is the driving force underlying cell-cell separation in 
Xenopus? We also found that basement membrane markers are atypically deposited in Xenopus 
vessels. Laminin and fibronectin are not only expressed on the basal surface of the vessels but 
also on the apical surface in contrast to findings in zebrafish and mouse (Jin et al., 2005; Xu and 
Cleaver, 2011; Xu et al., 2011). Interestingly, invertebrates do not have endothelial cells but still 
contain a rudimentary vascular system which includes a dorsal aorta (Hartenstein and Mandal, 
2006). In amphioxus, the dorsal aorta arises on top of a basement-membrane lined endoderm and 
unlike mammalian vessels, the lumen of the amphioxus aorta is lined with the basement 
membrane protein laminin (Kucera et al., 2009). These findings suggest that endothelial cells 
arose as a consequence of evolution to serve as a barrier between basal and apical surfaces. Thus, 
the absence of this polarized endothelium in Xenopus may signify the remnants of an early 
ancestor that survived the course of vertebrate evolution. The study in amphioxus further 
suggests that lumens may be generated by the action of phagocytic blood cells that degrade the 
extracellular matrix. It remains to be established whether this is the case in Xenopus or whether 
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cell-cell repulsion occurs via opposing charges similar to PODXL. It is also noteworthy that the 
major vessels in Xenopus arise in close association with basement membranes of other organs; 
for example, the kidney in the case of the posterior cardinal veins and the gut endoderm in the 
case of the dorsal aorta. It is therefore possible that these adjacent basal surfaces may play some 
role in the shaping of vascular tubes perhaps by providing a scaffold on which to assemble or in 
more direct ways by means of cell-cell crosstalk. Our results call for future studies aimed at 
examining the direct role of polarity, if any, in establishing vascular lumens in Xenopus. The 
continuous generation of specific antibodies in Xenopus will also help in addressing the 
localization of other known apical membrane markers.  
 
 We have further delineated the underlying basis for the lumen formation defects observed 
in EGFL7-depleted embryos. Angioblasts appeared indistinguishable between control and 
EGFL7-depleted embryos at stage 33 before the commencement of lumen formation. EGFL7-
depleted angioblasts maintained tight junctions expressing ZO-1 between each other and 
exhibited the characteristic polygonal cellular morphology indicative of cord-like structures. 
However, in the absence of EGFL7, angioblasts fail to elongate and resolve their junctions away 
from the cord center resulting in the absence of vascular lumens in the majority of cases. These 
findings are in line with the published literature. In EGFL7-depleted zebrafish, angioblasts of the 
major vessels also fail to redistribute ZO-1-containing junctions and thus remain coalesced 
together (Parker et al., 2004). Although the exact mechanisms underlying cell shape remain to be 
elucidated, it has been shown that Rho GTPase signaling is a major factor in modulating the 
cytoskeleton. In fact, in the mouse dorsal aorta, impaired Rho kinase (ROCK) signaling was 
associated with failure of cells to properly elongate and subsequently form lumens (Strilic et al., 
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2009). We have recently demonstrated that EGFL7 lies upstream of the RhoA pathway wherein 
EGFL7-depleted human endothelial cells exhibit significantly reduced RhoA mRNA as well as 
protein levels leading to altered cell morphology and aberrant focal adhesion formation 
(Charpentier et al., 2013a). Thus in line with these results, the failure of EGFL7-depleted 
angioblasts to undergo proper cell shape changes may be attributed to dysregulation of Rho 
signaling. However, it still remains to be determined how Rho signaling influences lumen 
formation in the context of the embryo. 
 
  The finding that Claudin-5 becomes expressed in tight junctions of EGFL7-depleted 
embryos despite the absence of a visible vascular lumen raises a number of questions and ideas. 
Does Claudin-5 mark mature vessels or differentiated endothelial cells? Thus the absence of 
Claudin-5 in stage 33 angioblasts and its onset at stage 36 in both control and EGFL7-depleted 
embryos would imply that Claudin-5 might serve as a marker of differentiated endothelial cells 
but not necessarily of functional vessels. This would therefore indicate that EGFL7 is not 
required for endothelial cell differentiation but rather the processes and behaviors associated with 
remodeling of the cells into distinct, perfusable vessels. However, studies on Claudin-5 strongly 
implicate its role in maintaining vascular barrier function, particularly that of the blood-brain-
barrier (BBB). In zebrafish, Claudin-5 is highly expressed in endothelial cells of the brain 
vasculature at a stage when the BBB is established consistent with the presence of a vascular 
barrier (Xie et al., 2010). Furthermore, Claudin-5-null mice do not exhibit any defects in 
vasculogenesis but at later stages display selective BBB defects further implying that only 
mature vessels express and require Claudin-5 within tight junctions (Nitta et al., 2003). Finally, 
Jin et al. and colleagues demonstrated that zebrafish angioblasts express ZO-1 prior to tube 
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formation and the onset of Claudin-5 expression coincides with the emergence of vascular 
lumens (Jin et al., 2005). Therefore, it is more likely that Claudin-5 becomes expressed in tight 
junctions once vessels require a barrier that is impermeable to diffusion of soluble particles. 
However, EGFL7-depleted embryos do not even have vascular lumens in need of gate-keeping 
yet express Claudin-5. We propose that the onset of Claudin-5 is temporally regulated and its 
appropriate expression at stage 36 likely reflects a delay in EGFL7-depleted angioblasts from 
undergoing cell shape changes or resolving cell-cell junctions in a timely manner. It is possible 
that the formation of Claudin-5-expressing tight junctions may even further exacerbate the 
defects associated with EGFL7-depletion as they may in fact further restrict the cells from 
altering their morphologies or prevent them from re-localizing these new junctions in addition to 
the preexisting ZO-1-containing junctions away from the cord center. Consequently, EGFL7-
depleted angioblasts may end up being "stuck" together and unable to generate lumens. It would 
be interesting to note whether there are differences in the stability of ZO-1 versus Claudin-5-
containing junctions, and whether the intracellular mechanisms responsible for the break down 
and reformation of each are distinct.  
 
 We have for the first time demonstrated how vascular lumens arise in the major vessels in 
Xenopus. Although some of the steps in lumen formation are conserved between Xenopus and 
mammals, we have also discovered some novel features in Xenopus vessels, such as the lack of 
distinct apical and basal surfaces, that may predate back to the simple cardiovascular systems of 
invertebrates. Thus Xenopus may serve as a useful model in which to study the evolutionary 
basis of endothelial cell development. Furthermore, we have performed detailed analysis of the 
lumen formation defects associated with EGFL7-depletion. These studies have raised interesting 
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questions about the expression of tight junction molecules during early vascular development in 
the embryo and how the distribution of tight junctions may be affected by extracellular matrix 
factors.  
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Figure 3.1. Time course analysis of lumen formation in Xenopus. (A) In situ hybridization 
was performed using the endothelial-specific probe Erg. At stage 33, angioblasts are arranged in 
the positions of the future posterior cardinal veins (PCV; bottom squares) and dorsal aorta (DA; 
top square). (B) At stage 36, lumens surrounded by Erg-expressing cells are evident. (C) Lumens 
continue to expand in size by stage 39. (D) In situ hybridization using the Erg probe 
demonstrates that un-manipulated embryos at stage 36 display normal lumens of the posterior 
cardinal veins and dorsal aorta. (E) Explants in which the head and heart have been removed at a 
stage prior to heart development also display normal lumens by stage 36 indicating that 
circulation is not a requirement for initial establishment of vascular lumens. Boxes correspond to 
areas magnified to 40x as seen in the bottom panels.  
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Figure 3.2. Cellular morphology of angioblasts undergoing lumen formation. (A) In situ 
hybridization using the Erg probe was performed on wildtype embryos injected with MEM-GFP 
RNA. At stage 33, polygonal cobblestone-like angioblasts can be detected in the Erg-expressing 
posterior cardinal vein (PCV) region. (B) At stage 36 when posterior cardinal vein lumens 
become discernible, angioblasts elongate their shape to accommodate the developing luminal 
compartment. Dotted lines correspond to angioblasts while solid lines correspond to the kidney. 
(C) In the dorsal aorta (DA), angioblasts appear slightly narrower in size compared to posterior 
cardinal vein angioblasts at stage 33. (D) Dorsal aorta angioblasts also undergo further 
elongation of their shape to accommodate the lumen. Dotted lines correspond to angioblasts 
while solid lines correspond to the hypochord.  
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Figure 3.3. Distribution of ZO-1 tight junctions during lumen formation. (A) In situ 
hybridization using the Erg probe (DIC) was performed on wildtype embryos injected with 
MEM-GFP RNA followed by immunohistochemistry using GFP (green) and ZO-1 (red) 
antibodies. Tight junctions can be found along cell-cell contact area between Erg-expressing 
angioblasts in stage 33 posterior cardinal veins (PCV). (B) ZO-1 tight junctions redistribute away 
from the cord center but remain between cells once posterior cardinal vein lumens have formed 
by stage 36. (C) Tight junctions are also found between angioblasts of the dorsal aorta (DA) at 
stage 33. (D) Tight junctions are redistributed between dorsal aorta cells during lumen formation 
at stage 36.    
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Figure 3.4. Distribution of Claudin-5 tight junctions during lumen formation. (A) In situ 
hybridization using the Erg probe (DIC) was performed on wildtype embryos injected with 
MEM-GFP RNA followed by immunohistochemistry using GFP (green) and Claudin-5 (red) 
antibodies. Claudin-5 expressing tight junctions are absent from angioblasts of the posterior 
cardinal vein (PCV) at stage 33. (B) The formation of Claudin-5 containing tight junctions 
becomes apparent between posterior cardinal vein angioblasts once lumens are formed at stage 
36. (C) Claudin-5 containing tight junctions are also absent from dorsal aorta (DA) angioblasts at 
stage 33. (D) Claudin-5-containing tight junctions are formed once dorsal aorta lumens develop.  
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Figure 3.5. atypical PKC is not enriched on the apical surface of vessels in Xenopus. (A) In 
situ hybridization using the Erg probe (DIC) was performed on wildtype embryos injected with 
MEM-GFP RNA followed by immunohistochemistry using GFP (green) and atypical PKC 
(aPKC; red) antibodies. While aPKC  is expressed on the apical surface of the kidney, apical 
enrichment in stage 33 angioblasts is not apparent in the posterior cardinal veins (PCV). (B) By 
stage 36, aPKC is still absent from the apical surface in posterior cardinal veins with lumens.  
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Figure 3.6. Basement membrane proteins are not exclusively deposited on the basal surface 
of vessels in Xenopus. (A) In situ hybridization using the Erg probe (DIC) was performed on 
wildtype embryos injected with MEM-GFP RNA followed by immunohistochemistry using GFP 
(green) and laminin (red) antibodies. Laminin can be detected on the basal surface of the kidney 
but is also deposited on the apical surface of the posterior cardinal veins (PCV) at stage 36. (B) 
Laminin can also be detected on the apical surface of the dorsal aorta (DA). (C) Fibronectin (red) 
is also deposited on the apical and basal surfaces of stage 36 posterior cardinal veins.  
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Figure 3.7. Time course analysis of lumen formation in EGFL7-depleted embryos. (A) In 
situ hybridization was performed using the endothelial-specific probe Erg. At stage 33, 
angioblasts of EGFL7-depleted embryos are correctly positioned at the future posterior cardinal 
veins (PCV; bottom squares) and dorsal aorta (DA; top square). (B) At stage 36, EGFL7-
depleted angioblasts fail to properly separate and generate vascular lumens. (C) In situ 
hybridization using the Erg probe (DIC) was performed on EGFL7-depleted embryos injected 
with MEM-GFP RNA (green). At stage 33, EGFL7-depleted angioblasts of the posterior cardinal 
veins display a normal, polygonal morphology similar to controls. (D) At stage 36, EGFL7-
depleted cells do not undergo proper cell shape changes and posterior cardinal vein lumens fail 
to form. (E) The cellular morphology of EGFL7-depleted angioblasts in stage 33 dorsal aortas is 
not significantly altered compared to control. (F) However in stage 36 EGFL7-depleted embryos 
at stage 36, the lack of discernible dorsal aorta lumens is accompanied by angioblasts that failed 
to elongate.  
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Figure 3.8. Distribution of ZO-1 tight junctions in EGFL7-depleted vessels. (A) In situ 
hybridization using the Erg probe (DIC) was performed on wildtype embryos injected with 
MEM-GFP RNA followed by immunohistochemistry using GFP (green) and ZO-1 (red) 
antibodies. Tight junctions can be found along cell-cell contact area between Erg-expressing 
angioblasts in stage 33 posterior cardinal veins (PCV). (B) EGFL7-depleted angioblasts of the 
posterior cardinal veins fail to redistribute ZO-1 tight junctions away from the cord center and 
vascular lumens fail to form. (C) Tight junctions are also found between angioblasts of the dorsal 
aorta (DA) at stage 33. (D) Failed lumen formation in EGFL7-depleted dorsal aortas is 
accompanied by retention of ZO-1 tight junctions between angioblasts at stage 36.    
137 
 
 
 
 
 
 
 
 
138 
 
Figure 3.9. Distribution of Claudin-5 tight junctions in EGFL7-depleted vessels. (A) In situ 
hybridization using the Erg probe (DIC) was performed on EGFL7-depleted embryos injected 
with MEM-GFP RNA followed by immunohistochemistry using GFP (green) and Claudin-5 
(red) antibodies. Claudin-5 expressing tight junctions are absent from angioblasts of the posterior 
cardinal vein (PCV) at stage 33. (B) Claudin-5 tight junctions are apparent between EGFL7-
depleted angioblasts of the posterior cardinal veins despite the lack of discernible lumens. (C) 
Claudin-5 expression is absent from tight junctions in stage 33 EGL7-depleted dorsal aortas 
(DA) similar to controls. (D) Claudin-5 tight junctions form between angioblasts in the absence 
of EGFL7 and in the absence of a vascular lumen  
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
 
 The formation of a highly branched and functional vascular system consisting of 
capillaries, veins, and arteries requires endothelial cells to carry out many dynamic behaviors 
including migration, proliferation, sprouting, changes in cell shape, and alterations in cell-cell 
and cell-matrix adhesion (Eilken and Adams, 2010; Geudens and Gerhardt, 2011; Udan et al., 
2013a). Endothelial cells must harness their individual behaviors and unite as a cohort to 
properly align and pattern vascular structures. A complex interplay among growth factors, 
cytoskeletal modulators, transcription factors, and intracellular signaling pathways must be 
coordinated to elicit proper endothelial cell movements for each step of vascular assembly 
(Marcelo et al., 2013; Park et al., 2013; Patel-Hett and D'Amore, 2011; Vieira et al., 2010). 
Although many aspects of this interplay have been described, we have yet to uncover networks 
that more fully account for how perturbations in a given factor, such as a transcription factor, 
change the expression, distribution, and activity of downstream effectors that result in particular 
cellular phenotypes. 
 
 CASTOR (CASZ1) is an evolutionarily conserved para-zinc finger transcription factor 
expressed in the cardiovascular system of vertebrate species (Christine and Conlon, 2008; Liu et 
al., 2006). CASZ1 is required for cardiomyocyte differentiation during Xenopus cardiac 
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development, but further functional studies elucidating the role of CASZ1 in vertebrate 
development are still needed. In addition to the heart, Casz1 transcripts are also found within 
developing Xenopus blood vessels, and recent genome-wide association studies have uncovered 
a link between the human Casz1 locus and vascular disease risk factors including hypertension 
and high blood pressure (Christine and Conlon, 2008; Takeuchi et al., 2010). The purpose of this 
dissertation, therefore, was to examine the mechanisms by which CASZ1 regulates blood vessel 
development. Using Xenopus embryos and a primary human endothelial cell line, we found that 
CASZ1 is critical for endothelial cell behaviors including adhesion, proliferation, and changes in 
cell shape associated with vessel assembly, sprouting, and lumen morphogenesis. By performing 
a screen for CASZ1 transcriptional targets, we found that CASZ1 regulates blood vessel 
development through the extracellular matrix (ECM) factor Epidermal growth factor-like domain 
7 (Egfl7). Moreover, we discovered that the CASZ1/Egfl7 transcriptional pathway regulates a 
major signaling cascade directly responsible for cell adhesion and morphology. This dissertation 
thus comprises a set of studies that more directly link the transcriptional regulation of gene 
expression to physiological outputs. Furthermore, this dissertation demonstrates that seemingly 
simple cellular processes, such as alterations in cell-matrix adhesion, require the combined 
efforts of transcriptional regulators, extracellular factors, and intracellular signaling networks.  
 
Expression and Function of CASZ1 in Endothelial Cells 
 Consistent with the results of a previous study (Christine and Conlon, 2008), in Chapter 2 
we confirmed that CASZ1 is expressed in the vasculature during embryonic development. In 
addition to its expression in Xenopus vessels, we showed that CASZ1 is also expressed in mouse 
and human endothelial cells, suggesting that the role of CASZ1 in vascular biology is 
evolutionarily conserved. CASZ1-depleted Xenopus embryos display several severe vascular 
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defects independent of the role of CASZ1 in cardiogenesis. First, the vitelline vein networks of 
CASZ1-depleted embryos are markedly underdeveloped. Vessels that do form run in a dorsal-to-
ventral direction with little branching and intermingling, resulting in a poorly assembled vascular 
plexus. Second, sprouting of intersomitic vessels from the posterior cardinal veins, a process 
known to occur via angiogenesis, is delayed or completely stunted. Third, in the absence of 
CASZ1, major vessels such as the posterior cardinal veins and dorsal aorta fail to generate 
vascular lumens and thus are not properly remodeled into functional tubes. Studies in human 
umbilical vein endothelial cells (HUVECs) provide insights into the underlying basis of vascular 
defects in vivo. For example, CASZ1-depleted HUVECs fail to progress through the cell cycle, 
exhibit a dramatically elongated morphology, and are unable to maintain adhesion to the 
underlying substrate. Proliferation, cell shape, and cell-matrix adhesion are all critical for proper 
vascular assembly, sprouting, and lumen morphogenesis (Fryer and Field, 2005; Lebrin et al., 
2004; Noseda et al., 2004; Strilic et al., 2009; Wary et al., 2012).  
 
 Outstanding questions remain as to whether CASZ1 has specific functions during 
different steps of vascular assembly that correlate with its expression. For example, although we 
showed that Casz1 transcripts localize to vitelline veins, their expression is lower than that in 
other Casz1-expressing tissues such as somites and heart. Therefore, could CASZ1 be expressed 
in discrete subsets of endothelial cells depending on their current behavior? Is CASZ1 expressed 
in sprouting endothelial cells during active vascular expansion or is it more broadly distributed in 
the vasculature? In particular, it would be interesting to carefully examine CASZ1 expression in 
endothelial cells from the standpoint of angiogenic sprouting. Endothelial cells undergoing 
angiogenesis display unique characteristics depending on whether they are actively sprouting. 
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Endothelial "tip cells" guide new vessels by loosening cell-cell adhesions, degrading the 
surrounding ECM, extending filopodia, and migrating out to form new sprouts in response to a 
gradient of soluble VEGF (Benedito et al., 2009; Gerhardt et al., 2003; Hellstrom et al., 2007; 
Leslie et al., 2007; Lobov et al., 2007). Endothelial cells that remain behind are known as "stalk 
cells" that are phenotypically distinct from tip cells, as they maintain the lumen and structure of 
the parent vessel and actively proliferate to allow the new sprout to extend. Thus, it would be 
fascinating to examine whether CASZ1 is preferentially expressed in tip versus stalk cells, as this 
would provide further clues to the precise function of CASZ1 during vascular assembly.  
 
 The vitelline vein network in Xenopus initially arises via vasculogenesis, but the extent to 
which this network expands and becomes remodeled by angiogenesis is unknown (Cleaver et al., 
1997; Levine et al., 2003). Our studies indicate that angiogenesis occurs within this region based 
on the following observations: 1) CASZ1-depleted endothelial cells are properly specified and at 
least initially coalesce into vascular structures within the vitelline vein network; 2) CASZ1-
depleted cells successfully migrate and coalesce at proper positions of major vessels; and 3) 
angiogenic sprouting of intersomitic vessels from properly patterned (but not remodeled) 
posterior cardinal veins is impaired in CASZ1-depleted embryos. Thus, we speculate that 
CASZ1 is not required for specification, migration, or initial patterning of vessels but is critical 
for further expansion by angiogenesis and vascular remodeling. Furthermore, based on the role 
of CASZ1 in the maintenance of adhesion, proliferation, and lumen morphogenesis, we speculate 
that CASZ1 may be expressed in endothelial stalk cells. Although CASZ1 expression throughout 
the major vessels may be required for lumen morphogenesis, CASZ1 expression could also be 
restricted in a network of small-caliber vessels such as vitelline veins. Although tip cells are 
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responsible for initiating and extending new sprouts, stalk cells are required for providing 
connectivity with the parent vasculature and proper vessel architecture, and impaired stalk cell 
function is associated with tip cell sprout regression (Phng et al., 2009; Sharghi-Namini et al., 
2014). Thus, the inability of CASZ1-depleted cells to make new connections may be due to 
impaired stalk cell behaviors, such as reduced proliferation and failure to undergo proper 
changes in cell shape to maintain a tubular structure. CASZ1-depleted stalk cells may thus be 
unable to keep up with tip cells and thereby prevent new vessel formation. Additionally, the 
characteristic cobblestone appearance of HUVECs is significantly altered in the absence of 
CASZ1. Although filopodial extensions and motility were not examined in our study, it is 
tempting to speculate that our findings are indicative of a change in cell fate from a structural 
stalk cell to a more tip cell-like phenotype. 
 
 Although the lack of robust antibodies and methods to visualize the vitelline vein 
network outside of its endogenous location overlaying a yolky and autofluorescent endoderm 
creates challenges in precisely characterizing the expression of CASZ1 in Xenopus embryos, the 
sprouting angiogenesis assay described in Chapter 2 is one way to examine CASZ1 localization 
during multiple steps of angiogenesis (Nakatsu et al., 2003). A more in vivo approach would be 
to employ the mouse retina angiogenesis model that has been extensively used in studies of tip 
and stalk cell dynamics (Fruttiger, 2007; Gariano and Gardner, 2005; Stahl et al., 2010; Uemura 
et al., 2006). Nonetheless, the studies described in Chapter 2 reveal a novel role for CASZ1 
during vascular assembly and provide a foundation for future studies aimed at deciphering the 
likely diverse roles played by CASZ1 during each step of vessel development.   
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 CASZ1 Regulates Blood Vessel Assembly and Morphogenesis through its Direct Target 
Egfl7 
 The studies described in Chapter 2 also aimed to uncover the mechanisms by which 
CASZ1 regulates vascular development, specifically by validating a putative transcriptional 
target of CASZ1 identified by a cloning chromatin immunoprecipitation (ChIP) screen from 
cardiovascular-enriched tissue. Egfl7 was chosen as the top candidate target given its previously 
established role in vascular lumen formation and sprouting angiogenesis and because intron 7 of 
Egfl7 houses the endothelial-specific microRNA miR-126, which was once heavily investigated 
for its role in maintaining vascular integrity and promoting angiogenic signaling (Fish et al., 
2008; Kuhnert et al., 2008; Parker et al., 2004; Schmidt et al., 2007; Wang et al., 2008). In 
addition to verifying that CASZ1 endogenously and directly binds to and activates transcription 
through a 114 bp enhancer element within intron 3 of the Egfl7 locus, we surprisingly found that 
CASZ1 is required for Egfl7 but not miR-126 expression in Xenopus endothelial cells. 
Furthermore, depletion of EGFL7 in Xenopus embryos phenocopies the vitelline vein branching 
and lumen formation defects of CASZ1-depleted embryos, but miR-126 depletion does not affect 
the initial assembly or remodeling of the vasculature. These studies strongly suggest that in 
Xenopus embryos, miR-126 may be differentially regulated from its host gene via a CASZ1-
independent mechanism. Consistent with this possibility, previous studies also show that intronic 
microRNAs can be transcribed independently of their host genes through alternative promoters 
(Bell et al., 2010; Monteys et al., 2010).  
 
 We further determined whether the regulation of these targets by CASZ1 is evolutionarily 
conserved. We found that CASZ1 is required for both Egfl7 and miR-126 expression in 
HUVECs and that depletion of EGFL7 in HUVECs phenocopies the adhesion and cell 
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morphology defects associated with the absence of CASZ1. However, only restoration of Egfl7 
levels rescued both adhesion and cell morphology, whereas restoration of miR-126 rescued only 
adhesion, indicating that these targets may function somewhat independently of each other while 
still relying on CASZ1 activity, at least in human cells. These results are in line with those of 
previous studies suggesting that EGFL7 functions early during vascular development to initiate 
lumen formation, whereas miR-126 functions later in development to maintain the integrity of 
vascular tubes (Fish et al., 2008; Parker et al., 2004; Wang et al., 2008). 
  
 Although we demonstrated that CASZ1 directly binds to and regulates Egfl7 expression 
in Xenopus, CASZ1 seems to be required for the maintenance but not the onset of Egfl7 in 
endothelial cells. Indeed, previous studies demonstrate that the Egfl7 locus is regulated by 
additional factors including the Ets transcription factors and GATA-2 (Harris et al., 2010; Le 
Bras et al., 2010; Wang et al., 2008). Transcription factors responsible for endothelial gene 
expression can also function cooperatively to regulate transcription (De Val and Black, 2009; De 
Val S., 2008). It would therefore be fascinating to explore the possibility that CASZ1 functions 
with other transcription factors to fully govern Egfl7 expression. Intron 3 of Xenopus Egfl7 is not 
well conserved among vertebrate species, implying that CASZ1 may function through an 
alternative element in mammalian cells. Therefore, when further establishing the mechanisms by 
which CASZ1 regulates Egfl7 in endothelial cells, it would be beneficial to map the region of the 
Egfl7 locus that requires CASZ1 through luciferase and ChIP assays, preferably in HUVECs. By 
mapping this domain, we could identify other putative endothelial transcription factor binding 
sites nearby and test whether CASZ1 acts in tandem with these elements to cooperatively 
regulate Egfl7 expression. 
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  CASZ1/Egfl7 Lies Upstream of the RhoA Signaling Pathway  
Beyond characterizing the CASZ1/Egfl7 transcriptional pathway, the studies described in 
Chapter 2 also examined how dysregulation of this pathway leads to aberrant endothelial cellular 
behaviors associated with adhesion and cell shape. These aberrant phenotypes are reminiscent of 
improper RhoA GTPase signaling, and, indeed, RhoA plays a major role in regulating 
cytoskeletal dynamics and cell-matrix contacts through the formation of stress fibers and focal 
adhesions (Burridge and Wennerberg, 2004; Chrzanowska-Wodnicka and Burridge, 1996; Katoh 
et al., 2011; Vouret-Craviari et al., 2002). We confirmed that in the absence of CASZ1 or 
EGFL7, RhoA mRNA and protein levels are significantly reduced, leading to impaired formation 
of stress fibers and mislocalization of focal adhesion proteins away from the cell periphery. 
Furthermore, restoration of Egfl7 levels in CASZ1-depleted cells improves the formation of 
stress fibers and proper distribution of focal adhesion, indicating that the CASZ1/Egfl7 
transcriptional pathway is required for proper RhoA expression and activity. Although RhoA 
activity is dynamic, it is rare to observe dramatic differences in steady-state levels of total RhoA. 
Thus, our studies provide a unique model in which to study the mechanisms of RhoA 
transcriptional regulation. The only transcription factor known to directly activate RhoA is Myc. 
Thus, it would be intriguing to examine whether CASZ1/Egfl7 is responsible for RhoA 
expression through a Myc-mediated pathway. Furthermore, it will be critical to determine 
whether RhoA is important for vascular assembly and lumen morphogenesis in ways similar to 
CASZ1 and EGFL7 in Xenopus. Because RhoA is not restricted to endothelial cells and plays 
major roles in morphogenetic cell movements very early during embryogenesis, examining the 
function of RhoA in Xenopus endothelial cells is not simple (Bement et al., 2005; Drechsel et al., 
1997; Kim and Han, 2005; Tanegashima et al., 2008). Recent technologies employing a 
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photoactivatable form of RhoA, however, may improve our ability to modulate RhoA activity in 
specific tissues at specific time points (Morckel et al., 2012). It would be especially interesting to 
investigate the role of RhoA during lumen morphogenesis given recent reports indicating that 
Rho kinase (ROCK) signaling in the mouse dorsal aorta is required for proper changes in cell 
shape that accompany the formation of the vascular lumen (Strilic et al., 2009).  
 
Distinct Mechanisms of Lumen Formation in Xenopus 
In Chapter 3, we focused on elucidating the molecular and cellular mechanisms 
underlying a more specific step during blood vessel development—vascular lumen formation. 
Although the studies described in Chapter 2 indicate that CASZ1 and EGFL7 are required for 
vascular lumen formation, virtually nothing is known about how lumens are generated in 
Xenopus. However, recent studies in zebrafish and mice reveal that similar sets of determinants 
and mechanisms are at play in these species. Endothelial cells initially coalesced into cord-like 
structures must undergo a series of morphogenetic movements, including the redistribution of 
cell-cell junctions away from the cord center and the alteration of cell shape to accommodate the 
luminal compartment. Although the driving force behind these movements appears to be the 
establishment of apicobasal polarity in the mouse dorsal aorta, we revealed that endothelial cell 
polarization is not a prerequisite for lumen formation in Xenopus major vessels. However, 
similar to zebrafish and mice, we observed that Xenopus endothelial cells reorganize their 
junctions and elongate during lumen formation, raising the question of what promotes cell-cell 
separation and cell shape changes in this species? Although our studies suggest that EGFL7 is 
required for changes in cell shape and proper redistribution of junctions, it is still not clear how 
EGFL7 accomplishes these functions.  
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 Current imaging techniques and the availability of endothelial-specific transgenic lines 
make zebrafish a top model for imaging the dynamics associated with vascular development, 
including lumen formation (Blum et al., 2008; Helker et al., 2013; Herwig et al., 2011; Kamei et 
al., 2006; Lenard et al., 2013; Wang et al., 2010). The ability to image lumen formation in 
Xenopus would greatly enhance our understanding of the endothelial cell behaviors needed to 
form functional tubes. Although we lack vascular-specific reporter lines at the time of lumen 
formation, one possible way to image lumen formation of posterior cardinal veins would be to 
use an injectable endothelial cell-specific fluorescent dye. As shown in Chapter 3, embryos at the 
one-cell stage could be injected with an mRNA encoding a form of GFP that sequesters to cell 
membranes throughout the embryo. Another mRNA encoding GFP tagged to histone H2B could 
also be co-injected to label cell nuclei. Prior to lumen formation at stage 33, embryos could be 
anesthetized with a low dose of tricaine and injected with DiI-acetyled (Ac)-LDL, which is 
specifically taken up by endothelial cells and fluoresces red along the length of the posterior 
cardinal vein (Levine et al., 2003). We could then immediately visualize dye uptake along this 
region using a fluorescent microscope, and as lumens open and circulation commences, we could 
visualize the distribution of the dye in the vasculature. Because posterior cardinal veins form just 
below the overlying epithelium, we would need to use confocal microscopy to image embryos at 
the level of veins. Using DiI-Ac-LDL to label endothelial cells and GFP to mark cell membranes 
and nuclei, we could image the opening of vessel lumens over the course of about six hours (i.e., 
the time between stages 33 and 36 when embryos are cultured at room temperature). These 
potential experiments would require optimization, as we do not know how embryos would 
tolerate being under a laser for an extended amount of time or how easily it would be to visualize 
lumens forming on the lateral surface of embryos rather than tissue sections. However, these 
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studies would provide valuable insights into the dynamics and complexity of this process, which  
currently cannot be gleaned from mere snapshots. 
 
  The importance of studying this specific step of vascular development arises from the 
fact that the delivery of therapeutics to tumor sites is often hindered by a lack of functional and 
efficient vessels. Tumor vessels are abnormal, leaky, tortuous, and prone to metastatic 
dissemination of cancer cells (Carmeliet, 2003; Carmeliet and Jain, 2011a). Thus, recent studies 
are exploring the process of tumor vessel normalization, in which instead of attempting to 
damage and prune back tumor vessels, the vasculature is conditioned to become more "normal" 
to permit more efficient drug delivery directly to the tumor (Carmeliet and Jain, 2011b). 
Understanding the basis for initiating and maintaining vascular lumens may therefore enhance 
vessel normalization efforts.  
 
Future Directions 
 Our studies clarify that CASZ1 has a critical function in the assembly and remodeling of 
blood vessels, in part by regulating its direct target Egfl7. In endothelial cells, CASZ1 appears to 
act as a transcriptional activator. However, the CASZ1 expression domain extends not only to 
the vasculature but also to the heart, neural tissue, and muscle (Christine and Conlon, 2008; Liu 
et al., 2006). It is also important to note that the function of CASZ1 in endothelial cells appears 
to differ from that in the heart. Whereas CASZ1 is critical for endothelial cell proliferation, 
CASZ1 appears to promote terminal differentiation over progenitor self-renewal in 
cardiomyocytes (Christine and Conlon, 2008). Furthermore, CASZ1 is described as a tumor 
suppressor in neuroblastoma cell lines, inhibiting cell growth while inducing differentiation (Liu 
et al., 2011c; Liu et al., 2011d). Thus, CASZ1 likely acts on unique sets of transcriptional targets 
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within each type of tissue. As transcription factors can act as activators or repressors depending 
on the context (Fujimoto et al., 2000; Peng and Jahroudi, 2002; Sakabe et al., 2012), it would be 
interesting to identify further transcriptional targets of CASZ1 in endothelial cells and other cell 
types such as cardiomyocytes to determine whether CASZ1 exhibits context-specific functions. 
Although isolating endothelial cells in Xenopus embryos is currently problematic due to 
difficulty in excising tissue consisting exclusively of vessels and a lack of endothelial-specific 
reporters, one way to identify additional CASZ1 targets would be to use HUVECs. Data from 
ChIP-Seq experiments of wildtype HUVECs and RNA-Seq experiments of control versus 
CASZ1-depleted HUVECs (by shRNA) could be combined to examine the elements to which 
CASZ1 directly binds and whether CASZ1 regulates these targets via activation or repression 
mechanisms. Such studies may provide further information about the targets through which 
CASZ1 may regulate cell cycle progression in HUVECs, as restoration of Egfl7 levels in 
CASZ1-depleted cells is unable to rescue proliferation deficits.  
 
 Moreover, our understanding of how CASZ1 mediates transcriptional activity is still 
extremely limited. Processes underlying heart development, such as specification of cardiac 
progenitor cells, cardiomyocyte differentiation, and patterning and growth, are known to rely on 
the combined actions of multiple transcription factors in a temporal fashion (Hiroi et al., 2001; 
Junion et al., 2012; Stennard et al., 2003; Vincentz et al., 2008). Likewise, transcription factors 
driving endothelial gene programs are known to function cooperatively (De Val and Black, 2009; 
De Val S., 2008; Pham et al., 2007; Sacilotto et al., 2013; Wei et al., 2009). It would therefore be 
fascinating to identify the core components of the CASZ1 transcription complex in each of these 
cellular contexts. These studies would contribute to our understanding of the mechanisms by 
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which CASZ1 regulates its target genes and may help explain apparent discrepancies in CASZ1 
function in different cell types. Proteomic studies greatly facilitate the identification of 
components of other transcription factor complexes (Kaltenbrun et al., 2013). Thus, the ability to 
isolate the CASZ1 transcription complex, especially from HUVECs, is not out of reach. 
Furthermore, the generation of new tools in Xenopus, such as the isolation of nuclei tagged in 
specific cell types (INTACT) method, will enable the enrichment of nuclear CASZ1 
transcriptional complexes, particularly from cardiac tissue. Genome editing tools, including 
TALEN and CRISPR platforms, have also garnered interest in many model organisms including 
bacteria, yeast, Drosophila, C. elegans, zebrafish, and mice given their ability to silence or to 
enhance and tag specific genes. Indeed, the capability of tagging endothelial-specific genes with 
fluorescent reporters would be valuable for generating a transgenic line in which pure endothelial 
cell populations can be visualized and isolated for downstream applications such as ChIP-Seq, 
RNA-Seq, and proteomics.  
 
 Another area of interest stemming from this thesis work is elucidating the pathways 
downstream of EGFL7 activity. Although associated with the ECM, the mechanism by which 
EGFL7 modulates cellular behavior is still unclear. Moreover, the discovery of the intronic miR-
126 in the Egfl7 locus complicates the analysis of phenotypes associated with loss of EGFL7 
(Kuhnert et al., 2008). Previous studies demonstrate that EGFL7 interacts with lysyl oxidases to 
negatively regulate the deposition of elastin fibers, suggesting that EGFL7 may remodel the 
ECM so that it is amenable to certain endothelial cell behaviors such as migration or adhesion 
(Lelievre et al., 2008). Another likely possibility is that EGFL7 functions as a ligand for cell-
surface receptors responsible for mediating intracellular signaling cascades. Indeed, EGFL7 
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competes with delta-like ligand-4 for Notch receptor binding, and a recent study shows that 
EGFL7 also interacts with integrin αvβ3 (Nichol et al., 2010; Nikolic et al., 2013; Schmidt et al., 
2009). Both Notch and integrin signaling are implicated in numerous endothelial cell processes 
(Brooks et al., 1994; Davis and Bayless, 2003; Friedlander et al., 1995; Funahashi et al., 2008; 
Hellstrom et al., 2007; Serini et al., 2006; Shawber et al., 2003; van der Flier et al., 2010). In 
addition to exploring the existence of other molecules that interact with EGFL7, it would be 
interesting to pursue the outcomes of these interactions. For example, what effectors are 
downstream of EGFL7/Notch or EGFL7/integrin αvβ3 interactions? One way to address this 
question would be to map the domains of EGFL7 that are required for interaction. EGFL7 is 
relatively small, composed of only 278 amino acids, with delineated domains that are implicated 
in protein-protein interactions of other factors (i.e., EGF) (Fitch et al., 2004). Initially, these 
studies could be performed by co-immunoprecipitating overexpressed proteins corresponding to 
EGFL7 deletion constructs with or without Notch or αvβ3 receptors in HEK293 cells, which are 
much easier to transfect than HUVECs. After the mapping of a domain, we could perform site-
directed mutagenesis to abolish the interaction and generate an adenovirus expressing mutated 
EGFL7. As HUVECs can be successfully co-infected with lentiviral shRNAs and adenovirus as 
demonstrated in Chapter 2, we could then knock down endogenous EGFL7 levels in HUVECs 
and introduce mutated EGFL7 via adenovirus, which would presumably prevent the endogenous 
interaction and fail to rescue a portion of the cellular defects. We could then screen for the 
effects of this impaired interaction through a proteomics-based comparison between control and 
mutated EGFL7 cells to identify the downstream effectors responsible for mediating EGFL7-
dependent processes. These studies would more clearly define the role of EGFL7 in specific cell 
behaviors and clarify the mechanisms by which EGFL7 primarily functions in endothelial cells.  
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 Studies in mice reveal that EGFL7 is dispensable for embryonic development and that 
previously noted functions of EGFL7 in vascular development are in fact ascribed to miR-126 
(Kuhnert et al., 2008; Schmidt et al., 2007). The disparity in EGFL7 loss-of-function phenotypes 
among mice, zebrafish, and Xenopus could be attributed to functional redundancy with its 
paralog EGFL8, which may not be conserved between amphibians and fish (Charpentier et al., 
2013a; Nikolic et al., 2010; Parker et al., 2004; Subhan et al., 2013). However, mouse studies do 
not discredit the role of EGFL7 in disease. Expression profiling reveals that EGFL7 is 
significantly upregulated in multiple cancer cell lines and tissues, especially in solid tumors 
(Delfortrie et al., 2011; Fan et al., 2013; Huang et al., 2010; Wu et al., 2009). The growth and 
survival of tumors depends on the establishment of a vascular network, although tumor vessels 
are often abnormal and inefficient. One major driver of tumor angiogenesis is an oxygen-
depleted microenvironment, primarily functioning through hypoxia inducible factor (HIF) 
signaling, which promotes the expression of numerous pro-angiogenic factors such as VEGF 
(Hirota and Semenza, 2006; Lee and Simon, 2012; Skuli et al., 2012). Interestingly, EGFL7 is 
upregulated in response to hypoxia in tissue culture and exerts a protective effect on endothelial 
cell survival under stressful conditions (Xu et al., 2008). This heightened activity in response to 
stress prompted investigators from the biotechnology company Genentech to pursue EGFL7 as a 
potential anti-angiogenesis target in cancer therapy (Yeung et al., 2009). Although anti-VEGF 
approaches have been at the forefront of anti-angiogenesis therapeutics for the last decade, 
progressive resistance to these treatments has been documented (Meadows and Hurwitz, 2012; 
Welti et al., 2013). Thus, efforts to identify an ideal cocktail of angiogenesis inhibitors are 
continuing. The generation of anti-EGFL7 antibodies can actually accentuate the efficacy of anti-
VEGF in damaging and pruning tumor vessels  in murine models of non-small cell lung cancers, 
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pushing anti-EGFL7 therapies into Phase II clinical trials (Johnson et al., 2013). These studies 
show that although EGFL7 may not play a major role in quiescent endothelial cells, it is critical 
for endothelial function in times of stress. Therefore, it may be of value to re-examine EGFL7-
null mice and their response to stress-induced pathological remodeling.  
 
 The study of cancer biology from a developmental standpoint reveals that many of the 
pathways and factors required for embryonic development are often aberrantly reactivated or 
shut off during cellular transformation and subsequent cancer progression. This certainly appears 
to be the case for EGFL7, which is normally downregulated in vessels after embryonic 
development while becoming highly activated during physiological neoangiogenesis in response 
to injury and also in tumor vessels. Although this thesis attempted to further address the role of 
CASZ1 during embryonic development, CASZ1 also emerged as an important modulator of 
neuroblastoma. Indeed, CASZ1 expression is downregulated in humans with neuroblastoma as 
well as primary cell lines, and its restoration in cells inhibits growth and tumorigenicity, 
indicating a tumor suppressive role for CASZ1 (Liu et al., 2011c; Liu et al., 2011d).  
 
 Given that CASZ1 is an important regulator of Egfl7 expression during endothelial cell 
development, it would be interesting to address whether this transcriptional pathway is similarly 
required during pathological remodeling. We do not know the function of CASZ1 in adult 
endothelial cells, but we hypothesize that because Egfl7 is significantly downregulated in the 
vasculature during adulthood, CASZ1 may be unnecessary for Egfl7 regulation or may regulate 
the expression of other targets. The pro-angiogenic cascade that is enhanced during cancer 
includes upregulation of Egfl7, raising the possibility that CASZ1 may lie downstream of stimuli 
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driving this cascade. One immediate way to test this possibility would be to examine CASZ1 
expression in HUVECs in response to treatment with angiogenic growth factors such as VEGF, 
FGF, and TGF-β or to determine whether CASZ1 is induced in a hypoxia-dependent manner by 
exposing cells to low oxygen. Ultimately, the generation of a conditional CASZ1 knock-out 
mouse is necessary to shed light on the potential function of CASZ1 during mammalian 
embryogenesis and pathological remodeling. Indeed, mice that stably express a floxed allele of 
Casz1 and endothelial-specific and inducible Cre-drivers are now available for future work on 
the role of CASZ1 in vasculature.  
 
 In summary, the studies within this dissertation comprise a foundation for future studies 
relating to the transcriptional control of vascular development and disease. We have shown that 
blood vessel assembly and lumen morphogenesis are driven by the transcriptional activation of 
an ECM factor, which mediates downstream signaling directly involved in the modulation of 
endothelial cell behaviors associated with proper adhesion and morphology. Understanding the 
complexity of the pathways involved in vascular development will provide a better foundation 
for studying and modifying these networks in disease and may help identify key targets 
amenable to therapeutic manipulation.   
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APPENDIX 1: TRANSCRIPTIONAL REGULATION OF BLOOD VESSEL 
FORMATION
3
 
 
 Formation of a functional vascular system is critical for the delivery of nutrients, the 
removal of waste, and gas exchange. During vasculogenesis, the de novo formation of blood 
vessels, mesodermal cells differentiate into endothelial cell precursors that proliferate and 
migrate to specified locations in the embryo before assembling into cord-like structures to form 
the primary vascular plexus.(Herbert and D.Y., 2011) Redistribution of junctional molecules, 
establishment of apicobasal polarity, and cell morphology changes all facilitate the opening of 
vessel lumens. These primitive blood vessels are further pruned and remodeled by angiogenesis 
when new vascular branches form by sprouting from pre-existing vessels. Additionally, 
endothelial cells become specified to contribute to either the venous or arterial 
vasculature.(Herbert and D.Y., 2011) Understanding the molecular and cellular mechanisms 
underlying endothelial cell behavior will enable us to develop more efficacious therapies for 
diseases, such as atherosclerosis, rheumatoid arthritis, and tumorigenesis.  
 
 The specification of the cardiovascular lineage and the subsequent morphogenesis of the 
heart and vessels depend on the combined activities of a number of transcription factors. Work 
within our lab revealed a novel role for the transcription factor CASZ1 in Xenopus cardiogenesis 
by regulating cardiomyocyte differentiation.(Christine and Conlon, 2008) In a recent study, we 
also showed that CASZ1 is required for blood vessel branching and lumen formation in Xenopus 
embryos, independent of its role in cardiac development.(Charpentier et al., 2013a) At the 
                                                          
3
This appendix previously appeared as a commentary in the journal Cell Cycle. The original citation is as follows: 
Charpentier M.S., Dorr K.M., and Conlon F.L. Transcriptional regulation of blood vessel formation: The role of the 
Casz1/Egfl7/RhoA pathway. Cell Cycle 12, no.14 (July 2013): 2165.   
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cellular level, depletion of CASZ1 in primary human endothelial cells results in impaired 
adhesion to the underlying substrate, aberrant contractility, and G1/S cell cycle arrest, indicating 
that CASZ1 is necessary for promoting endothelial cell behaviors associated with proper 
vascular assembly.(Charpentier et al., 2013a) Utilizing a chromatin immunoprecipitation-cloning 
screen, we found that CASZ1 modulates these endothelial cell behaviors by activating the 
expression of its direct transcriptional target, epidermal growth factor-like domain 7 (EGFL7). 
Depletion of EGFL7, an endothelial-secreted extracellular matrix (ECM) protein, resulted in 
poorly arborized vascular networks that were devoid of vessel lumens, indicating a requirement 
for EGFL7 in angiogenesis and lumen morphogenesis in accordance with previous 
reports.(Nichol and Stuhlmann, 2012; Nikolic et al., 2013) Moreover, the EGFL7-deficient 
vascular networks were similar to those in CASZ1-depleted embryos. We linked this 
CASZ1/EGFL7 transcriptional hierarchy to the RhoA GTPase signaling pathway, which directly 
controls the cellular outputs we observed to be defective under CASZ1 and EGFL7-depleted 
conditions. RhoA transcript levels and activity were significantly diminished in the absence of 
either CASZ1 or EGFL7. Consequently, formation of actin-based stress fibers and localization of 
focal adhesion markers at sites of substrate contact were aberrant in CASZ1-depleted cells, but 
these defects were rescued by reintroduction of EGFL7.  
 
 From these results, we propose a model whereby CASZ1 binds to and activates EGFL7 
gene expression in endothelial cells in order to release EGFL7 into the ECM. Through yet 
unknown mechanisms, we hypothesize that EGFL7 binds to cell-surface receptors, such as 
integrins, to activate a signaling cascade necessary for RhoA transcription and its subsequent 
activity. RhoA then directly modulates endothelial cell behaviors, such as adhesion and 
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contractility, to promote the proper assembly of vascular networks (Figure A1.1). While we have 
shown that activation of this pathway is necessary for the formation of a functional vascular 
system from a developmental standpoint, it is not surprising that improper activation of such a 
pathway could lead to pathological vascular remodeling in adult tissues, such as during 
tumorigenesis. While highly expressed in developing vessels, EGFL7 is downregulated in the 
quiescent vasculature of the adult, but is upregulated again in response to injury or cellular 
stress.(Nichol and Stuhlmann, 2012) Indeed, high EGFL7 levels are correlated with several 
tumors and cancer cell lines, and EGFL7 monoclonal antibodies are currently being tested in 
clinical trials for use in vascular tumor therapies (http://www.gene.com/medical-
professionals/pipeline).(Nichol and Stuhlmann, 2012) RhoA has been shown to be required for 
lumen formation, but increased RhoA activity also induces vascular permeability, which 
potentially associates RhoA with the unstable, leaky vasculature characteristic of 
tumors.(Karlsson et al., 2009) Therefore, uncovering the molecular networks underlying 
embryonic development may provide novel targets for the design of therapeutics to treat patients 
with cancer.  
 
There have been limited studies on mammalian CASZ1 in both development and disease. 
Recently, the human ortholog of Casz1 was identified and shown to be highly expressed in adult 
heart tissue.(Liu et al., 2006) The evolutionary role of CASZ1 in cardiovascular development is 
further emphasized by a recent genome-wide association study, demonstrating a genetic association 
between the Casz1 locus and both blood pressure and hypertension.(Takeuchi et al., 2010) However, 
despite the essential role of CASZ1 in cardiovascular development and human disease, the 
cellular requirements and molecular mechanisms by which CASZ1 regulates cardiac 
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development remain unknown. To address these issues, we generated a Casz1 knockout mouse that 
will provide a means to understand mechanistically how this transcription factor functions in 
cardiovascular disease. Future studies include identifying additional transcriptional targets of CASZ1 
in the heart and vasculature and investigating how CASZ1 regulates transcription. To that end, we 
are undertaking a number of proteomics-based approaches to determine how CASZ1 itself is 
regulated, to identify cardiac and/or vascular-specific co-factors with which CASZ1 interacts to 
regulate transcription, and to uncover novel downstream pathways dependent on CASZ1 function.  
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Figure A1.1. Function of CASZ1 in endothelial cells. (A) Proper expression and activity of 
CASZ1 in endothelial cells results in transcriptional activation of Egfl7 and subsequent RhoA 
activity thereby promoting the assembly of a well-branched, lumenized vascular system. (B) 
Disruption of CASZ1 function results in cords of endothelial cells lacking a central lumen and 
angiogenic sprouts. Branches that are apparent consist of thin, elongated cells that are unable to 
maintain adhesion to the underlying matrix or existing vasculature. 
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APPENDIX 2: THE CASZ1/EGFL7 TRANSCRIPTIONAL PATHWAY IS REQUIRED 
FOR RHOA EXPRESSION IN VASCULAR ENDOTHELIAL CELLS
4
 
 
 The cardiovascular system is the first organ system to develop and function during 
embryonic development. Proper establishment of the circulatory system is essential for meeting 
the demands of a rapidly growing embryo in need of nutrients, gas exchange, and waste removal. 
Blood vessel development occurs via vasculogenesis and angiogenesis. During vasculogenesis, 
endothelial cells, the building blocks of blood vessels, are first specified from the mesoderm 
whereby they subsequently migrate to precise locations within the embryo to assemble into 
primitive vascular structures.(Patan, 2000; Patel-Hett and D'Amore, 2011) From this point on, 
most of vascular development proceeds via angiogenesis in which vessels branch or sprout from 
pre-existing vessels ultimately giving rise to a specialized hierarchy of veins, arteries, and 
lymphatic vessels.(Geudens and Gerhardt, 2011; Lawson et al., 2001) The coordination of 
endothelial cell behaviors including migration, proliferation, and adhesive properties between 
cells and between the underlying extracellular matrix (ECM) is critical for these key steps of 
vascular assembly, and hence dysregulation of these behaviors can lead to a number of disease 
states such as atherosclerosis, stroke, rheumatoid arthritis, and tumorigenesis.(Carmeliet and 
Jain, 2011a; Chappell and Bautch, 2010) An understanding of the molecular and cellular 
mechanisms underlying endothelial cell behavior is therefore necessary to provide a basis for the 
design of therapeutics.  
 
                                                          
4
This appendix previously appeared as an editorial in the journal Small GTPases. The original citation is as follows: 
Charpentier M.S., Taylor J.M., and Conlon F.L. The Casz1/Egfl7 transcriptional pathway is required for RhoA 
expression in vascular endothelial cells. Small GTPases 4, no.4 (October 2013).  
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 Endothelial cells are highly sensitive to influences from the environment and alter their 
behaviors in response to signaling cascades typically initiated extracellularly through cell surface 
receptors. One key family of proteins known to play a critical role in signal transduction is the 
Rho family of small GTPases. The Rho GTPases, including members of the Rho, Rac and Cdc42 
sub-families, are critical regulators of the actin cytoskeleton and promote the formation of 
distinct actin bundles such as actin stress fibers, lamellipodia, or filopodia respectively.(Heasman 
and Ridley, 2008) Like all GTPases, RhoA is regulated by GTP binding and cycles between the 
active GTP-bound form and the inactive GDP-bound form. RhoA activity is tightly controlled by 
Guanine nucleotide Exchange Factors (GEFs) that facilitate exchange of GDP for GTP, GTPase 
Activating Proteins (GAPs) that facilitate RhoA’s intrinsic GTPase activity (to inhibit RhoA), 
and RhoGDIs which sequester RhoA into an inactive sub-cellular fraction. In its GTP-bound 
form, RhoA interacts with a variety of effector molecules that mediate its effects on the actin 
cytoskeleton including the Rho-kinases (ROCK 1 and II), diaphanous-related formins (mDia1 
and mDia2), protein kinase N, citron kinase, rhophilin, and Rhotekin. The mDia proteins directly 
catalyze actin polymerization in cooperation with the actin binding protein, profilin; while 
ROCK stimulates actin polymerization by inhibiting the disassembly of actin polymers through 
LIM-kinase-dependent inhibition of cofilin. ROCK also inhibits myosin phosphatase to stimulate 
actin-myosin based contraction, which promotes actin bundling and stress fiber 
formation.(Heasman and Ridley, 2008)   
 
Recent studies indicate that besides regulating cell shape changes, Rho-dependent signals 
can directly impact gene expression. Indeed, important SRF-cofactors including Myocardin-
related transcription factors (i.e. MRTF-A and MRTF-B) have been shown to contain monomeric 
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(G)-actin binding domains, and association with G-actin masks a nuclear localization targeting 
sequence resulting in their cytoplasmic sequestration. Thus, upon RhoA-induced G-actin 
polymerization, the fall in free cytoplasmic G-actin results in G-actin release from MRTFs 
therefore promoting nuclear accumulation and facilitating MRTF-dependent gene 
transcription.(Guettler et al., 2008; Miralles et al., 2003) The Rho/MRTF/SRF pathway is a key 
means by which the smooth muscle cell phenotype is regulated(Lockman et al., 2004) and recent 
studies indicate that it may also be particularly important for determining endothelial cell fates as 
perturbation of the Rho-MRTF axis impairs endothelial cell differentiation from mesenchymal 
stem cells and conversely, the endothelial to mesenchymal transition.(Mihira et al., 2012; Wang 
et al., 2013) RhoA-mediated signaling has also been implicated in NF-B-dependent gene 
transcription in various cell types including endothelial cells thereby promoting angiogenesis, at 
least in part, by up-regulating VEGFR2 levels.(Sivaraj et al., 2013)  
 
  Accumulating evidence has highlighted significant roles for RhoA in vascular biology 
including angiogenesis, lumen formation, and endothelial barrier function.(Bryan et al., 2010; 
Spindler et al., 2010; Xu et al., 2011). We have recently further implicated RhoA-mediated 
signaling in vascular development by showing that RhoA lies downstream of a transcriptional 
cascade involving the transcription factor CASTOR (CASZ1) and its direct target Epidermal 
Growth Factor-like Domain 7 (Egfl7).(Charpentier et al., 2013a; Charpentier et al., 2013b) 
CASZ1 is an evolutionarily conserved transcription factor originally characterized in Drosophila 
to maintain neural stem cell identity.(Cui and Doe, 1992; Mellerick et al., 1992) In addition to 
expression domains in the brain, Casz1 transcripts have been identified in cardiovascular tissues 
across vertebrate species, and work from our lab demonstrated that CASZ1 is required for 
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Xenopus cardiogenesis by regulating cardiomyocyte differentiation.(Charpentier et al., 2013a; 
Christine and Conlon, 2008; Liu et al., 2011d; Liu et al., 2006) Furthermore, genome-wide 
association studies have revealed a genetic link between the human Casz1 locus and high blood 
pressure implicating CASZ1 in cardiovascular disease as well as development.(Takeuchi et al., 
2010) Through the use of Xenopus and human endothelial cell models, we have recently 
demonstrated that CASZ1 is also required for blood vessel development.(Charpentier et al., 
2013a) In the absence of CASZ1, Xenopus embryos failed to generate a well-branched vascular 
network and lumen formation was impaired. At the cellular level, CASZ1-depletion by short 
hairpin RNA in human umbilical vein endothelial cells (HUVECs) resulted in the inability of 
cells to maintain adhesion to the underlying substrate and failure of cells to undergo the G1/S 
cell cycle transition; likely due to defective control of cell contractility. To elucidate the 
mechanism by which CASZ1 regulates these processes, we performed a cloning chromatin 
immunoprecipitation screen to identify direct transcriptional targets of CASZ1. One of the 
identified targets was EGFL7, a secreted ECM protein implicated in vessel morphogenesis.(Fitch 
et al., 2004; Parker et al., 2004) We subsequently confirmed that CASZ1 is bound to Egfl7 and 
that Egfl7 was a bona fide CASZ1 target gene. Indeed, Egfl7 levels were downregulated in the 
absence of CASZ1, and depletion of EGFL7 in embryos and cells phenocopied the defects 
associated with loss of CASZ1 providing evidence that CASZ1 was required for transcriptional 
activation of Egfl7 for subsequent vessel development.    
 
 Although EGFL7 was previously implicated in vessel morphogenesis, the mechanism(s) 
by which EGFL7 regulated endothelial cell behaviors was unclear prior to these studies. Upon 
closer examination of CASZ1 and EGFL7-depleted HUVECs which displayed a thin, elongated 
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morphology associated with impaired contractility of the trailing edge, we hypothesized that Rho 
GTPase signaling was dysregulated. In fact, staining with focal adhesion and F-actin markers 
revealed an absence of adhesions from sites of substrate contact and reduced, diffuse stress fibers 
reminiscent of RhoA inhibition.(Katoh et al., 2011; Narumiya et al., 2000) Accordantly, levels of 
active RhoA and phosphorylation of non-muscle myosin II light chain were significantly 
diminished in CASZ1 and EGFL7-depleted cells. Somewhat surprisingly, total protein levels as 
well as transcript levels of RhoA were also greatly reduced under both conditions indicating that 
impairment of the RhoA pathway occurred at the level of gene transcription. Upon re-expression 
of Egfl7 in CASZ1-depleted cells, endothelial cells no longer detached from the substrate and 
proper localization of focal adhesions and stress fibers was restored indicating that RhoA lies 
downstream of CASZ1/Egfl7 (Figure A2.1).   
 
 As described above, regulation of RhoA activity by GEFs, GAPs, and RhoGDI is well-
characterized and is presumed to be the main means by which RhoA activity is tightly controlled. 
However, it is well-documented that increased RhoA mRNA and protein expression are 
correlated with cancer progression, indicating that additional transcriptional layers of control 
likely exist and that it will be of importance to define the underlying mechanisms.(Bellizzi et al., 
2008; Faried et al., 2007; Fritz et al., 1999; Horiuchi et al., 2003; Pille et al., 2005) The only 
transcriptional pathway that has been shown to regulate the RhoA gene is the oncogenic Myc-
Skp2-Miz-p300 complex which promotes RhoA expression in breast carcinoma cell lines.(Chan 
et al., 2010)  Since Myc is required for proper embryonic development (Davis et al., 1993), and 
abnormal development of blood vessels has been attributed to both overexpression and depletion 
of Myc (Baudino et al., 2002; Kokai et al., 2009; Rodrigues et al., 2008), it will be of future 
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interest to  examine whether the Myc/RhoA transcriptional network is also operative in 
endothelial cells and (if so) how this pathway might contribute to the EGFL7-dependent 
regulation of RhoA during vascular assembly and morphogenesis.  
 
MicroRNAs have also been implicated in regulating RhoA transcript and protein 
abundance via direct binding to the 3' UTR of the RhoA gene. Again, regulation of RhoA 
expression by these means has been highlighted in a number of cancer cell models wherein  
miRs 185, 31, and 155 have each been shown to impart tight control of RhoA mRNA and protein 
levels(Kong et al., 2008; Liu et al., 2011b; Valastyan et al., 2009a; Valastyan et al., 2009b). 
Importantly, miR-31 was also shown to target RhoA in cardiomyocytes, wherein it limited 
hypertrophic remodeling, indicating that regulation of RhoA by microRNAs is not restricted to 
oncogenesis and likely represents a common regulatory mechanism.(Care et al., 2007) Therefore, 
it would be interesting to screen microRNA expression in CASZ1 or EGFL7-depleted cells as it 
is formally possible that aberrant microRNA activity downstream of CASZ1/Egfl7 may be 
responsible for the diminished RhoA mRNA and/or protein levels. 
 
 While the mechanism by which EGFL7 promotes RhoA transcription is currently 
unclear, recent studies have begun to shed light on how EGFL7 might initiate cell signaling. 
EGFL7 was shown to interact with lysyl oxidase (LOX) enzymes and to inhibit their ability to 
crosslink elastic fibers within the ECM, a process that imparts elasticity and resiliency to 
vessels.(Lelievre et al., 2008) Thus it is possible that changes in the rigidity of the ECM alone 
could initiate mechanosensitive signals, or EGFL7-induced ECM remodeling could alter the 
accessibility/ binding affinity of cell-surface receptors responsible for mediating intracellular 
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signaling cascades. Alternatively, EGFL7 may activate or antagonize signaling events by serving 
as a ligand for transmembrane receptors. For example, EGFL7 was recently shown to bind to and 
activate the integrin αvβ3 and this association was shown to be important for proper vessel 
morphogenesis and angiogenic sprouting.(Nikolic et al., 2013) While integrins have been 
intimately associated with mediating extracellular signals through activation of Rho 
GTPases(Huveneers and Danen, 2009; Shen et al., 2012), less is understood about how 
modulation of integrins may affect their gene expression, though it remains a possibility that 
RhoA gene expression may be facilitated by positive feedback in response to increased RhoA 
activity.(Thompson et al., 2002) EGFL7 has also been demonstrated to antagonize Notch 
signaling in endothelial cells as well as neural stem cells.(Nichol et al., 2010; Schmidt et al., 
2009) Again, however, it remains to be determined if RhoA is a direct or indirect downstream 
target of this pathway.  
 
 Although many questions still remain, our findings have uncovered a novel 
transcriptional pathway that may directly or indirectly promote RhoA gene expression. The 
depletion of CASZ1 or its direct target EGFL7 results in decreased RhoA mRNA, protein, and 
activity subsequently leading to improper endothelial cell behaviors associated with aberrant 
vascular development. These studies open up new models in which to probe the effects of 
dysregulated RhoA gene expression on cell behavior and to potentially provide insight into 
mechanisms directly controlling either RhoA gene expression or protein synthesis. 
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Figure A2.1. Model of CASZ1/Egfl7 function in endothelial cells. (A) The transcription factor 
CASZ1 directly binds to and activates expression of Egfl7 in endothelial cells. By a yet unknown 
mechanism, this transcriptional pathway promotes expression of the RhoA gene and subsequent 
GTPase activity which leads to proper adhesion of endothelial cells to the underlying substrate 
(as indicated by red lines). (B) In the absence of CASZ1 (or EGFL7), RhoA expression is 
diminished resulting in thin, elongated cells that cannot stably form adhesions resulting in their 
detachment from the underlying substrate.  
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